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1 SUMMARY 
 
Breast cancer is the most frequent cancer in women and the most common cause of cancer 
related deaths in females. 90% of all cancer related deaths are due to metastatic spread to 
distant organs. In cancer, signaling pathways controlling proliferation, survival and 
migration are frequently deregulated. Tyrosine phosphorylation, controlled by protein 
tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), plays an important role 
in cell signaling. While the role of PTKs in cancer pathogenesis has been extensively 
studied over the past 30 years, the role of specific PTPs is less defined. We therefore 
studied the effects of the Src homology 2 domain containing phosphatase 2 (SHP2) in 
breast cancer. SHP2, encoded by PTPN11, is the first identified bona fide PTP proto-
oncogene. It is a ubiquitously expressed phosphatase that acts as a signal enhancer 
downstream of growth factor, cytokine, and extracellular matrix receptors. 
 In the present study, we found an SHP2-dependent positive feedback loop that 
enhances the propagation of tumor initiating cells and the maintenance of breast tumors. 
We show that SHP2 is important for proliferation, loss of cell polarity, and invasion in a 
3D culture model of invasive breast cancer. SHP2 promotes the progression from in situ to 
invasive carcinoma in vivo and is required for the maintenance and tumor-seeding ability 
of tumor initiating cells. We further demonstrate that knockdown of SHP2 in different 
breast cancer cell lines blocks tumor growth in vivo. Mechanistically, SHP2 promoted 
ERK1/2 activation leading to the upregulation of the transcription factors c-Myc and 
ZEB1. Increased expression of c-Myc led to upregulation of LIN28B which in turn 
repressed let-7 miRNA leading to overexpression of let-7 targets, including RAS and 
c-Myc. SHP2 also increased the expression of ZEB1, a transcription factor important in 
Epithelial-Mesenchymal Transition (EMT). Knockdown of SHP2 decreased the expression  
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of the EMT markers fibronectin, vimentin and N-cadherin and reduced the metastatic load 
in a HER2-positive cell line.  
We then assessed the effects of SHP2 on tumor cell motility, invasion and 
dissemination; all of which are characteristics crucial for metastasis formation. We found 
SHP2 to be important for cell migration, chemotaxis, and invasion in vitro and also for 
tumor cell motility and dissemination in vivo, suggesting a role for SHP2 in the early steps 
of metastasis. In an unbiased proteomics screen, we found that SHP2 activates several Src 
family kinases to induce migration and invasion. Depletion of SHP2 led to inactivation of 
c-Src and several Src substrates and blocked cell migration and invasion in vitro and in 
vivo. 
 SHP2 was recently suggested to have nuclear functions. We explored the 
mechanism of its nuclear import and its nuclear roles in different breast cancer models. We 
confirmed nuclear localization of SHP2 in several breast cancer cell lines and identified a 
nuclear localization signal facilitating the nuclear import of SHP2. Future studies will be 
necessary to fully understand the nuclear functions of SHP2 in breast cancer.  
 In summary, we identified and validated SHP2 as a target in breast cancer. We 
identified its downstream effectors, which mediate its pro-migratory invasive effects and 
started the exploration of its nuclear functions. Future studies should address the effects of 
pharmacological inhibition of SHP2 in breast cancer, provided the availability of selective 
SHP2 inhibitors. In addition, assessment of the effects of nuclear SHP2 in breast cancer is 
warranted.  
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2 INTRODUCTION 
 
2.1 Breast cancer 
Breast cancer is the most frequent cancer in females and the second most common cause of 
cancer related mortality in women worldwide (Ferlay, Shin et al. 2010). 1.64 Million new 
cases of breast cancer were diagnosed in women worldwide in 2010 and 425,000 died 
from the disease (Ferlay, Forman et al. 2012). Using cancer death and population data 
from the World Health Organization (WHO) database, researchers from Italy and 
Switzerland estimated 88,101 deaths from breast cancer in Europe alone in 2012 
(Malvezzi, Bertuccio et al. 2012). This number corresponds to almost 16% of all cancer 
deaths in European woman, making breast cancer mortality the most frequent cause of 
death due to cancer in European females in 2012. 
 The first documented case of breast cancer dates back more than 5,000 years and 
was described in ancient Egypt (Farrow 1971). For a long time breast cancer was believed 
to be a ‘systemic’ disease caused by black bile as initially suggested by Hippocrates (460–
377 BC) and later elaborated by Galen (AD 131–203) (Sakorafas and Safioleas 2009). 
Over the centuries the knowledge increased and during the Renaissance the human 
anatomy was studied challenging Galen’s theory. An increasing number of surgeons 
developed techniques to excise breast tumors. However before the 19th century brought the 
development of anesthesia and antiseptic surgery conditions, operations had to be rapid 
and often ended fatal due to infections (Sakorafas and Safioleas 2009). In the middle of the 
18th century the French surgeon Le Dran (1685–1773) suggested the lymphatic spread of 
breast cancer during the progression of the disease and described tumor cell dissemination 
as “cancer is a local disease in early stages, and it is spread by lymphatics to regional 
nodes and then to the general circulation” (Naruke, Tsuchiya et al. 1999). A milestone in 
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 2 
the breast cancer treatment was the radical mastectomy, which is a surgical removal of the 
breast, the axillary lymph nodes and both underlying chest muscles in one block, 
introduced by the surgeon William Halsted (1852–1922) in 1894 (Halsted 1894). 
Additional landmarks altering the history of breast cancer treatment included the discovery 
of x-rays by Röntgen (1845–1923) in 1895, providing the basis for mammography and 
radiotherapy, the latter first applied to a breast cancer patient shortly after (Grubbe 1947, 
Ekmektzoglou, Xanthos et al. 2009). The Halsted mastectomy remained the most 
performed treatment for the next decade, until increasing criticism was voiced concerning 
the highly invasive procedure (Sakorafas and Safioleas 2010). Retrospective studies 
showed no increased survival benefit for surgeries done using Halsted`s technique when 
compared to less invasive procedures. This insight led to a gradual replacement of the 
radical mastectomy by the modified radical mastectomy (Williams, Murley et al. 1953, 
Handley and Thackray 1969). Breast conservation became an alternative to mastectomy 
and methods like quadrantectomy (a partial mastectomy removing about one quarter of the 
breast) and lumpectomy (local removal of the tumor mass) were developed, achieving the 
same relapse-free and overall survival rates as mastectomy (Fisher, Bauer et al. 1985). 
This was partly possible due to earlier detection allowing surgical removal at a smaller 
tumor size. The broad application of radiotherapy and systemic therapy, such as 
chemotherapy and hormonal therapy, before (neoadjuvant) and after (adjuvant) surgery 
further improved the success of breast cancer treatment in the 20th century (Sakorafas and 
Safioleas 2010).  
However, despite these advances in breast cancer management over the last 
decades, metastatic breast cancer remains a serious issue costing the lives of many women 
each year. Due to the heterogeneity of the disease, finding the right treatment regime for 
each patient remains a challenge. Therefore, great effort is put into finding targeted 
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 3 
therapies pinpointing the molecular alterations discriminating different subtypes of breast 
cancer.  
 
2.2 Classification of breast tumors 
Breast cancer is a heterogeneous disease, which can be classified based on the expression 
of the hormone receptors (HR) estrogen receptor (ER) and progesterone receptor (PR), the 
expression of the epidermal growth factor receptor 2 (ERBB2 or HER2), response to 
therapy, and outcome (Perou, Sorlie et al. 2000, Sorlie, Perou et al. 2001, Cancer Genome 
Atlas 2012). Genome wide gene-expression based profiling revealed the existence of six 
subtypes of breast cancer (Perou, Sorlie et al. 2000, Sorlie, Perou et al. 2001, Carey, Perou 
et al. 2006, Prat, Parker et al. 2010). Based on aggressiveness, invasive potential and 
available therapies, each of these subtypes is associated with a different prognosis. 
Generally women with hormone receptor positive breast cancer have a better prognosis 
than those with hormone receptor negative disease (Cordera and Jordan 2006). Basal-like, 
claudin-low and HER2-positive (before the introduction of trastuzumab) breast cancers are 
associated with the worst outcome (Perou, Sorlie et al. 2000, Sorlie, Perou et al. 2001, 
Carey, Perou et al. 2006, Prat, Parker et al. 2010).  
2.2.1 Luminal A and Luminal B breast cancers 
Luminal tumors are the largest group comprising ~60% of all breast cancer cases. These 
tumors are characterized by the expression of ER and a subpopulation expresses PR in 
addition. While luminal A tumors generally co-express ER and PR, only a subset of 
luminal B tumors have been shown to express PR (Sims, Howell et al. 2007). This means 
that luminal tumors are hormone dependent and their growth can be inhibited by endocrine 
therapy blocking the effects of estrogen. Patients with luminal A breast cancer are more 
responsive to hormone therapy and have a better overall survival than patients suffering 
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from luminal B breast cancer (Vargo-Gogola and Rosen 2007). For over 35 years, the ER 
antagonist tamoxifen that blocks the binding of estrogen to its receptor has been the 
standard treatment for HR-positive breast cancers. (Johnston and Dowsett 2003). 
Tamoxifen is a prodrug that is metabolized to 4-hydroxytamoxifen in the liver, which acts 
as an ER antagonist outcompeting estrogen to bind to the ER, therefore inhibiting the 
transcription of estrogen-dependent genes (Desta, Ward et al. 2004). More recently, the 
use of inhibitors that block estrogen synthesis, such as aromatase inhibitors, has been 
promoted. Aromatase inhibitors are recommended for post-menopausal women with 
ER-positive disease, either as initial therapy or as sequential therapy following 2-3 years of 
tamoxifen treatment. Both treatment regimes are equally effective and superior to 
tamoxifen alone (Johnston 2010). For pre-menopausal women tamoxifen remains the first 
line of treatment (Rao and Cobleigh 2012). Unfortunately, de novo or acquired endocrine 
resistance is a common problem encountered during the treatment. Resistance mechanisms 
are mediated by changes in ER signaling such as loss or decreased expression and 
crosstalk between ER and receptor tyrosine kinases (RTKs). Examples include the 
upregulation of the HER2, epidermal growth factor receptor (EGFR) or insulin-like growth 
factor I (IGF-I) receptor and pathways downstream of these RTKs such as the 
phosphoinositol-3-kinase (PI3K) pathway (Arpino, Wiechmann et al. 2008, Musgrove and 
Sutherland 2009, Aguilar, Sole et al. 2010). Downstream effectors of these pathways can 
trigger the transcription of ER-dependent genes in absence of the ligand, thus interfering 
with estrogen (by aromatase inhibitors and trastuzumab) is no longer effective (Fedele, 
Calvani et al. 2012). A second-line treatment for postmenopausal women who have 
progressed after initial endocrine therapy is fulvestrant, which works by degrading the ER 
(Croxtall and McKeage 2011). 
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2.2.2 HER2-positive breast cancer 
In 20% of breast cancers, the epidermal growth factor receptor 2 (ERBB2 or HER2) is 
amplified (Hynes and MacDonald 2009). HER2-amplified breast cancer is one of the more 
aggressive subtypes, however the development of targeted therapies improved the 
prognosis for this group of patients tremendously (Slamon, Clark et al. 1987, Slamon, 
Leyland-Jones et al. 2001). The current first-line treatment of HER2-positive breast cancer 
is the humanized monoclonal antibody trastuzumab (Herceptin) that is directed against the 
extracellular domain of HER2, in combination with chemotherapy (Baselga, Perez et al. 
2006). This combination prolongs disease free survival and shows improved outcome for 
many patients with early HER2-positive breast cancer (Romond, Perez et al. 2005). 
However, because 70% of HER2-positive breast cancers show intrinsic or acquired 
resistance to trastuzumab treatment, alternative therapies either as monotherapies or in 
combination with trastuzumab are being explored (Arribas, Baselga et al. 2011, Wong and 
Lee 2012). These include but are not limited to the tyrosine kinase inhibitors (TKIs) 
lapatinib, neratinib, and afatinib, trastuzumab-DM1 (trastuzumab emtansine), heat shock 
protein 90 (HSP90) inhibitors, and the dimerization inhibitor pertuzumab (Capelan, 
Pugliano et al. 2013). Currently trastuzumab, lapatinib, trastuzumab-DM1, and 
pertuzumab are approved for metastatic HER2-positive breast cancer. 
Lapatinib is a small molecule reversible TKI targeting EGFR and HER2. Unlike 
lapatinib, neratinib and afatinib are irreversible TKIs. Afatinib targets the same receptors 
as lapatinib, whereas neratinib is a pan-HER inhibitor used in patients with advanced 
breast cancer (Burstein, Sun et al. 2010, Wong and Lee 2012). Trastuzumab-DM1 is a 
recently FDA approved antibody–drug conjugate, consisting of the antibody trastuzumab 
and the microtubule inhibitor DM1. Being linked to the anti-HER2 antibody targets the 
cytotoxic drug to HER2-overexpressing cells and thus reduces side effects (Peddi and 
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Hurvitz 2013). The chaperone protein HSP90 assists in stabilizing and folding of many 
oncoproteins including HER2. Several HSP90 inhibitors are currently in clinical trials in 
combination with trastuzumab (Wong and Lee 2012). Another treatment option, which has 
been recently approved by the FDA, is the humanized monoclonal antibody pertuzumab. 
This antibody targets the extracellular dimerization domain of HER2, thereby blocking the 
heterodimerization of HER2 and HER3, which is a critical step in HER2 activation 
(Arpino, Gutierrez et al. 2007, Capelan, Pugliano et al. 2013). 
2.2.3 Triple-negative breast cancer 
The third group, representing 10-20% of all breast cancer cases, is triple-negative breast 
cancer (TNBC) (Morris, Naidu et al. 2007, Cancer Genome Atlas 2012). TBNCs do not 
express ER, PR or HER2 and include the basal-like and the claudin-low subtypes (Perou 
2011). Basal-like breast cancers got their name as they have a genetic profile similar to 
basal/myoepithelial cells in the normal breast (Perou, Sorlie et al. 2000). Molecular 
hallmarks of this tumor subtype include the expression of the basal cytokeratins 5/6, 14, 
and 17 (Elsawaf and Sinn 2011). Claudin-low tumors on the other hand, frequently show 
immune cell infiltration, stem cell and Epithelial-Mesenchymal Transition (EMT) 
characteristics. The EMT features include a low expression of cell-cell junction proteins 
such as E-cadherin and claudin 3, 4, and 7 (Perou 2010). The majority of TNBCs do not 
respond to endocrine or anti-HER2 therapies, leaving chemotherapy as the only treatment 
option besides surgery. To date, no targeted therapies are available for this subtype 
(Crown, O'Shaughnessy et al. 2012). Less than 30% of women diagnosed with metastatic 
TNBC will survive 5 years and the majority of the patients finally succumb to their disease 
(Dent, Trudeau et al. 2007). Generally initial response rates to chemotherapy are good and 
patients achieving a complete response to therapy have survival rates similar to other 
breast cancer subtypes (Carey, Dees et al. 2007). Unfortunately, complete response is 
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seldom achieved due to the high metastatic potential, leading to poorer overall survival 
prognoses of TNBC patients compared to patients with other breast cancer subtypes 
(Crown, O'Shaughnessy et al. 2012). 
There is an urgent need for new therapies to treat TBNC and numerous clinical 
studies are ongoing. Targets under investigation include proteins overexpressed in TNBC 
such as EGFR, c-kit or cytokeratins 5/6, 14, and 17. Anti-angiogenic therapies, such as the 
anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab and the 
anti-VEGFR tyrosine kinase inhibitors sunitinib and sorafenib are being investigated 
(Crown, O'Shaughnessy et al. 2012). Other possibilities currently tested include poly 
(ADP-ribose) polymerase (PARP) inhibitors such as olaparib (Tutt, Robson et al. 2010) 
and agents targeting mTOR and Src (Finn, Dering et al. 2007). Claudin-low breast tumors 
were shown to have stem cell characteristics (Creighton, Li et al. 2009). Therefore, agents 
targeting breast cancer stem cells are under investigation in connection with claudin-low 
breast cancers (Perou 2011). 
 
2.3 The breast cancer stem cell model 
According to the cancer stem cell (CSC) hypothesis, tumors are composed of 
hierarchically organized malignant cells (Sottoriva, Vermeulen et al. 2011). At the top of 
this hierarchy are the CSCs, also called cancer stem-like cells or tumor initiating cells 
(TICs), which drive and sustain the proliferation of the tumor. CSC are operationally 
defined as cells that form tumors after transplantation into immunodeficient mice giving 
rise to CSCs and non-stem cancer cells (NSCC) and thus recapitulating the heterogeneity 
of the tumor (Clarke, Dick et al. 2006). Others have suggested additional properties for 
these cells such as: metastatic potential, prolonged periods of dormancy, and resistance to 
radiotherapy and chemotherapy (Clevers 2011). 
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The hierarchical organization of tumors was noticed several decades ago, when the 
presence of TICs was assessed by a series of transplantation experiments (Clevers 2011). 
In 1937, Furth and Kahn showed that a single leukemic cell was sufficient to initiate 
leukemia when transplanted into a recipient mouse and subsequent studies estimated CSC 
frequencies in leukemia and solid tumors in the range of 1:1,000 to 1:10,000,000 (Clevers 
2011). Pierce and colleagues showed that single teratocarcinoma cells were capable to 
differentiate into multiple non tumorigenic cell types (Kleinsmith and Pierce 1964, Pierce 
and Wallace 1971). Based on his observations, Pierce described the CSCs concept in 1988 
as “a concept of neoplasms, based upon developmental and oncological principles, states 
that carcinomas are caricatures of tissue renewal, in that they are composed of a mixture of 
malignant stem cells, which have a marked capacity for proliferation and a limited 
capacity for differentiation under normal homeostatic conditions, and of the differentiated, 
possibly benign, progeny of these malignant cells” (Pierce and Speers 1988, Clevers 
2011). In the 1990s the CSC theory received new attention and grew into a field of 
intensive research. In 1995, Dick and colleagues identified CSCs in acute myeloid 
leukemia (AML) using newly developed Fluorescent-activated cell sorting (FACS) 
techniques based on the expression of specific surface markers in different cell 
compartments (Bonnet and Dick 1997). In 2003, Al-Hajj and colleagues validated the CSC 
hypothesis in some breast cancers. In a xenografts assay they showed that 100 
CD44high/CD24low cells were sufficient to form a tumor, containing both, CSCs and 
NSCCs, when transplanted into immunodeficient recipient mice. Other subpopulations 
failed to engraft even at much higher numbers (Al-Hajj, Wicha et al. 2003). Similar studies 
confirmed the CSC hypothesis in samples from other solid cancers such as brain (Singh, 
Hawkins et al. 2004), pancreas (Li, Heidt et al. 2007), colon (O'Brien, Pollett et al. 2007, 
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Ricci-Vitiani, Lombardi et al. 2007), liver (Yang, Ho et al. 2008), and melanoma 
(Schatton, Murphy et al. 2008). 
CSCs are believed to play a crucial role in relapse after initial successful treatment 
(Lawson, Blatch et al. 2009). Conventional chemotherapy and radiotherapy are tailored to 
target the bulk of the tumor cells but are not effective in depleting quiescent CSCs. While 
the overall tumor size decreases, a small amount of CSCs may remain or disseminate to 
distant organs resulting in local relapse or distant metastases later on (Aguirre-Ghiso 
2007). This was demonstrated in patients receiving neoadjuvant chemotherapy. Paired 
samples were evaluated for their percentage of CD44high/CD24low cells, before and after 
the treatment, and chemotherapy was found to increase the fraction of CD44high/CD24low 
cells (Li, Lewis et al. 2008). Therefore their intrinsic properties enable CSCs to escape 
current treatments and seed metastases (Li, Tiede et al. 2007, Li, Lewis et al. 2008, 
Charafe-Jauffret, Ginestier et al. 2009, Morrison, Schleicher et al. 2011). Ongoing research 
seeks to identify targets to develop therapies to deplete CSCs, rather than the bulk of the 
tumor cells. However, a more profound knowledge about the characteristics of CSCs is 
required. The development of more specific CSC markers is essential, and the stability of 
the CSC phenotype needs to be addressed, as studies have shown plasticity between the 
CSC and NSCC state suggesting a dynamic equilibrium (Clevers 2011, Vermeulen, de 
Sousa e Melo et al. 2012). Meyer and colleagues showed that the breast CSC markers 
CD44high/CD24low are under dynamic regulation by demonstrating that non-invasive, 
epithelial-like CD44high/CD24high cells gave rise to invasive, mesenchymal 
CD44high/CD24low progeny in vitro and in vivo (Meyer, Fleming et al. 2009). Iliopoulos 
and colleagues proposed a dynamic equilibrium between the CSC and the NSCC state 
mediated by interleukin 6 (Iliopoulos, Hirsch et al. 2011). Considering this plasticity of the 
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CSC state, it seems that the combination of therapies targeting CSCs and NSCCs will most 
likely be needed to cure cancer.  
 
2.4 Breast cancer progression  
Breast cancer arises from the epithelial cells of the mammary gland. The classical linear 
progression model suggests that breast cancer initiates as flat epithelial atypia (FEA) or 
hyperplasia, progresses to atypical ductal hyperplasia (ADH), evolves into ductal 
carcinoma in situ (DCIS), and culminates in the potentially lethal stage of invasive ductal 
carcinoma (IDC) (Figure 1). The final, and usually fatal step of breast cancer progression 
is metastatic spread to distant organs such as lung, bone, liver, and brain (Eckhardt, 
Francis et al. 2012).  
 In contrast, Klein and colleagues have proposed a parallel progression model. 
According to this model, metastatic cells can quit the primary tumor site as early as DCIS. 
Tumor cells leave the tumor before acquiring a fully malignant phenotype to then undergo 
rounds of selection and mutation at the distant sites (Klein 2009). Klein`s laboratory has 
found disseminated breast cancer cells which were detected in the bone marrow of 
patients, to be in a much less progressed genetic state than predicted by the linear 
progression model, which states that only fully transformed cells quit the primary tumor. 
These findings suggested, that early disseminated tumor cells might acquire the mutations 
needed for metastatic behavior at a later stage (Schmidt-Kittler, Ragg et al. 2003). They 
further showed in mouse models and in samples from breast cancer patients with DCIS, 
that disseminated tumor cells in bone and micrometastases could originate from the time of 
first epithelial alterations at the primary tumor site (Husemann, Geigl et al. 2008). Due to 
this progression at the distant metastatic site, the parallel progression model suggests a 
greater difference between the primary tumor and the distant metastases (Klein 2009). 
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Because early disseminated tumor cells are not fully transformed, they often only grow out 
years, or even decades, after dissemination (Aguirre-Ghiso 2007).  
 
 
 
Figure 1. Breast cancer linear progression model 
Schematic of the breast cancer progression steps according to the linear progression model. 
Breast cancer arises from the epithelial cells of the mammary gland as flat epithelial atypia 
or hyperplasia, which is a benign proliferative breast condition. It can progress into 
atypical ductal hyperplasia, where the proliferating cells look abnormal, and evolve into 
ductal carcinoma in situ, a non-invasive stage, in which the duct is filled with cancerous 
cells remaining inside the duct. The last and potentially lethal step of the metastatic 
cascade is the progression into invasive ductal carcinoma, in which the cancer cells spread 
from the duct to surrounding tissue, to seed and colonize at distant sites. 
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2.5 EMT during cancer progression and metastasis 
As described above, the final and often fatal step in the progression of breast cancer is the 
formation of distant metastases. Approximately 90% of all cancer related deaths are caused 
by metastatic dissemination to distant organs (Christofori 2006). Metastases formation is a 
multistep progress. First, metastatic tumor cells have to acquire the ability to emigrate 
from the primary tumor. To detach from the tumor mass, metastatic cells must lose their 
cell-cell junctions and become motile. To leave the primary tumor site, the cells must not 
only be motile, but also have to acquire invasive potential to degrade the surrounding 
extracellular matrix (ECM), basement membrane, and endothelial barrier to intravasate 
into the lymphatic vessels or bloodstream. This population of cells further needs to be 
capable to survive in the bloodstream. After traveling through the lymphatic or vascular 
system to a distant site, the cells require adhesion potential to attach to the endothelium. 
Finally, metastatic cells need the potential to extravasate through the vessel basement 
membrane to form micrometastases at the distant site (Friedl and Gilmour 2009) (Figure 
2). 
 
 
Figure 2. Schematic of the metastatic cascade 
Metastasis is a multistep progress. 1) Cells in the primary tumor undergo Epithelial-
Mesenchymal Transition (EMT), acquire invasive potential, and degrade the basement 
membrane. 2) Invasive tumor cells intravasate into the bloodstream either via the 
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lymphatic system or directly. 3) Metastatic cells are transported through the circulation to 
distant sites. 4) Circulating tumor cells attach to the endothelial membrane or are arrested 
in small capillaries and extravasate. 5) Extravasated tumor cells can stay dormant for years 
or 6) undergo Mesenchymal-Epithelial Transition (MET) and micrometastases can 
progress into macrometastases at the distant site. 
 
 
The currently accepted theory of how initially quiescent tumor cells acquire 
motility and metastatic potential is Epithelial-Mesenchymal Transition (EMT). First 
described in 1982 in three-dimensional cultures of corneal epithelial cells by Hay and 
colleagues (Hay 1982), EMT has gradually become better characterized. EMT can be 
grouped into 3 classes, depending on the context in which it appears (Kalluri 2009). 
Type 1 EMT and its reverse process Mesenchymal-Epithelial Transition (MET), have been 
well described in mammalian embryogenesis where the development of many organs 
depends on the switch between epithelial and mesenchymal cell fates (Micalizzi, 
Farabaugh et al. 2010). Type 2 EMT have been shown to play a role in tissue regeneration, 
wound healing, and fibrosis and are associated with inflammation (Kalluri 2009). More 
recently, the same cellular program, termed type 3 EMT, was implicated in cancer 
progression and metastasis formation (Lopez-Novoa and Nieto 2009). The exact molecular 
mechanism underlying the switch of epithelial tumor cells to an invasive phenotype, has 
been and still is subject of many studies. Type 3 EMT has emerged as the primary theory 
of how tumor cells acquire the attributes necessary to metastasize (Thiery 2002). 
The progression from polarized epithelial tumor cells to invasive carcinoma 
requires several steps (Kalluri 2009, Yilmaz and Christofori 2009). The first step of the 
EMT process in cancer progression is the loss of apico-basal polarity and tight junctions. 
Next, cell-cell junctions including adherens and gap junctions begin to disassemble and the 
underlying basement membrane is degraded (Peinado, Portillo et al. 2004). A molecular 
hallmark of EMT is the downregulation of cell-cell adhesion molecules and epithelial 
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markers such as E-cadherin, claudins and cytokeratins (Kalluri 2009). A downregulation of 
E-cadherin expression followed by an upregulation of N-cadherin has been proposed to be 
responsible for breast cancer cell invasion (Sommers, Thompson et al. 1991, Sommers, 
Gelmann et al. 1994). However, not all breast cancer cell lines express E-cadherin and/or 
N-cadherin and it has been shown that N-cadherin leads to cell motility and an invasive 
phenotype regardless of the E-cadherin expression level (Nieman, Kim et al. 1999, 
Nieman, Prudoff et al. 1999). Besides changes in the cadherin expression levels, 
cytoskeletal elements are reorganized during EMT. The peripheral actin cytoskeleton is 
replaced by stress fibers and the intermediate filaments are replaced by vimentin. 
Phenotypically, these changes alter the cell morphology from cuboidal cobblestone 
appearance to spindle shaped. The cells become invasive, motile, and resistant to anoikis 
and begin to respond to extracellular stimuli, directing the migrating cells (Micalizzi, 
Farabaugh et al. 2010) (Figure 3). 
 
 
Figure 3. Diagram of molecular and phenotypic transitions of cells undergoing EMT 
During the process of EMT, epithelial cells lose their cell-cell junctions and polarity which 
is accompanied by a change of morphology from cobblestone like to the elongated, motile, 
and invasive phenotype of mesenchymal cells (Chaffer, Thompson et al. 2007). 
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2.6 Cell migration 
The understanding of the mechanisms underlying the regulation of cell migration 
multiplied over the last two decades (Huttenlocher and Horwitz 2011). Significant 
advances have been made in the involvement of the actin cytoskeleton and its fine 
regulation in the maintenance of cellular integrity and the dynamic responses that drive 
cell migration (Vicente-Manzanares, Webb et al. 2005). 
Cell migration over a substrate has been described as the succession of protrusion 
at the leading edge and stabilization by the formation of new adhesions, followed by the 
release of adhesions at the rear of the cell, detachment and translocation (Abercrombie, 
Heaysman et al. 1971, Huttenlocher and Horwitz 2011) (Figure 4). The first step in the 
sequence, protrusion, is driven by actin polymerization at the leading edge of the cell 
(Pollard and Borisy 2003). Two morphological structures, lamellipodia and filopodia, 
which are comprised of different F-actin networks and dynamics are the basic units of cell 
migration (Svitkina, Verkhovsky et al. 1996). Protrusion is followed by retraction of the 
trailing edge and finally the cell translocates to a new position. 
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Figure 4. Model of cell migration 
Cell migration consists of the 
following successive steps: 
 
1. Protrusion 
Extracellular stimuli induce de novo 
actin polymerization at the leading 
edge resulting in the formation of F-
actin based membrane protrusions 
such as lamellipodia and filopodia. 
 
2. Adhesion 
Stabilization of protrusions at the 
leading edge by formation of new 
adhesions. 
 
3. Retraction 
Stress fibers and adhesive structures at 
the trailing edge are broken down. 
 
4. Translocation 
As a result, the cell moves to a new 
position. 
 
Integrins are the best described transmembrane receptors mediating interactions 
between the ECM and the actin cytoskeleton during cell motility (Hynes 2002, 
Huttenlocher and Horwitz 2011). Integrins are non-covalently linked heterodimers, 
composed of one of 18 different α chains and one of 8 different ȕ subunits in humans. 
Both subunits have a large extracellular domain binding to the ECM and a short 
cytoplasmic tail linking the cytoskeleton (Hynes 2002). The binding specificity is 
determined by the extracellular domain, which specifically recognizes matrix ligands. The 
α1ȕ1 and αβȕ1 integrins bind collagen, while α4ȕ1, α5ȕ1, and αvȕγ integrins are major 
fibronectin receptors and integrins αγȕ1 and α6ȕ1 are receptors for laminins (Hood and 
Cheresh 2002, Hynes 2002). Changes in integrin subtype expression have been correlated 
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with changes in migration and invasion (Huttenlocher and Horwitz 2011). Integrin 
expression has further been shown to be predictive for the outcome of breast cancer (dos 
Santos, Zanetti et al. 2012). Specifically, the integrins α6ȕ4 and αvȕγ have been linked to 
increased tumor metastases formation and decreased survival in breast cancer 
(Desgrosellier and Cheresh 2010). Highly migratory and invasive cells form specialized 
types of integrin-mediated adhesions, called podosomes or invadopodia (in invasive cells) 
(Weaver 2006). Both, podosomes and invadopodia are actin rich protrusions capable of 
matrix degradation and invadopodia are a hallmark of metastatic cancer cells (Weaver 
2006, Huttenlocher and Horwitz 2011). In breast cancer cell lines, the presence of 
invadopodia has been linked to their metastatic potential (Yamaguchi, Lorenz et al. 2005, 
Yamaguchi, Takeo et al. 2009). In addition, invadopodia-like structures have been 
observed in vivo by intravital imaging (Yamaguchi, Wyckoff et al. 2005, Sidani, Wyckoff 
et al. 2006). For cell migration, the dynamic formation and turnover of integrin-mediated 
adhesions, and the polarized assembly and disassembly of focal adhesions are crucial for 
optimum cell speed and directional persistence (Huttenlocher and Horwitz 2011).  
Focal adhesions, connecting the cytoskeleton to the ECM, are the best described 
cell-matrix adhesions. They consist of clusters of integrin receptors associated with large 
complexes of signaling and structural proteins linked to the actin cytoskeleton (Burridge 
and Chrzanowska-Wodnicka 1996, Yamada and Geiger 1997). The turnover of focal 
adhesions is regulated by focal adhesion kinase (FAK) and Src family kinases (SFKs). 
FAK deficient fibroblasts or cancer cells exhibit reduced migration rates and form 
increased numbers of large adhesions with an impaired turnover (Ilic, Furuta et al. 1995, 
Sieg, Hauck et al. 2000, Hsia, Mitra et al. 2003). Likewise, fibroblasts from mice lacking 
c-Src, Fyn, and Yes, or expressed a kinase-dead c-Src mutant, also showed impaired 
migration and large peripheral adhesions with reduced turnover (Fincham and Frame 1998, 
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Klinghoffer, Sachsenmaier et al. 1999). In addition to SFKs and FAK, the phosphatase 
SHP2 has also been implicated in cell migration. SHP2-deficient fibroblasts showed 
impaired migration and large peripheral adhesions, resembling the phenotype of FAK and 
Src deficient cells (Yu, Qu et al. 1998). 
 In conclusion, these studies show that dynamic cycles of phosphorylation and 
dephosphorylation at adhesion sites are fundamental for adhesion turnover and migration 
(Huttenlocher and Horwitz 2011). Both, tyrosine kinases and phosphatases play important 
roles in the regulation of cell migration. Cancer cell migration is the first step in the 
progression of the primary tumor towards metastatic spread (Etienne-Manneville 2008). It 
is therefore crucial to better understand the roles of kinases and phosphatases in this early 
step, to interfere with the cancer progression to the potentially lethal metastatic state. 
 
2.7 Cell signaling in cancer: Kinases & Phosphatases 
Many important signaling pathways in eukaryotic cells rely on reversible phosphorylation 
of tyrosine residues on proteins. Abnormal tyrosine phosphorylation is linked to the 
pathogenesis of a multitude of human diseases including cancer (Hunter 2009, Pawson and 
Kofler 2009). Although phosphotyrosines account only for 0.05-1.5% of a cells total 
phosphoamino acid content depending on the cell type, tyrosine phosphorylation plays an 
important role in cell signaling (Cooper and Hunter 1981, Frank and Sartorelli 1986, 
Conrads and Veenstra 2005). Phosphorylation at this residue can alter target proteins by 
inducing conformational changes that influence protein activity, by creating docking sites 
for other proteins therefore enabling protein complex formation, or by influencing the 
subcellular localization (Stoker 2005). This enzymatic reaction is controlled by protein 
tyrosine kinases (PTKs) that add phosphate groups to their substrates and protein tyrosine 
phosphatases (PTPs) that remove them (Tonks 2006). While the role of protein tyrosine 
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kinases in cancer pathogenesis has been thoroughly studied over the past 30 years 
providing a wealth of knowledge (Hunter 2009), the role of PTPs in the development of 
cancer is less well defined (Ostman, Hellberg et al. 2006). Initially, PTPs were thought to 
only play a signal attenuating role, but further research provided evidence that PTPs can 
act as positive signal transducers (signal enhancing) (Alonso, Sasin et al. 2004, Tonks 
2006). They can, for example, activate PTKs by dephosphorylation of inhibitory sites or 
prolong activation signals (Scott, Lawrence et al. 2010).  
 
2.8 Protein tyrosine phosphatases 
PTPs are a large family of related enzymes. They are divided into two families: Classical 
PTPs that dephosphorylate only tyrosine (Tyr) residues, whereas dual-specificity 
phosphatases can dephosphorylate serine (Ser), threonine (Thr) or Tyr residues (Tonks 
2006). The classical PTP family contains 37 different PTPs in the human genome, which 
are grouped into receptor-like PTPs and non-transmembrane or intracellular PTPs 
(Andersen, Mortensen et al. 2001) (Figure 5). 
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Figure 5. Schematic overview of the classical PTP family 
The family consists of 37 human members divided into receptor-like PTPs and non-
transmembrane PTPs. The receptor-like PTPs contain an intracellular PTP domain, 
consisting of the catalytic-site motif HC(X)5R, a transmembrane domain and different 
types of extracellular domains responsible for cell-cell, cell-matrix or cell-ligand 
interactions (Freiss and Vignon 2004). The intracellular PTPs are more diverse in their 
structure. They contain a PTP domain with the catalytic-site motif and several other types 
of domains including SH2, FERM, and PEST like domains that target them to specific 
cellular locations or enable binding to specific adapter proteins (Tonks 2006).  
 
 
 
All members of the PTP family follow the same catalytic mechanism to 
dephosphorylate their respective substrates. They catalyze the hydrolysis of a phosphoester 
bond via a phosphate-cysteine intermediate requiring the catalytic cysteine (Cys) residue. 
Therefore, the phosphatase activity depends on the catalytic cysteine (Cys459 in SHP2) 
located in the PTP signature motif, which sits at the base of the catalytic cleft and is crucial 
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for the substrate recognition (Andersen, Mortensen et al. 2001, Tiganis and Bennett 2007). 
In SHP2, the catalytic cleft is located at the base of the phosphate-binding loop (P-loop) 
that extends to a depth of up to 9 Å from the molecular surface (Hof, Pluskey et al. 1998). 
This depth determines the specificity for pTyr-containing peptides and prevents binding of 
shorter pSer and pThr side chains (Jia, Barford et al. 1995). The P-loop is composed of 
mainchain amide groups and the sidechain of an arginine (Arg) residue (Arg465 in SHP2) 
(Hof, Pluskey et al. 1998). During the two step catalysis, the catalytic Cys459 acts as a 
nucleophile to attack the phosphate of the phosphotyrosyl substrate (Barford, Flint et al. 
1994, Jia, Barford et al. 1995). First, the sulfur atom of the thiolate ion of Cys459 attacks 
the phosphorous atom of the phosphate group of the substrate. The P-O linking the 
phosphate group to the Tyr is protonated by a conserved aspartic acid residue (Asp425 in 
SHP2). This Asp425 resides in the WPD-loop and is brought in close proximity by a 
conformational change of the protein upon substrate binding. In the second step, the 
phosphate-cysteine intermediate is hydrolyzed by a water molecule and Asp425 (now 
functioning as a general base) resulting in the release of the phosphate (Hof, Pluskey et al. 
1998, Tonks 2006, Tautz and Mustelin 2007) (Figure 6). 
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Figure 6. Catalytic mechanism of cysteine-based protein tyrosine phosphatases 
The catalytic cysteine (Cys) is part of the PTP signature motif HC(X)5R located in the 
phosphate-binding loop (P-loop). The catalytic cysteine (Cys459 in SHP2) acts as a 
nucleophile to attack the phosphate on the substrate and is needed to catalyze the 
hydrolysis of the phosphoester bond via a phosphate-cysteine intermediate. A conserved 
invariant aspartic acid (Asp425 in SHP2), located in the WPD-loop, functions as the 
general acid/base during hydrolysis (Tautz and Mustelin 2007). 
 
 
 
 Flint and colleagues demonstrated that the mutation of amino acids playing a 
crucial role in the catalytic process (Cys and Asp) can generate PTP substrate-trapping 
mutants. These substrate-trapping mutant PTPs allow isolation of a PTP in complex with 
their trapped substrates (Flint, Tiganis et al. 1997). It was shown by several groups that 
PTP trapping-mutants can be obtained by exchanging the Asp residue in the conserved 
WPD-loop by alanine (Ala) in PTP1B, TC-PTP, and PTP-PEST (Garton, Flint et al. 1996, 
Flint, Tiganis et al. 1997, Tiganis, Bennett et al. 1998). It was further shown that alteration 
of the nucleophilic Cys at the catalytic site to Ser or Ala, results in a trapping mutant for 
some PTPs with varying efficiency (Zhang, Wang et al. 1994, Zhou, Denu et al. 1994, Jia, 
Barford et al. 1995). This demonstrates that not all mutations work equally well in 
different PTPs. The Agazie lab developed a SHP2 double trapping mutant by changing 
Cys459 to Ser and Asp425 to Ala. The trapping efficiency of this double mutant was found 
to be higher than the trapping efficiency of a single Cys459 to Ser mutant. They observed 
no trapping effect in the Asp425 to Ala single mutant in SHP2 (Agazie and Hayman 
2003). 
 
2.9 The proto-oncogenic phosphatase SHP2 
Mammalian Src homology 2 domain containing phosphatase 2 (SHP2) is also known as 
Syp, SH-PTP2, SH-PTP3, PTP1D or PTP2C and was identified by several groups in the 
early 1990s (Adachi, Sekiya et al. 1992, Freeman, Plutzky et al. 1992, Ahmad, Banville et 
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al. 1993, Feng, Hui et al. 1993, Vogel, Lammers et al. 1993). SHP2 is a member of the Src 
homology 2 (SH2) domain containing phosphatase family consisting of two human 
members: Src homology 2 domain containing phosphatase 1 (SHP1) encoded by the 
PTPN6 gene and SHP2 encoded by PTPN11 (Chan, Kalaitzidis et al. 2008). As indicated 
by their name, these PTPs contain two SH2 domains at their N-terminus and a phosphatase 
domain at the C-terminus. SHP2 is ubiquitously expressed, whereas the expression of 
SHP1 is primarily restricted to hematopoietic cells (Feng and Pawson 1994). Upon growth 
factor or cytokine stimulation, SHP2 was shown to bind a variety of receptor tyrosine 
kinases (Feng, Hui et al. 1993, Lechleider, Freeman et al. 1993, Vogel, Lammers et al. 
1993). SHP2 transduces mitogenic, pro-survival, cell fate and/or pro-migratory signals 
downstream of many cytokine, growth factor, and extracellular matrix receptors. Further, 
SHP2 is involved in positive regulation of the mitogen-activated protein kinase 
(MAPK)/extracellular signal-related kinase (ERK) pathway in response to most growth 
factors and cytokines (Bennett, Hausdorff et al. 1996, O'Reilly and Neel 1998). The 
regulation of other pathways is cell specific, receptor specific or both. Examples are the 
Janus kinase (Jak)-signal transducer and activator of transcription protein (STAT) and the 
PI3K pathways (Shi, Yu et al. 2000, Ostman, Hellberg et al. 2006, Chan, Kalaitzidis et al. 
2008). Another role of SHP2 was found in cell spreading and cell migration (Yu, Qu et al. 
1998, Manes, Mira et al. 1999, Oh, Gu et al. 1999). 
 Depending on the cellular localization, additional functions of SHP2 have been 
reported. At first, SHP2 was identified as an only cytoplasmic phosphatase. This finding 
was not questioned for several years, presumably because all functions discovered were 
linked with tyrosine dephosphorylation of membrane-associated proteins. In 2001, Craggs 
and Kellie showed that SHP1 was localized in the nucleus of non-hematopoietic cells, 
which was until then also believed to be solely cytoplasmic. They investigated the 
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subcellular localization of GFP-tagged SHP1 and SHP2 in human embryonic kidney 
(HEK) 293 cells and found SHP1 localized in the nucleus whereas SHP2 was 
predominantly seen in the cytoplasm. They found a cluster of the three basic amino acids 
Lysine (Lys)-Arg-Lys at the far end of the C-terminal domain of SHP1 which resembled 
half of a bipartite nuclear localization signal (NLS). This motif was not conserved in the 
SHP2 sequence (Craggs and Kellie 2001).  
Proteins above 40 kDa generally require a NLS to be translocated into the nucleus. 
To date, no mechanism of nuclear import of the 72 kDa SHP2 protein has been reported. 
However, over the last years evidence has mounted, that SHP2 is found in other cellular 
locations than the cytoplasm. It has been found in the nucleus (Chughtai, Schimchowitsch 
et al. 2002, Wu, Hong et al. 2002, Jakob, Schroeder et al. 2008) and in the mitochondria 
(Salvi, Stringaro et al. 2004). 
2.9.1 Structure and activation of SHP2 
SHP2 contains two Src homology 2 (SH2) domains (N-SH2 and C-SH2), a PTP domain, 
and a C-terminal region which consists of a proline-rich motif and two tyrosyl 
phosphorylation sites (Tyr542 and Tyr580) (Chan, Kalaitzidis et al. 2008) (Figure 7). 
 
 
 
 
 
Figure 7. Schematic structure of SHP2 
The phosphatase SHP2 consists of two N-terminal tandem SH2 domains, a catalytic 
phosphatase (PTP) domain, and a proline-rich motif at the C-terminus containing the two 
tyrosine residues Tyr542 (Y542) and Tyr580 (Y580).  
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SHP2 activity is controlled by its structural conformation (Figure 8). In the absence of 
upstream stimulation, the N-SH2 domain interacts with the PTP domain keeping SHP2 in 
an inactive state by autoinhibition (Hof, Pluskey et al. 1998). Upon stimulation by growth 
factors or cytokines, SHP2 is recruited to the membrane and binds to specific tyrosine 
phosphorylated sites on adapter binding proteins such as Growth factor receptor-bound 
protein 2 (GRB2)-associated-binding protein 1 (GAB1) and GRB2-associated-binding 
protein 2 (GAB2) via its SH2 domains. This binding induces a conformational change and 
releases the inhibitory effect between the N-SH2 domain and the PTP domain resulting in 
SHP2 activation (Cunnick, Mei et al. 2001). The PTP domain is now exposed and can 
remove phosphate groups from SHP2 substrates (Chan, Kalaitzidis et al. 2008). 
 
 
 
Figure 8. Mechanism of SHP2 activation 
Schematic showing the mechanism of SHP2 activation. Left: in the basal, inactive state, 
SHP2 is autoinhibited by binding of the N-SH2 domain to the PTP domain. Right: Upon 
stimulation, SHP2 is recruited to the membrane. Binding of the SH2 domains to 
phosphorylated adapter binding proteins induces a conformational change and releases the 
autoinhibition and leading to an increase in enzyme activity. SHP2 is now in the open, 
active conformation and can dephosphorylate its substrates.  
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2.9.2 SHP2 in normal development and disease 
SHP2 is widely expressed in both, embryonic and adult tissues (Neel 1993, Feng and 
Pawson 1994). SHP2 has been shown to be required for early mouse development and 
gastrulation as mice with a homozygous deletion of exon 2 (Arrandale, Gore-Willse et al. 
1996) or exon 3 (Saxton, Henkemeyer et al. 1997, Saxton and Pawson 1999) resulting in a 
truncated SHP2 died in utero at mid-gestation. SHP2 null mice died even earlier at 
peri-implantation (Yang, Klaman et al. 2006). Studies have shown that mutations of SHP2 
can lead to pathological conditions including cancer (Zheng, Alter et al. 2009) (Figure 9). 
Germline missense gain-of-function (GOF) mutations in the PTPN11 gene have 
been identified in ~50% of patients suffering from a developmental disorder called 
Noonan syndrome (NS) (Tartaglia, Mehler et al. 2001). With an estimated incidence rate 
of 1 in 1,000-2,500 live births, NS is a relatively common autosomal dominant 
developmental disorder (van der Burgt 2007). Symptoms include facial anomalies, short 
stature, congenital heart defects, and an increased risk of leukemia (Noonan and O'Connor 
1996). The missense mutations causing NS are mainly found in exon 3 and 8. These 
mutations were found to interrupt the autoinhibition between the N-SH2 and the PTP 
domain and render the enzyme constitutively active (Zheng, Alter et al. 2009). 
Another disease caused by mutations in the PTPN11 gene is LEOPARD syndrome 
(LS) (Digilio, Conti et al. 2002, Legius, Schrander-Stumpel et al. 2002). In 90% of LS 
cases, PTPN11 mutations in exons 7 and 12 corresponding to the PTP domain, have been 
identified (Zheng, Alter et al. 2009). LS shares similar clinical characteristics with NS. 
However, in contrast to NS, it is caused by loss-of-function (LOF) mutations in the PTP 
domain resulting in a dominant negative SHP2 protein that interferes with SHP2 mediated 
signaling. The catalytically defective LS-SHP2 adapts an open conformation and interferes 
with growth factor-induced activation of the ERK pathway (Kontaridis, Swanson et al. 
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2006). The question, how the catalytically impaired LS-SHP2 can result in LS, is still 
under investigation. Recently, Yu and colleagues have shown that LS-SHP2 mutants are 
hypersensitive to growth factors and are able to compensate decreased phosphatase activity 
by longer binding to scaffold proteins and upstream activators to therefore increasing 
substrate turnover (Yu, Wu et al. 2013).  
 
 
 
 
 
Figure 9. SHP2 mutations associated with disease 
Overview of frequent SHP2 mutations leading to disease. Left: In leukemia and Noonan 
syndrome, gain-of-function mutations are located mainly in the N-SH2 domain or in the 
PTP domain. These mutations interfere with the autoinhibition, rendering the phosphatase 
constitutively active, causing increased and sustained activation of downstream pathways. 
Right: LEOPARD syndrome loss-of-function mutations are found only in the PTP domain 
resulting in a catalytically defect SHP2 enzyme. The mutated SHP2 acts as a dominant 
negative and locks the ERK pathway inactive.  
 
2.9.3 SHP2 in cancer 
SHP2 is the first identified bona fide PTP proto-oncogene (Tonks 2006). GOF mutations 
in PTPN11 have been reported in various types of human cancers. These mutations disrupt 
the auto inhibitory binding between the N-SH2 and the PTP domain and render the SHP2 
constitutively active. Somatic missense mutations in PTPN11 have been identified in 
~35% of juvenile myelomonocytic leukemia (JMML) patients. Additional mutations have 
been found in other pediatric leukemias, namely in 10% of childhood myelodysplastic 
syndromes, in ~7% of B-cell precursor acute lymphoblastic leukemia, and in ~4% of cases 
of pediatric and adult acute myelogenous leukemia (AML) (Tartaglia, Niemeyer et al. 
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2003, Loh, Reynolds et al. 2004, Tartaglia, Martinelli et al. 2004). PTPN11 mutations in 
solid tumors have also been reported, however these mutations occur at lower frequency 
than in hematological diseases. Bentires-Alj and colleagues identified mutations in the N-
SH2 domain in cases of lung cancer, colon cancer, and neuroblastoma and mutations in the 
C-SH2 domain of SHP2 were found in melanoma, but no mutations of SHP2 have been 
found in breast cancer to date (Bentires-Alj, Paez et al. 2004). 
 However, there are other mechanisms that result in elevated SHP2 signaling 
besides SHP2 GOF mutations. In solid tumors, the oncogenic potential of SHP2 arises 
mainly from aberrant activation of the phosphatase, which can also be caused by over 
and/or inappropriate expression of SHP2 binding proteins or cytotoxin-associated gene A 
(CagA) in gastric cancer with H. pylori infections. In breast cancer the gene encoding the 
SHP2-activating protein GAB2 was found to be amplified or overexpressed in 10–15% of 
tumors (Bentires-Alj, Gil et al. 2006, Bocanegra, Bergamaschi et al. 2010). SHP2 is also 
implicated in CagA mediated gastric cancer (Hatakeyama 2002, Higashi, Tsutsumi et al. 
2002). CagA is secreted by virulent Helicobacter pylori (H. pylori) strains. SHP2 forms a 
complex with CagA in gastric epithelial cells which leads to oncogenic transformation of 
these cells resulting in the hummingbird phenotype. Disruption of the CagA-SHP2 
complex reverses the CagA dependent morphological changes (Hatakeyama 2002). 
Further, aberrant SHP2 activation can occur downstream of constitutive active forms of 
EGFR and fibroblast growth factor receptor 3 (FGFR3), upon BCR-ABL activation, and 
downstream of active RTKs such as RET and HER2 (Sattler, Mohi et al. 2002, Agazie, 
Movilla et al. 2003, D'Alessio, Califano et al. 2003, Zhan and O'Rourke 2004, Bentires-
Alj, Gil et al. 2006). Zhou and colleagues reported SHP2 to be overexpressed in 72% of 
infiltrating ductal carcinoma (Zhou, Coad et al. 2008). More recently, the Condeelis group 
Introduction 
 
 
 29 
reported overexpression of SHP2 in invasive migratory tumor cells (Patsialou, Wang et al. 
2012). 
 In contrast to this positive signal enhancing oncogenic role, SHP2 has been 
suggested to have a tumor-suppressive function in hepatocellular carcinoma (HCC). Bard-
Chapeau and colleagues showed that hepatocyte-specific deletion of SHP2 led to increased 
inflammatory signaling, regenerative hyperplasia, and tumor formation in aged mice. They 
further showed that SHP2 expression was decreased in a subset of human HCC patient 
samples (Bard-Chapeau, Li et al. 2011). 
 
2.10 The Src family kinase c-Src  
Src is the best characterized member of the largest family of non-receptor protein tyrosine 
kinases, the Src family kinases (SFKs) (Frame 2002). Other SFK members are Fyn, Yes, 
Blk, Yrk, Frk (also known as Rak), Fgr, Hck, Lck, Srm, and Lyn (Summy and Gallick 
2003, Yeatman 2004, Sen and Johnson 2011).  
Src was first discovered in 1911 by Peyton Rous, who described a transmissible 
noncellular transforming agent in chicken sarcomas that could give rise to new sarcomas 
(Rous 1910, Rous 1911). 60 years later, the agent responsible for this transformation 
process was identified as the viral SRC gene (v-SRC) (Martin 1970). Subsequently, it was 
found that normal avian DNA contained a gene that was closely related to v-SRC, termed 
cellular SRC (c-SRC), which was the first human proto-oncogene to be identified (Stehelin, 
Guntaka et al. 1976). In contrast to v-Src, which lacks the C-terminal negative regulatory 
domain and contains 12 substituted C-terminal amino acids along with numerous point 
mutations throughout the molecule allowing for higher levels of activity and greater 
transforming ability, c-Src is poorly transforming (Jove and Hanafusa 1987, Parsons and 
Weber 1989). 
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2.10.1 Structure and activation of c-Src 
The protein c-Src is a 60 kDa nonreceptor kinase consisting of an N-terminal 
myristoylation sequence (M), a unique region, a Src homology 3 (SH3) and a Src 
homology 2 (SH2) protein interaction domain, a kinase domain that contains a conserved 
autophosphorylation site (Tyr419 in humans, Tyr418 in mice, and Tyr416 in chicken), and 
a C-terminal regulatory domain that contains a negative-regulatory tyrosine residue 
(Tyr530 in humans, TyrY529 in mouse, and Tyr527 in chicken) (Figure 10).  
 
 
 
Figure 10. Schematic structure of c-Src 
The kinase c-Src consists of a myristoylation sequence (M) at the N-terminus, a unique 
region, a SH3 and a SH2 protein interaction domain, a kinase domain containing the 
autophosphorylation site Tyr419 (Y419) and a C-terminal regulatory domain containing 
the inhibitory phosphorylation site Tyr530 (Y530). The SH2-linker between the SH2 
domain and the kinase domain contains a proline-rich region that is bound by the SH3 
domain in the closed conformation. 
 
 
 
The N-terminal myristoylation site is important for membrane localization (Pawson 
1995) and is crucial for the transformation of oncogenic Src mutants (Frame 2002). The 
unique domain varies between Src kinase family members. The SH3 domain binds to 
proline-rich regions and the SH2 domain recognizes and binds to tyrosine-phosphorylated 
peptide sequences which determine the substrate specificity of the protein (Songyang, 
Shoelson et al. 1993). The interaction of these SH domains and therefore the activity of the 
Src kinase is dependent on phosphorylation of the autophosphorylation site in the kinase 
domain Tyr419 and the negative regulatory site in the C-terminal regulatory domain 
Tyr530 (Brown and Cooper 1996). 
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In the inactive state, Src kinase is phosphorylated at Tyr530, which is conserved among 
the SFK members. Upon phosphorylation, Tyr530 binds to the SH2 domain leading to a 
closed conformation. In addition, the SH3 domain interacts with a proline-rich region in 
the SH2-linker forming an intramolecular bond further stabilizing the closed conformation 
(Shoji, Kurosawa et al. 1990) (Figure 11). Src is inactive in this closed conformation as 
the substrate binding sites in both, SH2 and SH3 domains are blocked. Dephosphorylation 
of Tyr5γ0 by phosphatases including SHP1, SHPβ, protein tyrosine phosphatase α (PTP 
α), and protein tyrosine phosphatase 1B (PTP1B) breaks the intramolecular bonds, leading 
to an open and active conformation (Zheng, Wang et al. 1992, Bjorge, Pang et al. 2000, 
Jung and Kim 2002). Full Src activation further requires autophosphorylation at the 
activating site Tyr419 (Roskoski 2005). 
 
 
 
Figure 11. Mechanism of c-Src activation 
Schematic of the mechanism of c-Src activation. Left: Inactive Src is kept in a closed 
conformation by two intramolecular interactions. The inhibitory tyrosine Tyr530 (Y530) is 
phosphorylated and binds the SH2 domain and the SH3 domain interacts with a proline-
rich region in the SH2-linker (***). Right: Src is activated either by dephosphorylation of 
Y530 or by interaction of the SH2 and SH3 domains with Src binding partners. This 
results in an open conformation of the kinase, allowing autophosphorylation of Tyr419 
(Y419) leading to full Src kinase activity. Inactive Src is usually located in the cytoplasm, 
whereas activated Src is translocated to the membrane for full activation. The N-terminal 
myristoylation (M) sequence is important for binding to the membrane. 
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Besides phosphorylation, subcellular localization is an important mechanism to regulate 
c-Src activity (Bjorge, Jakymiw et al. 2000). SFKs are present at different subcellular 
locations, but are most abundant in the cytoplasm. For example, Fincham and colleagues 
studied the role of the SH3 domain in the assembly of focal adhesions and found inactive 
Src to be localized in the perinuclear region of the cell. Upon activation, Src was 
transported to the plasma membrane where it is recruited to focal adhesions (Fincham, 
Brunton et al. 2000). Generally, inactive Src phosphorylated at Tyr530, resides in the 
cytoplasm and is translocated to the membrane upon activation, where it is 
autophosphorylated at the activating site Tyr419 further enhancing catalytic activity 
(Cooper and Howell 1993). Localization at the membrane was found to be essential for the 
transforming potential of Src as it brings Src in close proximity of its upstream and 
downstream effectors (Nigg, Sefton et al. 1982, Cowan-Jacob, Fendrich et al. 2005).  
 Elevated c-Src activity can result from activating mutations or gene amplification, 
but generally it results from structural alternations mediated by upstream kinases and 
phosphatases (Sen and Johnson 2011). Src interacting cytoplasmic proteins include focal 
adhesion kinase (FAK) or its molecular partner Crk-associated substrate (CAS), which are 
important for integrin signaling (Burnham, Bruce-Staskal et al. 2000, Xing, Ge et al. 
2000). Growth factor receptors regulating c-Src activity include EGFR, HER2, platelet-
derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and 
vascular endothelial growth factor receptor (VEGFR) (Landgren, Blume-Jensen et al. 
1995, Thomas and Brugge 1997, Tice, Biscardi et al. 1999, Bowman, Broome et al. 2001, 
Chou, Wang et al. 2002).  
Alternatively, Src activation was found to be elevated in some human tumors due 
to a reduced expression of c-Src kinase (Csk), a negative regulator of Src (Sen and 
Johnson 2011). In hepatocellular carcinoma, levels of Csk were found to be reduced in 
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comparison with normal liver correlating with high Src activity in these tumors (Masaki, 
Okada et al. 1999). 
2.10.2 c-Src in normal development 
Each SFK member has a different distribution in normal tissues. c-Src is expressed 
ubiquitously in many adult tissues with greater levels of expression in platelets, neurons 
and osteoclasts (Thomas and Brugge 1997, Roskoski 2004). Blk, Hck, and Fgr are found 
solely within blood cells, while Lck and Lyn are found mainly in blood cells and in the 
brain and Srm is expressed in keratinocytes. Yes and Fyn are ubiquitously expressed. Frk 
is expressed in bladder, breast, brain, colon, and lymphoid cells. (Thomas and Brugge 
1997, Sen and Johnson 2011). 
 The kinase c-Src is involved in numerous cellular processes such as cell cycle 
progression, adhesion, angiogenesis, migration, apoptosis, and differentiation (Tatosyan 
and Mizenina 2000, Frame 2002). Soriano and colleagues reported mice with a null 
mutation of the c-SRC gene to be viable, possibly due to the functional overlap between 
members of the SFKs (Soriano, Montgomery et al. 1991). A direct role of c-Src in 
osteoblast/osteoclast regulation was suggested, as c-Src knockout mice develop 
osteopetrosis, a disease caused by failure of osteoclastic bone resorption (Soriano, 
Montgomery et al. 1991, Lowe, Yoneda et al. 1993, Yoneda, Niewolna et al. 1993). Mice 
with double knockouts of Src/Fyn or Src/Yes were found to die perinatally (Stein, Vogel et 
al. 1994). Mouse embryos with homozygous triple null mutations in c-SRC, YES and FYN 
genes, died in utero by day 9.5 and displayed severe developmental defects (Klinghoffer, 
Sachsenmaier et al. 1999). Germline deletion of c-Src was shown to cause defects in the 
initial stages of mammary ductal outgrowth as well as in uterine and ovarian development 
(Kim, Laing et al. 2005). Fibroblasts isolated from these Src null embryos showed reduced 
cell spreading and migration potential when plated on extracellular matrix (ECM) proteins 
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(Klinghoffer, Sachsenmaier et al. 1999). Similarly, Src-deficient mammary epithelial cells 
were unresponsive to estrogen stimulation and displayed reduced cell spreading and 
migration capacities when plated on ECM proteins (Kim, Laing et al. 2005).  
2.10.3 c-Src in cancer 
The kinase c-Src was the first proto-oncogene discovered (Stehelin, Varmus et al. 1976). 
Overexpression and/or activation of c-Src have been shown to play an important role in 
cell survival, growth, adhesion, and invasion and lead to an overall aggressive and 
metastatic phenotype of many human cancers (Frame 2002). Studies indicate that c-Src 
expression and/or activity is elevated in several types of human cancers, including 
melanoma (Barnekow, Paul et al. 1987), colon (Irby, Mao et al. 1999), pancreatic (Lutz, 
Esser et al. 1998), esophageal, gastric, ovarian (Wiener, Nakano et al. 1999) as well as 
head and neck cancer (van Oijen, Rijksen et al. 1998), and breast cancer (Jacobs and 
Rubsamen 1983, Ottenhoff-Kalff, Rijksen et al. 1992, Verbeek, Vroom et al. 1996, Egan, 
Pang et al. 1999). In some cancers including breast cancer, a positive correlation between 
elevated c-Src expression and cancer aggressiveness has been found (Egan, Pang et al. 
1999). Consistent with this, c-Src inhibition was reported to suppress the transformed 
phenotype of breast cancer cell lines (Ishizawar, Tice et al. 2004) and resulted in the 
reduction of cancer progression in several cancer types including breast cancer (Gonzalez, 
Agullo-Ortuno et al. 2006). These observations and the positive correlation between 
increased Src activity and cancer progression, suggested Src as a promising target for 
anticancer therapy.  
There are several small molecule Src inhibitors currently undergoing clinical trials 
after promising preclinical studies, such as the ATP-binding competitive inhibitors 
dasatinib, bosutinib, and saracatinib or the substrate binding-site inhibitor KX2–391 (Sen 
and Johnson 2011). Despite promising preclinical data, Src inhibitors have shown little 
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activity in monotherapy trials in unselected solid tumor patient populations. With the 
development of suitable biomarkers, the effects in selected patients, who are more likely to 
benefit from treatment, will be evaluated. Further, several combination strategies are 
currently tested in clinical trials (Puls, Eadens et al. 2011). 
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3 RATIONALE OF THE WORK 
 
 
Breast cancer is the most frequent cancer and cause of death in women worldwide. 
Signaling pathways controlling critical cellular functions become frequently deregulated 
during the progression of cancer. An in-depth understanding of signaling events 
influencing tumor onset, progression and metastatic spread is crucial for identifying new 
therapeutic targets. Many cellular functions in eukaryotic cells rely on the reversible 
phosphorylation of tyrosine residues governed by PTKs and PTPs. Previous work from our 
lab had implicated the phosphatase SHP2 in breast tumor growth and proliferation. We 
asked whether SHP2 is important for breast tumor maintenance and progression and 
assessed its cellular and molecular mechanism of action in these processes. 
 
Specifically I wanted to elucidate the following aspects of SHP2 effects in breast cancer: 
 
i. What is the molecular mechanism of action of SHP2 in breast cancer progression? 
ii. What are the effects of SHP2 on cell motility, invasion and in metastatic spread? 
iii. What are the physiological substrates of SHP2? 
iv. How is SHP2 translocated into the nucleus and what is its nuclear function? 
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4 RESULTS PART1 – Effects of SHP2 on breast cancer 
progression 
 
Manuscript published in Nature Medicine. 
 
 
 
 
 
 
 
 
 
 
 
This work was done in collaboration and only data to which I contributed is shown. 
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4.1 INTRODUCTION 
Breast cancer is a heterogeneous disease that progresses to the fatal hallmark of metastasis 
(Nguyen, Bos et al. 2009). Breast tumors, like normal breast, are hierarchically organized 
at the cellular level (Al-Hajj, Wicha et al. 2003, Dontu, Al-Hajj et al. 2003, Visvader 
2009). Tumor-initiating cells (TICs) are operationally defined as cells that form tumors 
after transplantation into immunodeficient mice (Clarke, Dick et al. 2006). Although 
identification of the ‘Achilles’ heel’ of tumorigenic cells is of paramount clinical 
importance in the search for therapeutic targets, signaling networks influencing TICs 
remain poorly defined. 
 In cancer, many signaling networks are subverted at the biochemical level 
(Vogelstein and Kinzler 2004, Pawson and Kofler 2009). Abnormal tyrosine 
phosphorylation underlies various diseases of deregulated growth and differentiation, 
including cancer (Hunter 2009, Pawson and Kofler 2009). The first identified bona fide 
protein-tyrosine phosphatase (PTP) proto-oncogene was the Src-homology 2 domain-
containing phosphatase SHP2 (encoded by PTPN11), a ubiquitously expressed PTP that 
transduces mitogenic, pro-survival, cell-fate and/or pro-migratory signals from numerous 
growth-factor, cytokine and extracellular-matrix receptors. SHP2 is required for the full 
activation of the mitogen-activated protein kinase (MAPK)/extracellular signal-related 
kinase (ERK) pathway downstream of most receptors; however, its regulation of other 
pathways (for example, the Janus kinase (Jak)-signal-transducer and activator of 
transcription protein (STAT) and phosphoinositide-3-kinase (PI3K) pathways) is cell 
specific, receptor specific or both (Shi, Yu et al. 2000, Ostman, Hellberg et al. 2006, Chan, 
Kalaitzidis et al. 2008). Notably, gain-of-function germline mutations of SHP2 cause 
~50% of the instances of Noonan syndrome developmental disorder (Tartaglia, Mehler et 
al. 2001). Moreover, mouse genetics, gene silencing and sequencing studies have shown a 
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broad role for SHP2 in development, cell fate and tumorigenesis (Tartaglia, Mehler et al. 
2001, Feng 2007, Chan, Kalaitzidis et al. 2008, Grossmann, Rosario et al. 2010). 
 In malignancies, SHP2 is hyperactivated either downstream of oncoproteins or by 
mutations. Gain-of-function somatic mutations are found in ~35% of juvenile 
myelomonocytic leukemias and at various incidences in other myeloid malignancies but 
are rarely present in solid cancers (Tartaglia, Niemeyer et al. 2003, Bentires-Alj, Paez et al. 
2004, Chan, Kalaitzidis et al. 2008). SHP2 is also activated downstream of oncogenes in 
gastric carcinoma, anaplastic large-cell lymphoma and glioblastoma (Higashi, Tsutsumi et 
al. 2002, Voena, Conte et al. 2007, Chan, Kalaitzidis et al. 2008, Zhan, Counelis et al. 
2009). Although we did not find SHP2 mutations in breast cancer in our previous studies, 
we and others have found that the gene encoding the SHP2-activating protein growth 
factor receptor bound protein 2-associated protein 2 (GAB2) is amplified and 
overexpressed in 10-15% of human breast tumors (Bentires-Alj, Paez et al. 2004, Bentires-
Alj, Gil et al. 2006, Bocanegra, Bergamaschi et al. 2010). 
 
Summary of previous results 
Using inducible small hairpin RNAmiRs (miRs) to deplete SHP2 in a 3D culture model of 
invasive breast cancer, we showed that SHP2 is necessary for invasion, proliferation and 
loss of polarity. Overexpression of HER2 and HER3 caused the immortalized but non-
transformed human breast epithelial cells MCF10A to form invasive, unpolarized and 
hyperproliferative 3D structures with a filled lumen and SHP2 knockdown blocked 
HER2/3-evoked invasion by 85%. Expression of a non-targetable SHP2 cDNA in cells 
expressing SHP2 miR2 rescued the MCF10A-HER2/3 cell-invasiveness. To test the effect 
of SHP2 knockdown on in vivo invasiveness of breast cancer cells, a human-in-mouse 
intraductal transplantation model was used (Behbod, Kittrell et al. 2009) and we found that 
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knockdown of SHP2 markedly decreased the ability of BT474 cells to progress from DCIS 
to IDC.  
 To shed light on the role of SHP2 in breast tumor growth and progression in vivo, 
xenografts of three HER2-positive (BT474, SKBR3 and MCF10A-NeuNT) and two triple-
negative (SUM159 and SUM1315) breast cancer cell lines expressing dox-inducible 
CTRL or SHP2 miRs were used. Depletion of SHP2 significantly decreased tumor growth 
and studies using the HER2-positive BT474 cells subsequently showed a decrease in the 
number of lung metastases as a consequence of decreased tumor burden. 
 Next, the influence of SHP2 on self-renewal of spherogenic breast cancer cells was 
examined. Assessing the tumorsphere-formation efficiency of HER2-positive and triple-
negative breast cancer cell lines in the presence or absence of SHP2, we found that SHP2 
knockdown reduced self-renewal of breast tumorsphere-forming cells of both HER2-
positive and triple-negative tumors. SHP2 depletion was found to decrease the proportion 
of cells with the CSC phenotype as shown by a decrease of the CD44high/CD24low 
population in MCF10A HER2/3 cells and a decrease in ALDH activity upon SHP2 
knockdown in SUM159 cells. This observation suggested a role of SHP2 in cancer stem 
cell regulation.  
 To characterize this effect of SHP2 on the tumor-seeding capacity of breast tumor 
initiating cells (TICs), single cells from SHP2 knockdown xenografts were isolated and 
serially transplanted in limiting dilutions into recipient mice in the absence of dox and 
used for tumorsphere forming assays. While CTRL cells efficiently seeded new tumors, 
depletion of SHP2 in vivo strongly impaired both tumorsphere formation and tumor 
seeding capacity. The fact that neither the mice transplanted with cells nor the cells grown 
as tumorspheres were treated with dox indicated that depletion of TICs or tumorsphere-
forming cells upon knockdown of SHP2 occurred in vivo during dox treatment of the 
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primary tumors. These data indicated that SHP2 is active in the maintenance and 
propagation of breast TICs. 
 In summary, this previous work from our lab showed that SHP2 is necessary for 
invasion, proliferation and loss of polarity in a 3D culture model of invasive breast cancer. 
SHP2 promotes the transition from in situ to invasive carcinoma in vivo and is required for 
the maintenance and tumor-seeding ability of tumor initiating cells. Knockdown of SHP2 
in different breast cancer cell lines blocked the tumor growth in vivo. However, the 
mechanism of action remained undefined. 
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4.2 RESULTS 
SHP2 acts via activation of the ERK pathway in vivo and in vitro. 
We sought to define the biochemical pathways in breast cancers in vivo that rely upon 
SHP2 action. A screen for changes in phosphorylation upon SHP2 knockdown in tumors 
using a reverse-phase protein array (RPA) revealed a decrease in phosphorylation of 
several signaling molecules. Immunoblotting of tumor lysates confirmed decreases in the 
phosphorylation of ERK5, ERK1/β, AKT, PLCȖ, EGFR and HERβ Analysis of protein 
phosphorylation in lysates from BT474 tumorspheres showed a phosphorylation of ERK5 
and ERK1/β and to a lesser extent of PLCȖ, AKT, EGFR and HER2. Consistently, we also 
observed reduced phosphorylation of ERK5 and ERK1/2 in MCF10A-HER2/3 
tumorspheres upon knockdown of SHP2. 
We then used shRNAs to knockdown ERK5 and measured the tumorsphere-
formation efficiency of BT474 and MCF10A-HER2/3 cells in the presence (CTRL vector) 
or absence of ERK5. Knockdown of ERK5 reduced tumorsphere formation (~30% fewer 
primary and secondary tumorspheres in ERK5 shRNA cells than in CTRL cells) but did 
not affect self-renewal (Figure 12A). 
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Figure 12. SHP2 acts via activation of the ERK pathway 
(A) ERK5 knockdown partially reduces the tumorsphere-forming capacity but does not 
affect self-renewal of BT474 cells. Bar graphs showing self-renewal capacities and the 
mean number of BT474 tumorspheres/104 cells ± SEM (n=3). **P < 0.004. 
(B) Left: Immunoblot of lysates from BT474 primary tumorspheres in the presence or 
absence of ERK5 (n=3). Right: The bar graph shows the percentage of normalized protein 
± SEM (n=3). 
(C) Immunoblot of lysates from BT474 primary tumorspheres expressing ERK5 shRNA 
alone or in combination with PD184352 treatment. 
(D) Inhibition of ERK1 and ERK2 phosphorylation alone or in combination with ERK5 
inactivation decreased BT474 tumorsphere-formation efficiency and the self renewal of 
tumorsphere-forming cells. The bar graph shows the self renewal capacities and the mean 
number of BT474 tumorspheres ± SEM (n=3). *P < 0.001, **P < 0.0008 by Student’s t 
test. 
 
 
 
These results showed that ERK5 depletion is not sufficient to phenocopy the effect 
of SHP2 loss on tumorsphere-forming cells. Interestingly, BT474 and MCF10A-HER2/3 
tumorspheres expressed higher levels of active ERK1/2 upon ERK5 knockdown, 
suggesting that phosphorylation of ERK1/2 compensated for ERK5 loss (Figure 12B). We 
next combined ERK5 depletion with the MEK inhibitor PD184352. Consistent with 
previous observations (Mody, Leitch et al. 2001), PD184352 blocked ERK1/2 
phosphorylation at 1 μM and both ERK1/β and ERK5 phosphorylation at 10 μM (Figure 
12C). Knockdown of ERK5 and treatment of BT474 and MCF10A-HER2/3 tumorspheres 
with PD184γ5β at 1 μM, or a treatment with 10 μM PD184γ5β that abrogates 
phosphorylation of both ERK5 and ERK1/2, reduced tumorsphere-formation efficiency 
and self renewal similar to SHP2 knockdown (Figure 12D). To assess whether inhibition 
of both ERK1/2 and ERK5 is required for mimicking the effect of SHP2 knockdown on 
tumorsphere-forming cells, we treated BT474 tumorspheres with PD184γ5β at 1 μM, 
which inhibits ERK1/2 but not ERK5. This dramatically reduced tumorsphere formation 
and self-renewal, thus recapitulating the effect of SHP2 knockdown (Figure 12D). These 
results suggested that SHP2 action on tumorsphere forming cells is predominantly 
dependent on ERK1/2 activation. 
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To dissect the effects of SHP2-evoked activation of ERK5 and ERK1/2 on the number of 
cells with the CSC phenotype, we examined MCF10A-HER2/3 cells lacking ERK5 and/or 
treated with PD184352 by measuring the proportion of CD44high/CD24low cells. A 
complete depletion of the CD44high/CD24low population was only seen upon simultaneous 
inhibition of ERK5 and ERK1/2, or ERK1/2 inhibition alone while ERK5 depletion led to 
a decrease of ~35% suggesting that SHP2 signals primarily through ERK1/2. Further, 
inhibition of ERK1/2 alone or in combination with ERK5 inactivation completely blocked 
HER2/3-evoked invasion. Rescue experiments using a wt SHP2 construct or phosphatase 
dead SHP2 C459S (SHP2 C/S) in MCF10A-HER2/3 cells lacking endogenous SHP2, 
showed that catalytic activity of SHP2 was required for ERK1/2 phosphorylation, self-
renewal of spherogenic cells and invasion.  
Altogether, these results showed that although ERK5 is hyperactivated in the 
presence of SHP2, it contributes only partially to the multiple effects of SHP2 in breast 
cancer. Thus, SHP2 acts predominantly by activating ERK1/2. 
 
 
SHP2 activates stemness-associated transcription factors that repress let-7 miRNA 
and increases self-renewal of spherogenic cells, invasion and breast tumor growth. 
The effects of SHP2 on gene expression in cancer have not been examined. To address 
this, we analyzed gene expression profiles of BT474 CTRL and SHP2 miRs tumors after 
30 days of dox-induced knockdown of SHP2. The 180 downregulated genes identified are 
referred to as the “SHPβ signature” (Figure 13A). Gene ontology analysis of the signature 
revealed enrichment in development-associated genes, mainly of the HOX gene family 
(Figure 13B and C).  
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Figure 13. SHP2 induces the expression of a set of development-associated genes 
(A) Plot of the gene expression contrast in BT474 SHP2 miR1 minus control miR tumors 
compared to SHP2 miR2 minus control miR tumors. The blue line circles the genes in the 
SHP2 signature.  
(B) Gene ontology analysis (Ingenuity) of the “SHPβ signature” revealed a remarkable 
enrichment in development-associated genes. This enrichment was mainly determined by 
the presence of 9 HOX genes in the SHP2 signature.  
(C) Quantitative real-time PCR confirmed the decrease in the expression of HOX genes 
upon depletion of SHP2. RNA was isolated from BT474 tumors expressing CTRL or 
SHP2 miRs treated for 30 days with dox. Quantitative real-time PCR was performed using 
primers against HOXA5, HOXA9, HOXA13, HOXB5, HOXB6, HOXB9, HOXD10, 
HOXD11 and HOXD13. Results represent means ± SEM (n=3). *P < 0.05. 
 
 
To identify the transcription factors whose activity is responsible for the observed 
changes, we used a computational method (Suzuki, Forrest et al. 2009) to model global 
gene expression patterns in terms of genome-wide predictions of transcription factor 
binding sites. This analysis identified 10 transcription regulators that are inferred to cause 
significant downregulation of their targets upon SHP2 inactivation (Figure 14A). Among 
these transcription factors is ZEB1, a zinc finger E-box-binding homeobox 1 that has been 
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shown to induce EMT (Wellner, Schubert et al. 2009). Consistently, ZEB1 was 
downregulated in microarrays of BT474 tumors lacking SHP2. Analysis of RNA from 
BT474 and SUM159 tumors by real-time PCR confirmed that ZEB1 expression was 
repressed upon SHP2 knockdown (Figure 14B). The repression of ZEB1 was 
accompanied by downregulation of the EMT markers fibronectin1, vimentin and 
N-cadherin (Figure 14C), indicating the influence of SHP2 on EMT in vivo.  
 
 
 
Figure 14. SHP2 activates stemness-associated transcription factors and induces 
EMT in vivo 
(A) Table showing the MARA mean activity scores (± SD) of 10 transcription factors 
whose activity was reduced upon SHPβ knockdown. “P down” values show for each factor 
the probability of a decreased activity in SHP2 miRs compared with CTRL miR samples. 
(B) Quantitative real-time PCR of ZEB1. Bar graph showing the percentage of ZEB1 
expression in BT474 and SUM159 tumors in the presence or absence of SHP2. Results are 
means ± SEM (n=3). *P < 0.029, **P < 0.018 by Student’s t test.  
(C) Quantitative real-time PCR of the EMT markers fibronectin1, vimentin, and 
N-cadherin. The bar graphs show the percentage of EMT marker expression in BT474 and 
SUM159 tumors in the presence or absence of SHP2. Results represent means ± SEM 
(n=3). *P < 0.05. 
 
Results and Discussion Part 1 – Effects of SHP2 on breast cancer progression 
 
 
 47 
To assess the functional role of ZEB1 downstream of SHP2, we generated pools of 
MCF10A-HER2/3 cells expressing inducible ZEB1 miR (Figure 15A). Knockdown of 
ZEB1 dramatically reduced invasion in MCF10A-HER2/3 cells grown in 3D cultures 
(Figure 15B). Moreover, ZEB1 depletion reduced the self-renewal of MCF10A-HER2/3 
tumorsphere-forming cells (Figure 15C), although to a lesser extent than depletion of 
SHP2. These data indicate that ZEB1 acts downstream of SHP2 to enhance invasion and 
self-renewal, but also suggest that additional mediators are involved in the effect of SHP2 
on the self-renewal capacity of tumorsphere-forming cells/TICs. 
 
 
 
Figure 15. ZEB1 enhances invasion and self-renewal downstream of SHP2 
(A) Quantitative real-time PCR of the transcription factor ZEB1. The bar graph shows the 
mean percentage of ZEB1 expression in MCF10A-HER2/3 cells expressing an inducible 
ZEB1 miR ± SEM (n=3). *P < 0.00054. 
(B) Bar graph showing the mean percentage of invasive structures of MCF10A-HER2/3 
cells grown in three-dimensional cultures in the presence or absence of ZEB1 ± SEM 
(n=3). *P< 0.01 by Student’s t test. 
(C) Bar graphs showing the self-renewal capacity of tumorsphere-forming cells and the 
mean number of MCF10A-HER2/3 tumorspheres/104 cells in the presence or absence of 
ZEB1 ± SEM (n=3). *P < 0.05. 
 
 
 
To address this further, we analyzed transcriptome changes upon SHP2 knockdown 
in vivo with the Ingenuity resource. This analysis revealed that SHP2 knockdown strongly 
affected genes belonging to the c-Myc network (Figure 16A), confirming that c-Myc 
transcriptional activity is reduced upon SHP2 knockdown in vivo (Figure 14A). 
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Figure 16. SHP2 acts via ERK1/2-mediated activation of ZEB1 and c-Myc 
transcription factors 
(A) Network analysis (Ingenuity) of downregulated and upregulated genes (greater than ± 
0.5 logarithmic fold change) upon SHP2 knockdown in BT474 tumors. The top-ranked 
network is shown, displaying c-Myc as a key factor. Downregulated genes are shown in 
green, upregulated genes in red. Ingenuity network score = 47.  
(B) Quantitative real-time PCR of LIN28B. Bar graph showing the percentage of LIN28B 
expression in BT474 and SUM159 tumors in the presence or absence of SHP2. Results are 
means ± SEM (n=3). *P < 0.03, **P < 0.02 by Student’s t test.  
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(C) Network analysis (Ingenuity) of predicted let-7 targets within the SHP2 signature. The 
top-ranked network is shown, indicating that let-7 target genes within the SHP2 signature 
strongly associate with the c-Myc network. Ingenuity network score = 28. 
(D) Quantitative real-time PCR of mature let-7a and let-7b miRNAs. The bar graph shows 
the mean percentage of let-7a and let-7b expression in MCF10A-HER2/3 cells grown in 
three-dimensional cultures in the presence or absence of SHP2 ± SEM (n=3). *P < 0.04 by 
Student’s t test.  
(E) Downregulation of let-7 target genes in the absence of SHP2. Curves showing the 
relative frequency (density) of genes that are not targeted by let-7 (non-target), genes that 
are predicted let-7 targets (let-7 targets) and the 100 genes most likely to be let-7 targets 
(top 100 let-7 targets) after SHP2 knockdown in MCF10A-HER2/3 cells grown in three-
dimensional cultures or BT474 tumors (in vivo). 
 
 
 
Moreover, expression of the known c-Myc target LIN28B (Chang, Zeitels et al. 
2009), a suppressor of miRNA biogenesis, was decreased in microarrays from tumors 
lacking SHP2. These observations prompted us to dissect the role of c-Myc and LIN28B 
downstream of SHP2. First, we quantified the expression of LIN28B by real-time PCR in 
BT474 and SUM159 tumors and confirmed that it was transcriptionally repressed upon 
SHP2 knockdown in both models (Figure 16B). LIN28B was shown previously to 
suppress biogenesis of let-7 miRNA (Viswanathan, Daley et al. 2008, Chang, Zeitels et al. 
2009, Iliopoulos, Hirsch et al. 2009). Consistently, we observed that 20 genes of the 
“SHPβ signature” are predicted let-7 targets, the majority of which are tightly associated 
with the c-Myc pathway (Figure 16C). To avoid cross-detection of stromal mouse let-7 
miRNA present in the tumors, we analyzed its expression in MCF10A-HER2/3 cells 
grown in 3D cultures in the presence or absence of SHP2. Remarkably, biogenesis of 
mature let-7a and let-7b increased in these cells in the absence of SHP2 (Figure 16D). 
Consistently, whole gene expression analysis of MCF10AHER2/3 cells grown in 3D 
cultures or xenografts of BT474 cells showed a greater decrease in the expression of RNAs 
encoding predicted let-7 target genes than other genes in the absence of SHP2 (Figure 
16E). We further confirmed the downregulation, at the protein level, of the let-7 targets 
RAS and c-Myc (Roush and Slack 2008) in tumors lacking SHP2 (Figure 17A). Next, we 
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assessed whether the expression levels of ZEB1 and LIN28B are dependent on activation 
of ERK1/2. Treatment with PD184352 showed that MEK1/2 inhibition reduced the 
expression of ZEB1 and LIN28B in both SUM159 and MCF10A-HER2/3 cells (Figure 
17B). These data suggested that the effects of SHP2 on ZEB1 and LIN28B expression are 
mediated by ERK1/2. 
Our findings suggested that SHP2-evoked activation of ERK1/2 increases the 
expression of c-Myc and LIN28B in breast cancer. To test this model directly, we asked 
whether restoring the expression of c-Myc or LIN28B rescues the effects of SHP2 
knockdown. Notably, expression of c-Myc restored expression of LIN28B in MCF10A-
HER2/3 cells lacking SHP2 (Figure 17C). Consistently, expression of either c-Myc or 
LIN28B restored invasion and self renewal of tumorsphere-forming cells in MCF10A-
HER2/3 cells lacking SHP2. Moreover, c-Myc restoration abolished the effects of SHP2 
knockdown in BT474 and SUM159 tumor growth (Figure 17D). 
Finally, to assess the generality of our mechanistic findings, we analyzed the 
expression of the let-7 targets c-Myc and RAS (Roush and Slack 2008) upon SHP2 
knockdown in all the models tested in vivo. c-Myc expression was decreased in all models 
and RAS expression in 3 of 5 models (Figure 17A, E). 
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Figure 17. SHP2 increases the activity of key transcription factors and represses let-7 
miRNA 
(A) Immunoblot showing the expression of SHP2, pERK1/2, ERK2 and the let-7 targets 
c-Myc and RAS in lysates from BT474 tumors treated with dox. 
(B) Quantitative real-time PCR of ZEB1 and LIN28B. Bar graph showing the mean 
percentage of ZEB1 and LIN28B expression in MCF10A HER2/3 (left) and SUM159 
(right) cells after treatment with PD184352 ± SEM (n=3). *P < 0.05 by Student’s t test. 
(C) Quantitative real-time PCR of LIN28B. The bar graph shows the percentage of 
LIN28B expression in MCF10A-HER2/3 cells in the presence or absence of SHP2 and 
expressing a c-Myc or LIN28B rescue. Results represent means ± SEM (n=3). *P < 0.05. 
(D) c-Myc rescues the effects of SHP2 knockdown on breast tumor growth. BT474 tumor 
growth curves in the presence or absence of SHP2 and c-Myc. Curves showing the mean 
tumor volume (mm3) ± SEM (n=4). *P < 0.01β by Student’s t test. 
(E) Immunoblot showing the expression of SHP2, P-ERK, ERK and the let-7 targets 
c-Myc and RAS in lysates from SKBR3, MCF10A-NeuNT, SUM159 or SUM1315 tumors 
grown in the presence or absence of SHP2. 
 
 
 
In summary, our data demonstrate that SHP2 promotes ERKs activation, causing 
upregulation of ZEB1 and c-Myc-dependent expression of LIN28B, which leads to 
repression of let-7 miRNA and overexpression of let-7 target genes including RAS and c-
Myc (Roush and Slack 2008) (Figure 18). These data identify a key positive feedback 
signaling loop that is involved in the maintenance of breast TICs and in breast cancer 
progression. 
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Figure 18. Model of the mechanism of action of SHP2 
SHP2 activates the ERK pathway, which in turn promotes ZEB1 transcription and c-Myc 
dependent LIN28B expression. The expression of LIN28B blocks the processing of let-7, 
maintaining high expression levels of let-7 targets, including RAS and c-Myc. RTK, 
receptor tyrosine kinase. 
 
 
 
SHP2 is active in a large subset of primary breast tumors associated with poor 
prognosis. 
It has been proposed that SHP2 is overexpressed both, in breast cancer cell lines and 
infiltrating ductal carcinoma of the breast (Zhou, Coad et al. 2008). To assess whether 
expression of the “SHPβ signature” could be used to stratify patients with breast cancer, 
we examined whether the genes from this signature are co-overexpressed in human breast 
tumors. In four independent publicly available datasets, the “SHPβ signature” genes were 
found to be co-regulated and cluster the patients into two groups: one with downregulation 
(group 1) and the other with overexpression (group β) of the “SHPβ signature” genes. 
Notably, the clear split into “SHPβ signature” low- and high-expression groups was hardly 
ever observed in 10,000 randomly-selected gene groups of the same size. In contrast, we 
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observed no co-overexpression of the “SHPβ signature” genes in unsorted normal breast 
cells, highlighting the importance of SHP2 predominantly in malignant breast tissue 
(Figure 19A). We grouped the data from the four breast cancer datasets and found that 
~55% of all primary breast cancers overexpress the “SHPβ signature” (Figure 19B). 
Strikingly, analysis of two of these datasets for which the molecular subtypes were 
reported showed that the “SHPβ signature” was high most frequently in triple-negative 
breast cancers (Figure 19C), a subtype characterized by poor outcome and lack of 
efficient therapy. In addition, we used two-independent datasets to analyze the expression 
of “SHPβ signature” genes in ductal carcinoma in situ (DCIS) and invasive ductal 
carcinoma (IDC) (including matched biopsies). We found co-overexpression of the “SHPβ 
signature” in IDCs (Figure 19D). Moreover, we tested the expression of “SHPβ signature” 
genes in two-independent datasets containing information about patients’ prognosis and 
found them to be highly expressed in patients characterized by bad prognosis in both 
datasets (Figure 19E). Finally, we depleted SHP2 in a primary human triple-negative 
breast tumor grown as a xenograft to further address its clinical relevance. We found that 
SHP2 knockdown in vivo reduced tumor growth and abolished tumorsphere formation. 
Microarray data analysis of the primary tumors revealed that, while “SHPβ signature” 
genes were highly expressed in CTRL tumors, knockdown of SHP2 decreased their 
expression. 
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Figure 19. SHP2 is active in a large subset of breast tumors associated with poor 
prognosis 
(A) SHP2 signature genes are simultaneously overexpressed in breast cancers but not 
normal breast cells. Expression heatmap for SHP2 signature genes in normal human breast 
and primary breast cancer. Mean expression of each gene is indicated in gray, and 
expression level z scores are mapped to colors from red (z = -5.0, below the mean) to blue 
(z = 5.0, above the mean). Genes (rows) and patients (columns) are clustered by expression 
of these genes, resulting in the patient groups 1 and 2. Expression polarization between the 
groups of patients is shown as a red line for the SHP2 signature against 10,000 randomly 
selected gene signatures of the same size (bottom); P = 0.423 for the normal breast data, 
P = 0.0001 for the breast cancer data.  
(B) Bar graph showing the percentage of all patients with breast cancer belonging to 
group 1 (low SHP2 signature genes) or group 2 (high SHP2 signature genes).  
(C) Bar graph showing the percentage of patients from groups 1 and 2 in each breast 
cancer molecular subtype. Genes of the SHP2 signature are upregulated in all the 
molecular subtypes but are most frequently upregulated in the triple-negative tumors. 
P = 6.24 x 10-7 by Fisher’s exact test. ER, estrogen receptor; PR, progesterone receptor.  
(D) Bar graph showing the percentage of patients from groups 1 and 2 with IDC or DCIS. 
Genes of the SHP2 signature are upregulated more frequently in IDC than DCIS. 
P = 0.0033 by Fisher’s exact test.  
(E) Bar graph showing the percentage of patients from groups 1 and 2 with bad or good 
prognosis (progn.). Genes of the SHP2 signature are upregulated more frequently in 
tumors characterized by a bad prognosis. P = 0.01 by Fisher’s exact test. 
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4.3 DISCUSSION 
The signaling networks influencing TICs are not well defined, although their delineation 
could lead to the development of targeted, potentially curative cancer therapies. In this 
study, we provide new insights into the multiple effects of SHP2 in breast cancer. We 
discovered that SHP2 action increases the propagation of breast TICs and promotes breast 
tumor maintenance and progression, showing that SHP2 is a high-quality target in human 
breast cancer. 
One line of evidence for an effect of SHP2 on the propagation of TICs is that serial 
transplantation of limiting dilutions of several breast cancer cell lines after SHP2 
knockdown reduced the number of TICs. We gathered evidence that SHP2 enhances breast 
tumor maintenance and progression from our in vivo and three-dimensional culture 
experiments. First, SHP2 knockdown reduced the growth of established breast tumors and 
decreased the number of lung metastases. SHP2 depletion in invasive three-dimensional 
cultures also reduced proliferation and prevented a loss of polarity, two crucial steps in the 
oncogenic process (Bissell, Radisky et al. 2002, Zhan, Rosenberg et al. 2008). Third, 
knockdown of SHP2 prevented invasion in three-dimensional cultures and in a human-in-
mouse intraductal transplantation model. 
The finding that SHP2 knockdown reduces tumor growth and TIC frequency raised 
the possibility that SHP2 influences CSCs. The CSC model posits a hierarchical 
organization of malignant tumors composed of phenotypically and functionally distinct 
subpopulations of cancer cells (Al-Hajj, Wicha et al. 2003, Dontu, Al-Hajj et al. 2003, 
Stingl and Caldas 2007, Rosen and Jordan 2009). In this model, tumorigenic cells self 
renew and produce phenotypically distinct non-tumorigenic cells, recapitulating the 
heterogeneity of the original tumor. Four of the cell lines we used to assess the effects of 
SHP2 on tumor initiation, self renewal and regulation of the CD44high/CD24low phenotype 
Results and Discussion Part 1 – Effects of SHP2 on breast cancer progression 
 
 
 56 
were previously reported to propagate according to a CSC model (Fillmore and 
Kuperwasser 2008, Charafe-Jauffret, Ginestier et al. 2009, Deng, Yang et al. 2010), which 
suggests that SHP2 is a key factor affecting breast CSCs.  
Mechanistically, we found that the effects of SHP2 on TICs, the self renewal of 
spherogenic cells and the invasion of breast cancer cells require activation of the ERK 
pathway. Further, we found that SHP2 activation of ERK1 and ERK2 induces expression 
of the transcription factors ZEB1 and c-Myc, the latter of which mediates an increase in 
LIN28B expression. In our studies, c-Myc–induced LIN28B expression repressed let-7 
miRNA and led to overexpression of let-7 targets, including RAS and c-Myc (Roush and 
Slack 2008). These findings uncover a previously unknown mechanism of ERK regulation 
by SHP2 and identify an SHP2-dependent positive feedback loop that enhances the 
propagation of TICs and the maintenance and invasiveness of breast tumors. 
 Our work has led to the discovery of a SHP2 signature, comprised of a set of genes 
that are overexpressed in ~55% of human primary breast tumors and also correlated with 
invasive ductal carcinoma and poor prognosis. The results suggest that inhibiting SHP2 
might be effective in patients with high expression of SHP2 signature genes, particularly 
those patients with the triple-negative subtype of breast cancer recently found to be 
dependent on active receptor tyrosine kinases (Sun, Aceto et al. 2011) that require SHP2 
for full activation of ERK (Chan, Kalaitzidis et al. 2008). As SHP2 has been shown to act 
downstream of most growth-factor and cytokine receptors, targeting SHP2 may be 
therapeutic in other cancers in which SHP2 is hyperactivated (Higashi, Tsutsumi et al. 
2002, Voena, Conte et al. 2007, Chan, Kalaitzidis et al. 2008, Zhan, Counelis et al. 2009). 
Our findings suggest further experiments to address whether SHP2 also influences TICs, 
tumor maintenance and progression in these malignancies. 
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In summary, we have shown that knockdown of SHP2 markedly reduces the propagation 
of breast TICs and inhibits breast cancer maintenance and progression. These findings 
reveal a fundamental SHP2-dependent positive feedback loop acting on several features of 
breast cancer and reinforce the concept of developing selective inhibitors of SHP2 to treat 
aggressive malignancies. 
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5 RESULTS PART2 –  Effects of SHP2 on migration and 
metastasis 
 
 
5.1 INTRODUCTION 
Despite continuous advances in the understanding of breast cancer and increasing 
therapeutic options, metastasis, the spread of tumor cells to distant sites, remains one of the 
most life-threatening pathological events (Yilmaz and Christofori 2009). Tumor cells 
undergo molecular and morphological changes to gain motility, become able to 
intravasate, survive in the bloodstream, extravasate, and colonize to form a secondary 
tumor (Bonnomet, Brysse et al. 2010). According to the currently accepted theory, tumor 
cells undergo Epithelial-Mesenchymal Transition (EMT) before they enter the bloodstream 
either directly or via the lymphatic system to be transported to distant sites (Yang and 
Weinberg 2008). The EMT program is characterized by a loss of cell-cell adhesions and 
cell polarity, in combination with the downregulation of epithelial and the upregulation of 
mesenchymal markers (May, Sphyris et al. 2011). Tumor cell adhesion, spreading and 
migration play a fundamental role during early steps of invasion and metastasis of 
carcinoma cells. These cell motility-related functions are tightly controlled by intracellular 
signaling mechanisms. Therefore, a thorough understanding of the molecular mechanisms 
and signals promoting invasive cell behavior might lead to novel approaches for treatment 
of breast cancer metastases. 
We have previously shown that the proto-oncogenic phosphatase SHP2 is 
necessary for the loss of polarity, proliferation, and invasion in a 3D culture model of 
invasive breast cancer. We found that SHP2 was required for the maintenance and tumor-
seeding ability of tumor initiating cells and the knockdown of SHP2 in HER2-positive and 
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triple-negative breast cancer cell lines and primary derived xenografts after overt tumor 
development decreased tumor growth (Aceto, Sausgruber et al. 2012). 
SHP2 has been shown to play a role in multiple signaling processes mediating cell 
adhesion and migration. Fibroblasts lacking functional SHP2 showed impaired cell 
spreading, migration and showed an increased number of focal adhesions (Yu, Qu et al. 
1998). Manes and colleagues found that MCF7 cells expressing a dominant-negative SHP2 
mutant had a reduced migratory capacity and an increased number of focal adhesions.  
 Consistent with its role in cell migration, SHP2 is involved in the onset and/or 
progression of metastases. SHP2 overexpression in MCF7 cells resulted in decreased 
E-cadherin expression, secretion of MMP-9 and dephosphorylation of FAK leading to 
increased migration and metastatic potential (Wang, Liu et al. 2005). In line with this 
finding, we previously observed a role of SHP2 in EMT and metastasis in a HER2-positive 
cell line. The knockdown of SHP2 in BT474 tumors decreased not only tumor size, but 
also metastatic burden. ZEB1, a transcription factor involved in EMT, was downregulated 
upon knockdown of SHP2. We also found the EMT markers fibronectin, vimentin and 
N-cadherin downregulated in absence of SHP2 by quantitative real-time PCR (Aceto, 
Sausgruber et al. 2012).  
Triple-negative breast cancers (TNBCs) are highly migratory and metastatic (Perou 
2010). However, little is known about the role of SHP2 in tumor cell migration, 
dissemination, seeding, and metastatic colonization in this subtype. Recently, Hartman and 
colleagues showed that SHP2 mediated lamellipodia persistence and cell polarity to 
promote directional cell migration in MDA-MB-231 and MDA-MB-468 cells in vitro. 
They further showed that SHP2 exerts these effects through dephosphorylation of FAK at 
Tyr397 (Hartman, Schaller et al. 2013). Moreover, using a micro needle assay to capture 
motile tumor cells, SHP2 was found 80 x upregulated in migratory cells isolated from 
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MDA-MB-231 primary tumors in response to epidermal growth factor (Patsialou, Wang et 
al. 2012). 
 Given the roles of SHP2 in cell migration in TNBC cell lines in vitro and in MCF7 
and BT474 metastases formation in vivo, we hypothesized that SHP2 also may play a role 
in the metastatic cascade in triple-negative disease. Therefore, we investigated the 
significance of SHP2 in breast cancer progression to metastasis in TNBC using in vitro 
and in vivo models. In addition, we attempted to identify downstream targets or substrates 
of SHP2 in these models.  
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5.2 RESULTS 
Knockdown of SHP2 decreases cell motility and chemotaxis in TNBC in vitro. 
To investigate the role of SHP2 in cell motility, we first analyzed patterns of random 
migration of the TNBC cells SUM159 and MDA-MB-231 in presence or absence of 
SHP2. We used a dox-inducible system with two different shRNAs SHP2 miR1 and SHP2 
miR2 efficiently targeting endogenous SHP2 (Figure 20A and B).  
 
 
 
 
Figure 20. Dox-inducible knockdown of endogenous SHP2 
(A) Schematic of the doxycycline (dox)-inducible construct used to knockdown 
endogenous SHP2 using a small hairpin shRNA (miR). Addition of dox led to the 
expression of the miR and turbo RFP (tRFP). 
(B) Dox-inducible knockdown of SHP2 in cells expressing SHP2 miR1 or SHP2 miR2 but 
not in cells expressing the CTRL miR. Representative immunoblots showing the 
expression of SHP2 and the loading control ERK2 in presence (+) or absence (-) of dox in 
SUM159 (top) and MDA-MB-231 cells (bottom). Cells were lysed after 5 days of dox 
treatment. 
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We monitored the trajectories of random migrating cells in presence and absence of SHP2 
and found cells lacking SHP2 to move significantly less, as shown by the colored 
trajectories in the phase contrast pictures (Figure 21A) and by overlaying 100 trajectories 
of SUM159 and MDA-MB-231 cells expressing either CTRL miR or SHP2 miR2 for 
better visual representation (Figure 21B). Whereas SHP2 expressing cells migrated in 
random directions on the dish, the majority of knockdown cells moved significantly less or 
circled around the starting point. By analyzing the trajectories of over 100 cells per cell 
line and condition, we found that knockdown of SHP2 significantly decreased random cell 
motility. The average velocity as well as the total path travelled in 12 h was significantly 
decreased in SUM159 and MDA-MB-231 cells lacking SHP2 (Figure 21C). SHP2 
knockdown cells showed increased ruffling, but less movement. We further found a 
significant decrease of the distance to start (D2S), which is a measure of directionality 
(Figure 21D). In contrast to the total path length, D2S represents the distance from the 
starting point of the cell to the location 12 h later.  
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Figure 21. Depletion of SHP2 reduces random migration 
(A) Representative images of the time-lapse microscopy. Shown are randomly migrating 
cells in phase contrast and cell tracks created using the ImageJ/Fiji plugin MTrackJ. 
Colored trajectories for SUM159 cells (left) and MDA-MB-231 (right) expressing CTRL 
miR or miR2 targeting SHP2 at time 0 h and after 12 h are shown. Time-lapse microscopy 
was performed using a Zeiss Axiovert 200M microscope equipped with a heated stage and 
a CCD camera. 3-4 positions per well were imaged using a 10 x phase objective every 
10 min for a total duration of 12 h using MetaMorph software. Scale bars represent 
100 µm.  
(B) Cell migration trajectories showing the paths in µm travelled by 100 cells per 
condition in 12 h. The start of all tracks was calculated to be at the origin. Shown are 
exemplary graphs from SHP2 wt and knockdown SUM159 (left) and MDA-MB-231 cells 
(right).  
(C) Bar graphs representing the average path length covered by SHP2 wt or knockdown 
cells in 12 h and the average velocity in µm/min for SUM159 (left, black) and 
MDA-MB-231 (right, blue). 100-140 cells per condition from 2-3 experiments were 
analyzed using the ImageJ/Fiji plugin MTrackJ and the mean values ± SEM are plotted. 
*P < 0.001 by Student`s t test. 
(D) Schematic illustrating the difference between path length and distance to start (D2S). 
The path length is defined as the total distance covered in a given time and increases even 
if the cell moves in circles, while the D2S is the distance between the starting point and the 
end point. 
(E) Bar graphs showing the distance to start measured in SUM159 (left, black) and 
MDA-MB-231 (right, blue) SHP2 wt or knockdown cells in 12 h. Plotted are mean values 
± SEM. *P < 0.001 by Student`s t test. 
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Next, we tested the effects of SHP2 depletion on chemotaxis, i.e. the migration towards a 
gradient, using transwell Boyden chambers. Depletion of SHP2 in SUM159 and 
MDA-MB-231 cells resulted in a significant decrease of chemotaxis in both cell lines. In 
SUM159 cells, knockdown of SHP2 led to a significant reduction of migration of 83% and 
75% in cells expressing SHP2 miR1 and miR2, respectively, when compared to the SHP2 
expressing control cells (Figure 22A). Similar changes were observed in MDA-MB-231 
cells, in which the knockdown of SHP2 reduced chemotaxis by 70% or 85% in cells 
expressing miR1 or miR2 respectively (Figure 22B) 
 
 
Figure 22. Depletion of SHP2 reduces chemotaxis 
15,000 starved cells were plated in Boyden chambers in medium containing 0.25% FBS 
(SUM159) or 0.5% FBS (MDA-MB-231) and allowed to migrate through the 8 m pores 
towards a gradient of FBS. Migrated cells were stained with Crystal violet and imaged 
using a Leica MacroFluo microscope with a 2 x objective. The number counted for cells 
expressing CTRL miR was set to 100%. 
(A) Left: Bar graphs showing the relative percentages of SUM159 cells migrated in 24 h. 
Shown are mean values ± SEM (n=3). *P < 0.05 by Student`s t test. Right: Representative 
pictures of the bottom of the membranes showing the migrated cells after staining with 
Crystal violet.  
(B) Left: Bar graphs showing the relative percentages of MDA-MB-231 cells migrated in 
24 h. Shown are mean values ± SEM (n=3). *P < 0.002 by Student`s t test. Right: 
Representative pictures of the bottom of the membranes showing the migrated cells after 
staining with Crystal violet.  
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Knockdown of SHP2 decreases invasion in vitro. 
A crucial step in metastasis is the ability of a tumor cell to attach to and penetrate the 
basement membrane in order to enter the bloodstream (Yamaguchi, Wyckoff et al. 2005). 
To test the role of SHP2 in this process, we used an in vitro matrigel invasion assay 
(Figure 23A). Using 2 different miRs targeting SHP2, we found that the invasive potential 
of cells lacking SHP2 towards a gradient of FBS was greatly diminished. In SUM159 
cells, the number of invasive cells was reduced by 94% and 81% for SHP2 miR1 and 
miR2, respectively (Figure 23B). In MDA-MB-231 cells, the number of invasive cells was 
reduced by 86% and 96% for SHP2 miR1 and miR2, respectively (Figure 23C).  
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Figure 23. SHP2 knockdown blocks invasion in vitro 
(A) Schematic of the matrigel invasion assay. 15,000 starved cells were plated in medium 
containing 0.25% FBS (SUM159) or 0.5% FBS (MDA-MB-231) in the upper chamber and 
allowed to invade through a layer of matrigel covering the 8 m pores towards a gradient 
of FBS. After 40 h of incubation, invasive cells were counted after removal of non-
invasive cells, fixation, and staining with Crystal violet. The whole membranes were 
imaged using a Leica MacroFluo microscope with a 2 x objective and 0.9 x motor zoom 
and invasive cells were counted. The average number of invasive cells expressing the 
control construct was set to 100%.  
(B) Left: Bar graph showing the relative percentages of invasive SUM159 cells. Shown are 
mean values from 3 independent experiments ± SEM. Right: Representative pictures of the 
bottom of the membranes showing the invasive cells after staining with Crystal violet. 
*P < 0.001 by Student`s t test. 
(C) Left: Bar graph showing the relative percentages of invasive MDA-MB-231 cells. 
Shown are mean values from 3 independent experiments ± SEM. Right: Representative 
pictures of the bottom of the membranes showing the invasive cells after staining with 
Crystal violet. *P < 0.01 by Student`s t test. 
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Knockdown of SHP2 inhibits tumor cell motility in vivo. 
To investigate the effects of SHP2 on cell motility, invasion, and dissemination under 
physiological conditions, we used intravital multiphoton (IVM) microscopy. Intravital 
imaging is a powerful technique to study motile tumor cells in the bulk of the tumor at 
single cell resolution. SHP2 knockdown was induced once tumors had reached 6-8 mm 
diameter and 10 days later, single cell movement in tumors was imaged by IVM using a 
custom built two-photon microscope (Bonapace, Wyckoff et al. 2012) (Figure 24A). Since 
we had obtained comparable effects on random migration and chemotaxis towards FBS 
and invasion in vitro for both miRs targeting SHP2, we chose one knockdown construct 
for the in vivo experiments.  
We used SUM159 and MDA-MB-231 cells expressing the dox-inducible miR2 
targeting SHP2 or CTRL miR and stably infected these cells with a constitutively active 
GFP-Luciferase construct, to allow fluorescent and bioluminescent monitoring of the cells 
by GFP and Luciferase expression (Figure 24B). 
 We observed that the knockdown of SHP2 significantly decreased tumor cell 
motility in SUM159 xenografts. The motile cells per field were analyzed in each movie 
(Figure 24C) and depletion of SHP2 resulted in a 74% decrease of cell motility, 
corresponding to an average of 8.4 moving cells per field in the control group versus only 
3.2 moving cells per field in the SHP2 depleted tumors. Figure 24D shows a 
representative picture series of a moving GFP-expressing tumor cell in the control group 
after 10, 20, and 30 min. 
We assessed overall tumor morphology examining tumor cell and blood vessel 
density and quantified the collagen matrix density imaged by the 2nd harmonic generation. 
Further, paraffin embedded tumors were cut and stained with H&E to assess overall 
morphology and stained with anti-mouse CD31 to visualize the vascularization (Figure 
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24E). We found no differences between the control and the SHP2 knockdown tumors after 
this short term knockdown in already established tumors. 
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Figure 24. SHP2 knockdown decreases tumor cell migration in SUM159 xenografts 
(A) Drawings of the intravital imaging experimental setup. GFP-Luciferase positive cells 
were injected into gland 4 and tumor onset was controlled by Luciferase bioluminescent 
signal two weeks after injection. Tumors were allowed to reach 6-8 mm diameter before 
the knockdown of SHP2 was induced by feeding the mice with dox for 10 days. Then, 
motile cells were analyzed by intravital microscopy (IVM).  
(B) For the in vivo experiments, cells expressing dox-inducible SHP2 miR2 or CTRL miR 
and tRFP were superinfected with a constitutive active GFP-Luciferase construct. 
Immunoblot demonstrating the knockdown of endogenous SHP2 in SUM159 cells 
expressing miR2 targeting SHP2. Representative fluorescence microscopy pictures 
showing the GFP expression. Upon addition of 150 µg/ml Luciferin to the cell culture 
medium, Luciferase expression was visualized with an IVIS Lumina XL imaging system. 
(C) Bar graph showing the number of motile tumor cells per field. Knockdown of SHP2 
led to a 74% decrease in tumor cell motility. For both groups, n=4 mice from 2 
independent experiments were used. Per mouse, 5-7 movies were acquired and analyzed. 
Shown are means of motile tumor cells per field ± SEM. *P < 0.005 by Student`s t test.  
(D) Representative time-lapse image series of a migratory tumor cell in a SUM159 control 
tumor. The white arrow indicates the distance traveled by the motile cell at the beginning 
of the movie (time 0) and after 10, 20, and 30 min (green: GFP-expressing tumor cells; 
red: dextran-red labeled blood vessels). Scale bar represents 25 m.  
(E) Representative images of tumor morphology in SHP2 wt and knockdown tumors. 
Overall tumor morphology was compared by fluorescence images (green: GFP-expressing 
tumor cells; red: dextran-red labeled blood vessels) and collagen density imaged with the 
two-photon microscope. Paraffin sections were stained for H&E and mouse CD31 to 
visualize the tumor vascularization. No differences in tumor morphology were observed 
after 10 days of SHP2 knockdown. Scale bars represent 100 m. 
 
 
To exclude cell line specific effects of SHP2 depletion on in vivo tumor cell 
migration, we repeated the experiment with the same set-up using a second triple-negative 
cell line MDA-MB-231 (Figure 25A). Consistent with the result from SUM159 cells, 
knockdown of SHP2 in MDA-MB-231 cells resulted in a dramatic decrease of tumor cell 
motility. We observed 79% less motility in cells lacking SHP2 corresponding to a mean of 
only 7.7 moving cells per field compared to a mean of 36.4 motile cells in the control 
group (Figure 25B). Figure 25C shows an example of a migratory tumor cell in a mouse 
from the MDA-MB-231 control group expressing the non-targeting CTRL miR.  
 We compared the overall morphology on fluorescence images and collagen density 
was visualized using the 2nd harmonic generation. There was no difference between H&E 
and CD31 staining when comparing control and SHP2 knockdown tumors (Figure 25D).  
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We therefore concluded that SHP2 is not only important for cell migration in vitro, but 
also in vivo in xenografts of human triple-negative breast cancer cells. 
 
 
 
Figure 25. SHP2 knockdown decreases tumor cell migration in MDA-MB-231 
xenografts 
(A) For in vivo experiments, cells expressing dox-inducible SHP2 miR2 or CTRL miR and 
tRFP were superinfected with a constitutive active GFP-Luciferase construct. Immunoblot 
demonstrating the knockdown of endogenous SHP2 in MDA-MB-231 cells expressing 
miR2 targeting SHP2. Representative fluorescence microscopy pictures showing the GFP-
expression in both cell lines. Upon addition of 150 µg/ml Luciferin to the cell culture 
medium, Luciferase expression was visualized with an IVIS Lumina XL imaging system. 
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(B) Bar graph showing the motile tumor cells per field. Knockdown of SHP2 led to a 79% 
decrease in tumor cell motility. Both groups n=3 mice and 5-7 30 min movies were 
acquired and analyzed per mouse. Shown are means of motile tumor cells per field ± SEM. 
*P < 0.001 by Student`s t test.  
(C) Representative time-lapse image series of a migratory tumor cell in a MDA-MB-231 
control tumor. The white arrow indicates the motile cell at the beginning (time 0) and after 
4, 8, 12, 16, and 20 min (green: GFP-expressing tumor cells). Scale bar represents 25 m.  
(D) Representative images of tumor morphology in SHP2 wt and knockdown tumors. 
Overall tumor morphology between SHP2 wt and KD tumors was compared by 
fluorescence images (green: GFP-expressing tumor cells; red: dextran-red labeled blood 
vessels) and collagen density. Paraffin sections were stained for H&E and mouse CD31 to 
visualize the tumor vascularization. No difference in tumor morphology was observed 
after 10 days of SHP2 knockdown. Scale bars represent 100 m.  
 
 
SHP2 depletion results in a decrease of circulating tumor cells. 
Tumor cell motility is the first step in the metastatic cascade, before invasive tumor cells 
intravasate into the circulation. To address the role of SHP2 at this stage of metastases 
formation, we investigated the effect of SHP2 knockdown on the number of circulating 
tumor cells. As previously shown (Aceto, Sausgruber et al. 2012), SHP2 knockdown 
resulted in a significant decrease of tumor growth of SUM159 xenografts correlating with 
a significant reduction of tumor weight (Figure 26A-C).  
 Blood was drawn from animals bearing SHP2 wt or knockdown tumors and 
assessed for circulating tumor cells (CTCs) by Fluorescence-activated cell sorting (FACS). 
We detected CTCs expressing RFP and GFP in all blood samples from the control group 
and in only two blood samples from the SHP2 knockdown group, but at significantly 
lower levels than in the SHP2 expressing animals (Figure 26D). An average of 5.8 CTCs / 
100 µl was detected in the blood of mice with CTRL miR SUM159 xenografts having an 
average tumor volume of 193 mm³, whereas only an average of 1.7 CTCs / 100 µl blood 
were detected in SHP2 knockdown animals, resulting in a 3.5 fold decrease (Figure 26E).  
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Figure 26. Effects of SHP2 depletion on circulating tumor cells 
(A) Schematic of the experimental setup. Mice were injected orthotopically into gland 4 
with 1 x 106 SUM159 cells expressing CTRL or SHP2 miR2 and treated with dox for 
25 days once tumors became palpable (tumor onset). At day 23, blood was drawn to 
measure the number of circulating tumor cells (CTCs) before the tumors were surgically 
removed at day 25 and the mice were kept alive without dox. Metastasis formation was 
monitored weekly by bioluminescence imaging.  
(B) Luciferase bioluminescence images showing the tumors at onset in both groups. 
Tumors were allowed to develop before dox was added to induce the knockdown of SHP2 
in one group. 
(C) Left: Tumor growth curve of SUM159 xenografts in presence (CTRL miR) or absence 
of SHP2 (SHP2 miR2) showing mean tumor volumes ± SEM (n=6). *P < 0.05 by 
Student`s t test. Right: Tumor weight 25 days after tumor onset. Shown are means ± SEM 
(n=6). *P < 0.05 by Student`s t test. 
(D) FACS analysis of circulating SUM159 tumor cells. Representative dot blots showing 
the number of circulating tumor cells (CTCs) in the control group (CTRL miR) and in the 
SHP2 knockdown group (SHP2 miR2). GFP is plotted against RFP expression and CTCs 
are double positive.  
(E) Bar graph showing the mean number of CTCs per 100 µl blood ± SEM (n=6). 
*P < 0.05 by Mann Whitney test.  
(F) FACS analysis of circulating MDA-MB-231 tumor cells. Representative dot blots 
showing the number of CTCs in the control group (CTRL miR) and in the SHP2 
knockdown group (SHP2 miR2). EpCAM was used to gate for epithelial cells and plotted 
against GFP expression.  
(G) Bar graph showing the mean number of CTCs per 100 µl blood from n=5 per group 
measured at two timepoints ± SEM.  
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To investigate the effect of SHP2 on SUM159 CTC survival in the blood stream, 
extravasation, seeding, and proliferation at the metastatic site, we surgically removed the 
primary tumors. We then monitored metastasis formation by bioluminescence on a weekly 
basis. Three months after the tumor dissection, the mice had not developed any detectable 
metastases yet. 
 We then repeated the experiment with the more aggressive MDA-MB-231 cells. 
We detected CTCs in the blood of all animals in the control group (5 animals) and only in 
2 out of 5 animals in the SHP2 knockdown group (Figure 26 F and G). 
 
 
Phosphotyrosyl proteomic analysis reveals Src family kinases as SHP2 substrates. 
To identify the mechanism of action of SHP2 on cell motility and invasion, we set out to 
find substrates responsible for this phenotype. The physiological substrates of PTPs remain 
poorly defined, but they are important to understand the molecular mechanism of action of 
PTPs (Ostman, Hellberg et al. 2006). We used label-free phosphoproteomics on SUM159 
cells in presence or absence of SHP2 as an unbiased approach to identify putative 
substrates. 
 Randomly growing cells were lysed and the proteins were quantified followed by 
in-solution tryptic digest of the proteins into peptides. To enrich for phosphopeptides, 
immunoprecipitation with anti-phosphotyrosine antibodies was performed. After another 
phospho enrichment step using Titanium dioxide and desalting, the peptides were analyzed 
by mass spectrometry (Figure 27A). Notably, we found 5 out of 11 Src family kinases 
(SFK), including Src as top hit, to be highly phosphorylated at their inhibitory site Tyr530 
in absence of SHP2 (Figure 27B). Four of the 5, namely Src, Yes, Fyn and Lyn were 
among the top 10 highest phosphorylated proteins indentified (Figure 27C). We further 
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found decreased phosphorylation of the Src substrates Paxillin (PXN) at Tyr118, 
p190RhoGAP (ARHGAP35) at Tyr1105 and Protein zero-related (PZR, MPLZ1) at 
Tyr263 (Figure 27B). Network analysis using the Ingenuity Knowledge Base with the list 
of identified phosphopeptides confirmed cell migration as a significantly associated 
network function (Figure 27D). When uploading the set of 239 differentially 
phosphorylated proteins (appendix 9.3), the top networks identified were cellular 
morphology, cellular movement and cellular assembly and organization. The top five 
canonical pathways identified were integrin signaling, leukocyte extravasation signaling, 
actin cytoskeleton signaling, FAK signaling, and ephrin receptor signaling. Concordantly 
the top bio functions were cellular movement, cellular assembly and organization, cellular 
function and maintenance, cell morphology and cellular growth and differentiation. 
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Figure 27. Quantitative phosphoproteomics identified SFKs as SHP2 substrates 
(A) Schematic overview of the proteomics workflow. Briefly, SUM159 SHP2 wt or 
knockdown cells were harvested, lysed and the proteins were digested into peptides. After 
two steps of phosphopeptide enrichment (IP with anti-phosphotyrosine antibodies and 
TiO2 phospho enrichment), the phosphopeptides were analyzed by mass spectrometry.  
(B) Scatter plot depicting proteins differentially phosphorylated in presence or absence of 
SHP2 identified in a quantitative phosphoproteomics experiment. The results are shown as 
log2 ratios of SHP2 KD/SHP2 wt plotted against the rank of the log2 ratios. Proteins 
significantly higher phosphorylated in absence of SHP2 (=putative substrates) are shown 
on top.  
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(C) List of the top 10 proteins highest phosphorylated in absence of SHP2. Gene names, 
phospho tyrosine (pY) sites and identified peptide fragments are shown.  
(D) Ingenuity pathway analysis of 239 proteins differentially phosphorylated in absence of 
SHP2. Shown are the top networks (top), top bio functions (middle) and top canonical 
pathways (bottom). 
 
 
 
Validation of the interaction between SHP2 and c-Src. 
First, we tested the effect of SHP2 knockdown on Src phosphorylation at Tyr530 by 
immunoblotting. As for the phosphoproteomics experiment, we used SUM159 cells 
expressing the dox-inducible miR2 targeting SHP2 and checked for levels of pSrc Tyr530 
in presence or absence of SHP2. We confirmed the increased phosphorylation of pSrc at 
Tyr530 in absence of SHP2 (Figure 28A). We then used fluorescence resonance electron 
transfer (FRET) acceptor photobleaching (Figure 28B) to confirm the direct interaction 
between SHP2 and Src or pSrc Tyr530 in fixed SUM159 and MDA-MB-231 cells. FRET 
efficiencies were measured between SHP2 and Src and SHP2 and pSrc Tyr530. Significant 
FRET was found between both pairs in both cell lines. An average FRET efficiency of 
23.3% was measured between SHP2 and Src and 28.1% between SHP2 and pSrc Tyr530 
in SUM159 cells showing that they interact. In MDA-MB-231 cells, FRET efficiencies of 
5.3% were detected between SHP2 and Src and 15.4% between SHP2 and pSrc Tyr530. 
No FRET was detected in the negative control (Figure 28C-E). 
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Figure 28. FRET revealed interaction between SHP2 and Src / pSrc Tyr530  
(A) Immunoblot showing the phosphorylation of Src in SUM159 cells expressing the dox-
inducible miR2 targeting SHP2 in presence (+) or absence (-) of dox. Blotting with anti-
SHP2 confirms the knockdown of endogenous SHP2 upon addition of dox and pSrc 
Tyr530 levels are increased in these cells. ERK2 was used as a loading control.  
(B) Schematic overview of FRET interactions and controls. FRET acceptor 
photobleaching on fixed cells is based on labeling two endogenous proteins with primary 
antibodies raised in different species, for example rabbit and mouse (protein 1 mouse, 
protein 2 rabbit), and secondary donor and acceptor fluorophore-conjugated antibodies e.g. 
protein 1 anti-mouse donor and protein 2 anti-rabbit acceptor. As a negative control only 1 
primary antibody is used and labeled with the secondary donor antibody. The secondary 
acceptor antibody specific for the other species cannot bind and is therefore not close 
enough to the donor antibody for FRET to occur. In the positive control, 2 secondary 
antibodies raised against the same species are used both binding to the same protein 
ensuring FRET signal. 
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(C) Representative pictures of fixed SUM159 cells immunostained for SHP2 and Src (left), 
or SHP2 and pSrc Tyr530 (right) before and after FRET acceptor photobleaching. Src and 
pSrc were labeled with rabbit primary antibodies and anti-rabbit Alexa 568 donor 
fluorophore (pseudocolor green) and SHP2 was labeled with mouse anti-SHP2 antibody 
and anti-mouse Alexa 633 acceptor secondary antibody (red). ROI 1 indicates the region 
bleached, ROI 2 is a control region to check for unspecific bleaching of the donor and ROI 
3 is a region to measure the background fluorescence. Scale bars represent 25 m. 
(D) Representative pictures of fixed MDA-MB-231 cells immunostained for SHP2 and Src 
(left) or SHP2 and pSrc Tyr530 (right) before and after FRET acceptor photobleaching. 
Src and pSrc were labeled with rabbit primary antibodies and anti-rabbit Alexa 568 donor 
fluorophore and SHP2 was labeled with mouse anti-SHP2 antibody and anti-mouse Alexa 
633 acceptor secondary antibody. Scale bars represent 25 m. 
(E) Bar graph showing the quantification of the FRET efficiencies between SHP2 and Src 
and SHP2 and pSrc Tyr530 in SUM159 and MDA-MB-231 cells. In each experiment 4-10 
individual cells were measured. As a negative control, Src (rabbit) was labeled with anti-
rabbit Alexa 568 and measured in presence of anti-mouse Alexa 633. For each measure 
Alexa 633 bleaching had to be over 95% and FRET efficiency (%E) was calculated after 
background subtraction and Alexa 568 bleaching correction as follows: %E = (Dpost-
Dpre)/Dpost, where Dpre and Dpost are the donor (Alexa 568) intensities in the bleached region 
before (Dpre) and after (Dpost) bleaching. Shown are means ± SEM.  
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5.3 DISCUSSION 
SHP2 is required for cell migration, chemotaxis and invasion in vitro. 
The main cause of death in cancer patients are metastases (Christofori 2006). We 
investigated the influence of SHP2 on random cell migration by analyzing the migration 
patterns of SHP2 wt or knockdown cells and found that cells lacking SHP2 moved 
significantly less than their SHP2-expressing counterparts. We detected significant 
decreases in the path length, velocity and distance to start. Our findings were in line with 
previous observations showing a decreased migratory and spreading potential of 
fibroblasts lacking SHP2 (Yu, Qu et al. 1998). We further found that SHP2 is required for 
chemotaxis towards an FBS gradient, as depletion of SHP2 resulted in a significant 
decrease of cell migration. To disseminate from the primary tumor, cells need to acquire 
not only motility but also invasive potential. Indeed, we further showed that knockdown of 
SHP2 also strongly inhibited invasion in vitro using a matrigel invasion assay. As the 
majority of previous studies were done either in fibroblasts or HER2-positive breast cancer 
cells (Yu, Qu et al. 1998, Wang, Liu et al. 2005) we tested the effects of SHP2 inhibition 
in metastatic triple-negative breast cancer models. In summary, we found that SHP2 is 
important for invasion in triple-negative breast cancer, suggesting a broader role for this 
phosphatase in cell migration and invasion. 
 
SHP2 is required for tumor cell migration and dissemination in vivo. 
To validate the role of SHP2 in early metastatic steps under physiological conditions, we 
used intravital microscopy (IVM). We found that SHP2 depletion led to a massive 
decrease in tumor cell motility in TNBC cell lines. Similar to the cells on plastic, increased 
membrane ruffling paired with decreased motility was observed in the xenografts lacking 
SHP2. We had previously shown that knockdown of SHP2 inhibits tumor cell proliferation 
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in xenografts (Aceto, Sausgruber et al. 2012). To exclude any artifacts resulting from 
different tumor volumes at the time of imaging, we let the tumors develop before inducing 
the knockdown of endogenous SHP2. As expected, histological analysis of the tumors did 
not reveal morphological differences after this short-term depletion of SHP2. Previous 
reports mainly showed functions of SHP2 in cell migration in vitro and its function in vivo 
is less understood. While classical endpoint methods, such as tumor size measurements, 
only allow a snapshot at the end of the experiment and average the whole tumor cell 
population, IVM allows the study of the minority of cells having the capacity to leave the 
primary tumor and metastasize to distant organs (Condeelis and Weissleder 2010, 
Beerling, Ritsma et al. 2011, Zomer, Beerling et al. 2011). In accordance with our results, 
SHP2 was recently found to be highly upregulated in motile tumor cells (Patsialou, Wang 
et al. 2012). These findings suggest that depletion of SHP2 not only inhibits primary tumor 
growth, but also blocks metastatic spread by impairing tumor cell motility and invasion.  
 We then tested the requirement of SHP2 in tumor cell dissemination and assessed 
the number of circulating tumor cells in the blood of tumor bearing mice. Corresponding to 
the decreased number of motile tumor cells, the number of CTCs was decreased upon 
depletion of SHP2. These findings were in line with the results of Patsialou and 
colleagues, which assessed the number of circulating tumor cells using the small molecule 
SHP1/SHP2 inhibitor NSC87877 (Chen, Sung et al. 2006). These observations 
demonstrate a crucial role of SHP2 in tumor cell motility, intravasation, and dissemination.  
 Studies to assess effects of SHP2 on later steps in the metastatic cascade, such as 
cell survival in the blood stream, extravasation, and colonization potential at the distant 
site are ongoing and will elucidate the importance of SHP2 in metastatic progression. 
Several experimental approaches were applied, such as surgical removal of the xenografts 
or tail vein injections, and the mice are being monitored for lung metastasis formation by 
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bioluminescence. Another interesting aspect worth testing would be if SHP2 inhibition 
will be effective after overt onset of metastases.  
 In summary, we observed strong effects of SHP2 inhibition on the early steps of 
metastases formation in vivo and in vitro, namely migration, chemotaxis, matrigel 
invasion, tumor cell migration, and dissemination. These findings validate SHP2 as a 
valuable target in the treatment of breast cancer. 
 
SHP2 regulates cell migration and invasion via c-Src. 
To explain the effects of SHP2 on migration and invasion mechanistically, we aimed to 
identify the physiological substrates of SHP2. Unbiased quantitative proteomics revealed 5 
of the 11 Src family kinases (SFKs) to be highly phosphorylated in absence of SHP2 at 
Tyr530. Four of them were among the ten highest phosphorylated proteins and Src was 
found to be the top hit, followed by Yes and Fyn. SFKs are inhibited by phosphorylation 
of the C-terminal inhibitory site Tyr530 and positively regulated by phosphorylation of the 
activating site Tyr419 (Zhang, Yang et al. 2004). The hyperphosphorylation of the 
inhibitory site Tyr530 in several SFKs including c-Src upon knockdown of SHP2 could 
explain the SHP2 meditated effects on cell migration and metastatic spread. Increased SFK 
activity strongly correlates with breast cancer invasion and metastasis, and these kinases 
are frequently activated in human cancers (Ishizawar and Parsons 2004).  
 In line with these findings, the phosphorylation of two Src substrates implicated in 
cell migration, paxillin and p190RhoGAP, was found to be strongly decreased in the 
absence of SHP2. Paxillin is a phosphotyrosine containing adapter protein localized in 
focal adhesions. It mediates signaling between integrin receptors and the cytoskeleton 
(Turner, Glenney et al. 1990, Burridge, Turner et al. 1992). Phosphorylated paxillin was 
found to be involved in controlling actin cytoskeleton rearrangements and thereby changes 
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of cell morphology and motility (Nakamura, Yano et al. 2000, Iwasaki, Nakata et al. 
2002). Paxillin was initially identified as a tyrosine phosphorylated substrate in SRC-
transformed fibroblasts (Glenney and Zokas 1989, Schaller 2001). Klinghoffer and 
colleagues showed that Src-, Fyn- and Yes-deficient fibroblasts exhibited strongly reduced 
adhesion potential which was dependent on the tyrosine phosphorylation of paxillin 
(Klinghoffer, Sachsenmaier et al. 1999). Furthermore, c-Src was shown to phosphorylate 
paxillin at Tyr118 alone or concomitantly with FAK to transduce pro-migratory signals 
(Sachdev, Bu et al. 2009).  
 The Rho regulatory protein, p190RhoGAP regulates actin dynamics and cell 
spreading (Arthur and Burridge 2001) and is phosphorylated by c-Src at Tyr1105 (Roof, 
Haskell et al. 1998). Overexpression of c-Src was shown to increase p190RhoGAP 
phosphorylation whereas expression of a dominant-negative c-Src construct decreased the 
phosphorylation (Chang, Wilson et al. 1993, Chang, Gill et al. 1995).  
 PZR is another Src substrate we found to be hypophosphorylated at Tyr263 in the 
absence of SHP2 and active Src. Conceivably, it might serve as a scaffold protein targeting 
SHP2 and Src to the membrane in the context of integrin signaling. PZR belongs to the 
immunoglobulin superfamily and was found to recruit and bind SHP2 through its 
intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs) (Zhao and Zhao 
1998, Zhao and Zhao 2000). Phosphorylation of PZR at Tyr241 and Tyr263 was found to 
recruit and activate the phosphatase by inducing a conformational change, thereby altering 
downstream signaling (Zhao and Zhao 2003, Eminaga and Bennett 2008). This adapter 
protein has been shown to be phosphorylated by c-Src and other SFK such as Fyn and Lyn 
and the Src inhibitor PP1 was found to inhibit PZR phosphorylation (Zhao, Guerrah et al. 
2002, Zhao and Zhao 2003, Kusano, Thomas et al. 2008).  
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Src has previously been shown to be important in the regulation of focal adhesion turnover 
(Huttenlocher and Horwitz 2011). This process is tightly controlled by Rho GTPases (Parri 
and Chiarugi 2010), which mediate the formation of protrusions at the leading edge of the 
cell, followed by adhesion, deadhesion, and retraction at the rear (Ridley, Schwartz et al. 
2003, Jaffe and Hall 2005). The GTPase-activating protein p190RhoGAP is a functional 
regulator of RhoA (Arthur and Burridge 2001). Src signaling is transduced through its 
substrates that regulate GTPase activity and therefore ultimately cell migration 
(Huttenlocher and Horwitz 2011). Src was found to activate p190RhoGAP which in turn 
decreases Rho activity and leads to the recruitment of Rac, resulting in an increased focal 
adhesion turnover (Schober, Raghavan et al. 2007). Conversely, increased Rho activity 
was shown to stabilize focal adhesion and decrease cell motility in Src deficient fibroblasts 
(Fincham and Frame 1998, Klinghoffer, Sachsenmaier et al. 1999). Interestingly, SHP2-
deficient fibroblasts were also shown to have impaired cell migration and large peripheral 
focal adhesions (Yu, Qu et al. 1998).  
 In conclusion, we found SHP2 to play a role in the early steps of metastasis, as 
depletion of SHP2 impaired tumor cell migration and dissemination into the blood stream. 
Mechanistically, we found that SHP2 exerts its effect on cell migration and invasion in 
vitro and in vivo through the regulation of Src activity. Notably, Src has previously been 
implicated in the early steps of metastatic dissemination in studies using the Src inhibitor 
saracatinib (Siemann, Dong et al. 2012). Similar results were obtained using other Src 
inhibitors (Jallal, Valentino et al. 2007). Mechanistically, we suggest that SHP2 activates 
c-Src by dephosphorylating the inhibitory site Tyr530 in the C-terminal domain of Src, 
which then in turn activates several downstream effectors including Paxillin and 
p190RhoGAP by phosphorylation. Paxillin and p190RhoGAP, both important for the 
regulated turnover of focal adhesions, transduce the positive migratory signal to RhoA 
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resulting in increased cell migration (Figure 29). The Src substrate PZR might act as an 
adaptor protein in this SHP2-Src mediated signaling downstream of integrin receptors. 
 
 
 
 
Figure 29. Hypothetical working model of SHP2 signaling in cell migration 
We propose that downstream of integrin receptors, SHP2 exerts pro-migratory and pro-
invasive signaling through activation of Src by dephosphorylating the inhibitory site 
Tyr530 and therefore Src substrates implicated in focal adhesion turnover and cell 
migration. The scaffold protein PZR might serve as an adapter in this setting.  
 
 
In previous studies, SHP2 has been proposed to regulate the activity of c-Src and 
SFKs. However, it remains controversial whether this regulation is direct or indirect. 
Zhang and co-workers reported inhibition of SFKs and downregulation of their substrates 
in SHP2-deficient cells. In contrast to our observation of a direct interaction of SHP2 and 
c-Src, they found SHP2 to regulate phosphorylation of the Csk regulator PAG/Cbp, 
thereby controlling Csk access to SFKs (Zhang, Yang et al. 2004). Ren and colleagues 
proposed yet another mechanism. According to their model, SHP2 dephosphorylates 
Paxillin leading to the dissociation of Csk from paxillin. Csk is a negative regulator of c-
Src phosphorylating Src at the inhibitory C-terminal tyrosine. The dissociation of Csk 
Results and Discussion Part 2 – Effects of SHP2 on migration and metastasis 
 
 
 86 
from the Src-Paxillin complex resulted in a decreased phosphorylation of the inhibitory 
site Tyr530 and hence increased Src activity (Ren, Meng et al. 2004). Other reports 
suggested SHP2 to regulate Src activity by a non-enzymatic mechanism (Walter, Peng et 
al. 1999). The same group previously published that SHP2 can dephosphorylate Src at 
Tyr527 in vitro (Peng and Cartwright 1995). Although different mechanisms of action are 
proposed, all studies have in common that SHP2 leads to the activation of Src/SFK which 
in turn leads to downstream signaling important in the context of cell migration. Our 
studies demonstrate that SHP2 directly activates c-Src and SFKs by dephosphorylation of 
the inhibitory site Tyr530. 
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6 RESULTS PART3 –  The role of nuclear SHP2 in breast 
cancer 
 
 
6.1 INTRODUCTION 
When SHP2 was identified more than 20 years ago, it was described as a solely 
cytoplasmic phosphatase (Adachi, Sekiya et al. 1992, Freeman, Plutzky et al. 1992, 
Ahmad, Banville et al. 1993, Feng, Hui et al. 1993, Vogel, Lammers et al. 1993). Later, 
functions of SHP2 in the nucleus have been proposed (Chughtai, Schimchowitsch et al. 
2002, Wu, Hong et al. 2002, Jakob, Schroeder et al. 2008, Takahashi, Tsutsumi et al. 
2011). Furthermore, SHP2 was the first phosphatase found to be located in the 
mitochondria (Salvi, Stringaro et al. 2004). 
In 2002, Wu et al. showed that nuclear SHP2 dephosphorylates the signal 
transducer and activator of transcription 1 (STAT1) thereby inhibiting its transcriptional 
activity (Wu, Hong et al. 2002). In the same year, Chughtai and colleagues found that 
prolactin stimulation of mouse mammary HC11 and human T47D breast cancer cells led to 
nuclear translocation of SHP2 in complex with signal transducer and activator of 
transcription 5a (STAT5a). This complex of SHP2 and STAT5a was found to bind to 
DNA and to regulate transcription of milk protein genes (Chughtai, Schimchowitsch et al. 
2002). Nuclear SHP2 was further reported to dephosphorylate telomerase reverse 
transcriptase (TERT), the catalytic subunit of telomerase, at Tyr707, thus preventing 
nuclear oxidative stress-dependent nuclear export of TERT, and thus enhancing nuclear 
telomerase activity (Jakob, Schroeder et al. 2008). Takahashi and colleagues recently 
showed that nuclear SHP2 dephosphorylates parafibromin/Cdc73 which is a component of 
the nuclear RNA polymerase II-associated factor complex, transforming parafibromin 
from a tumor suppressor to an oncogenic activator. They argued, as parafibromin is a 
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strictly nuclear protein, dephosphorylation by SHP2 must occur in the nucleus. Based on 
their observation that SHP2 was abundant in the nuclei of proliferating cells but not of 
confluent cells, they proposed nuclear accumulation of SHP2 upon growth-stimulating 
signals (Takahashi, Tsutsumi et al. 2011). Whether nuclear SHP2 is important for its 
effects in breast cancer remains unknown.  
 
Nuclear import. 
The mechanism of SHP2 translocation into the nucleus is unknown. Access to the nucleus 
is limited by a double-membrane structure called the nuclear envelope. The only way to 
cross the membrane is through large pores, called nuclear pore complexes (NPC), which 
are embedded in the nuclear envelope (Poon and Jans 2005). While proteins with a size 
smaller than 40 kDa can diffuse through the NPCs, larger proteins need to be actively 
transported through the NPCs by the nuclear import machinery (Gasiorowski and Dean 
2003). Usually proteins above 40 kDa contain a nuclear localization signal (NLS) that 
targets them into the nucleus through the NPC (Figure 30). 
 
 
Figure 30. Simplified scheme for nuclear import 
1) Nuclear localization sequence (NLS) on proteins above 40 kDa is recognized and bound 
by importin in the cytoplasm. 2) Then the importin/NLS protein complex translocates 
actively into the nucleus through the nuclear pore complex (NPC). 3) The release of the 
NLS containing protein requires the binding of RanGTP (GTP) to importin.  
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Although it is possible for proteins > 40 kDa without a NLS to enter the nucleus via co-
transport with a protein that has a NLS, as suggested for SHP2 and STAT5a (Chughtai, 
Schimchowitsch et al. 2002), many nuclear proteins have their own NLS. NLS are short 
sequences of basic amino acids such as lysine (Lys) or arginine (Arg) that are exposed on 
the protein surface. These amino acids are recognized by importins that target the proteins 
through the NPCs. The most commonly found NLS are the pat4 and pat7 classical NLS 
and the bipartite NLS (Hicks and Raikhel 1995). The pat4 NLS consists of 4 basic amino 
acids (Lys or Arg) or of 3 basic amino acids and one histidine (His) or proline (Pro). The 
pat7 NLS starts with a Pro, followed by a basic segment within 3 residues from the starting 
Pro containing 3 out of 4 basic Lys or Arg residues. The bipartite NLS was first described 
in Xenopus nucleoplasmin (Robbins, Dilworth et al. 1991) and consists of 2 basic residues 
and a 10 residue spacer, followed by another basic segment containing at least 3 basic 
residues out of 5 residues. To date, no NLS has been described for SHP2. However, with a 
size of 72 kDa, it cannot simply diffuse through nuclear pores.  
 Therefore, we were interested to study the mechanism of nuclear import of SHP2 in 
our models. We further wanted to elucidate the roles of nuclear SHP2 in breast cancer. 
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6.2 RESULTS 
SHP2 is present in the nucleus of breast cancer cell lines. 
Nuclear SHP2 has been previously described in A431 and HEK293T cells (Wu, Hong et 
al. 2002), in fibroblasts (Jakob, Schroeder et al. 2008), and in AGS and lacC9 cells 
(Takahashi, Tsutsumi et al. 2011). In breast cancer, nuclear SHP2 has only been described 
in T47D cells (Chughtai, Schimchowitsch et al. 2002). Therefore, we first wanted to 
confirm the nuclear localization of SHP2 in other breast cancer cell lines. 
 Using nuclear and cytoplasmic fractionation followed by immunoblotting, we 
detected SHP2 in the cytosolic and nuclear fraction of all cell lines tested (BT474, 
SUM159, SUM1315, MDA-MB-231, and MCF10A HER2/3) (Figure 31A). To ensure the 
purity of the fractions, the nuclear enzyme Poly (ADP-ribose) polymerase (PARP) was 
used as a marker for the nuclear fraction and tubulin  was used as a cytoplasmic marker. 
The amount of nuclear SHP2 was found to be cell line-dependent between 21.5% and 
43.5% (Figure 31B). Nuclear localization of SHP2 was further confirmed by 
immunofluorescence (Figure 31C and D) and mass spectrometry (Figure 39D) of nuclear 
and cytoplasmic fractions.  
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Figure 31. Nuclear and cytoplasmic localization of SHP2 
(A) Representative immunoblots of subcellular fractionations of several breast cancer cell 
lines showing SHP2 in the cytoplasmic (C) and in the nuclear (N) fraction. To ensure the 
purity of the fractions, the enzyme PARP was used as a nuclear marker and tubulin  was 
used as a cytoplasmic marker. 
(B) Bar graph showing the percentage of nuclear SHP2 in each cell line measured by 
densitometry of SHP2 immunoblots. Shown are means ± SEM (n=3).  
(C) Representative pictures of SHP2 immunostaining in MCF10A HER2/3 (top) and 
BT474 cells (bottom). Cells were seeded on Poly-L-Lysine coated coverslips and stained 
with anti-SHP2 antibodies (green). Nuclei are visualized with DAPI staining (blue). 
Images were taken with a Zeiss Z1 widefield microscope. Scale bars represent 20 m. 
(D) Representative 3D images of deconvoluted z-stacks taken with a Zeiss Z1 widefield 
microscope showing that SHP2 staining (green) localizes inside the nucleus (DAPI 
staining, blue). After deconvolution, surface objects were defined around the nuclei using 
Imaris software. Next, the SHP2 signal outside these objects was removed. Then the 
surface object masks were removed, leaving the nuclei with DAPI and SHP2 staining. 
After switching off the DAPI channel, SHP2 staining could be observed in the nuclei. 
Scale bar represents 20 m. 
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Nuclear import of SHP2 requires a pat4 NLS. 
Although there are several reports on nuclear SHP2, it remains unclear how SHP2 is 
translocated into the nucleus. To elucidate the mechanism of its nuclear import, we 
analyzed the SHP2 amino acid sequence using a web based bioinformatics program for 
subcellular localization prediction based on amino acid sequence (PSORT II) (Nakai and 
Horton 1999).  
 We identified a potential pat4 NLS in the SHP2 sequence that could facilitate the 
nuclear import of SHP2. The pat4 NLS identified by PSORT II consists of Lys-Pro-Lys-
Lys located at amino acid 322-325 in the phosphatase domain of SHP2. We then assessed 
whether the pat4 NLS was required for SHP2 nuclear translocation. The putative NLS 
found in the SHP2 sequence was deleted or mutated in a dox-inducible pLKO-TREX-
SHP2-HA expression construct. To conserve the 3D structure, we did not alter the last Lys 
as it is important for the folding of SHP2. The other two basic residues were exchanged for 
serine (Ser), an uncharged amino acids of the same size, resulting in a change from Lys-
Pro-Lys-Lys to Ser-Pro-Ser-Lys. In the NLS deleted mutant, the first three amino acids of 
the NLS and the four amino acids before the NLS were deleted (resulting in the deletion of 
amino acids 317-324) (Figure 32A). Direct DNA sequencing of the complete SHP2 
sequence showed the correct insertion of the desired mutation or deletion without frame 
shifts or other errors (Figure 32B). 
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Figure 32. Mutation and deletion of the NLS in pLKO-TREX-SHP2-HA 
(A) Schematic overview of the mutations introduced in the phosphatase domain of SHP2 
by site directed mutagenesis.  
(B) Pictures showing the chromatographic results of the direct sequencing of SHP2 around 
amino acids 322-325. Top: wild-type (wt) SHP2 sequence. Middle: SHP2 NLS mutated 
sequence. The nucleotide 965A was changed to G resulting in an amino acid change from 
Lys322 to Ser. In addition, the nucleotide 971A was changed to G altering the amino acid 
Lys324 to Ser. Bottom: SHP2 NLS deleted sequence. The 7 amino acids 317-324, 
indicated in blue in the wt sequence on top, were deleted shifting amino acid Lys325 of the 
original sequence to position 317 in the mutated sequence (blue dashed underlined).  
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To investigate the effect of this potential pat4 NLS, we attempted to rescue a dox inducible 
knockdown of endogenous SHP2 with constructs expressing either HA-tagged wild-type 
SHP2 with an intact NLS sequence (wt) or HA-tagged SHP2 NLS deleted (del) or SHP2 
NLS mutated (mut), respectively (Figure 33A). First, cell lines were stably infected with a 
dox-inducible shRNA construct SHP2 miR2 targeting SHP2 or a control miR. Addition of 
dox to the cell cultures for 5-7 days led to the knockdown of endogenous SHP2 in the cells 
infected with SHP2 miR2 as shown for SUM159, SUM1315, and MCF10A HER2/3 cells 
(Figure 33B). These SHP2 miR2 expressing cells were then stably infected with dox 
inducible HA-tagged SHP2 NLS wt, mut or del and selected with Neomycin. Hence, upon 
addition of dox, endogenous SHP2 was knocked down and HA-tagged SHP2 NLS variants 
were expressed as shown by immunoblotting using anti-HA antibodies (Figure 33C). To 
test whether the NLS is indeed functional and required for SHP2 import into the nucleus, 
we performed subcellular fractionations of the dox induced cells expressing either SHP2 
NLS wt, del or mut followed by immunoblotting using anti-HA antibodies. As before, 
tubulin  was used to ensure the purity of the cytoplasmic fraction and PARP was used as 
a nuclear marker. Whereas HA-tagged SHP2 was detectable in the cytoplasmic and 
nuclear fraction for cells infected with SHP2 NLS wt, deletion or mutation of the NLS 
prevented nuclear import of SHP2 as shown by the absence of SHP2 in the nuclear fraction 
(Figure 33D). We could therefore show that the identified NLS Lys-Pro-Lys-Lys at amino 
acid 322 of SHP2 targets SHP2 into the nucleus.  
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Figure 33. Nuclear import of SHP2 requires a pat4 NLS  
(A) Schematic drawing of the constructs used to simultaneously knockdown endogenous 
SHP2 using a small hairpin RNA and to express HA-tagged SHP2 with either the wild-
type NLS sequence (wt), a mutated NLS sequence (mut) or a deleted NLS sequence (del) 
upon addition of dox. 
(B) Immunoblots of lysates from SUM159 (top), SUM1315 (middle), and MCF10A 
HER2/3 cells (bottom) infected with dox inducible CTRL miR or miR2 targeting SHP2. 
Addition of dox for 5-7 days induced knockdown of endogenous SHP2.  
(C) Immunoblots of lysates from SUM159 (top), SUM1315 (middle), and MCF10A 
HER2/3 cells (bottom) expressing SHP2 miR2 and HA-tagged SHP2 NLS wt, SHP2 NLS 
del or SHP2 NLS mut upon addition of dox as shown by probing with anti-HA antibodies. 
(D) Immunoblot of lysates from a subcellular fractionation of SUM159 cells showing that 
cells expressing HA-tagged SHP2 NLS del or NLS mut have no SHP2 in the nuclear 
fraction (N), whereas cells expressing HA-tagged SHP2 NLS wt have cytoplasmic (C) and 
nuclear (N) SHP2 as shown by anti-HA detection. PARP was used as a nuclear marker and 
tubulin  was used as a cytoplasmic marker. 
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Effects of nuclear SHP2 in vitro. 
To address the function of nuclear SHP2, we tested the effects of depleting SHP2 from the 
nucleus on proliferation, colony formation and matrigel invasion in three-dimensional (3D) 
assays in vitro. We found that the absence of nuclear SHP2 had no effects the number of 
viable cells (Figure 34A). Next, the effect of the absence of nuclear SHP2 on colony 
formation was tested. We found that the absence of nuclear SHP2 increased the colony 
forming potential of SUM1315 cells expressing SHP2 NLS del or NLS mut significantly 
(Figure 34B). 
 
 
Figure 34. Effects of depletion of nuclear SHP2 in vitro 
(A) Bar graphs showing that depletion of nuclear SHP2 did not affect cell numbers. 2,000 
SUM1315 cells were plated in triplicates in 96-well plates and incubated for 5 days. Cell 
numbers were measured by WST-1 colorimetric assay. Results normalized to the NLS wt 
control are shown in means ± SEM (n=3). n.s. = not significant. 
(B) Bar graphs showing the relative colony area. 2,000 SUM1315 cells were plated in 6-
well plates for 14 days. Then, the colonies were fixed, stained with Crystal violet and the 
area covered by the colonies was analyzed using ImageJ software. Results are means ± 
SEM normalized to the wt control that was set to 100% (n=3). *P < 0.005 calculated by 
Student’s t test. 
 
 Next, we assessed the invasive potential of cells lacking nuclear SHP2 using a 3D 
matrigel invasion assay. We first validated the morphological changes upon removal of 
SHP2 in the three cell lines. For MCF10A HER2/3 cells, we have previously shown that 
knockdown of SHP2 decreased the percentage of HER2/3-evoked invasive structures in 
MCF10A HER2/3 cells (Aceto, Sausgruber et al. 2012). A similar decrease in invasive 
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structures was observed in SUM1315 and, to a lesser extent, in SUM159 cells (Figure 
35A and B, first 2 columns/bars). We then expressed pLKO-TREX-SHP2-HA NLS wt, 
NLS del or NLS mut in cells lacking SHP2. The reduction of invasive structures caused by 
SHP2 knockdown was rescued by all SHP2 constructs. These results showed that nuclear 
SHP2 is not required for the invasive phenotype of MCF10A HER2/3, SUM159 or 
SUM1315 cells in 3D cultures (Figure 35A and B, columns/bars 3-5). 
 
 
Figure 35 Nuclear SHP2 is not required for invasive behavior in 3D matrigel cultures 
(A) Knockdown of endogenous SHP2 led to a decrease of invasive structures which could 
be rescued by all NLS constructs. Representative phase contrast images of MCF10A 
HER2/3 (top), SUM159 (middle), and SUM1315 cells (bottom) grown in 3D cultures 
expressing CTRL miR or SHP2 miR2, or SHP2 miR2 and SHP2 NLS wt, del or mut 
constructs as indicated. Scale bars represent 50 m.  
(B-D) Bar graphs showing the percentage of invasive structures. The invasive phenotype 
of MCF10A HER2/3 (B), SUM159 (C), and SUM1315 cells (D) lacking endogenous 
SHP2 could be rescued by expression of SHP2 NLS wt, del or mut. Results are shown in 
means ± SEM.  
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Effects of nuclear SHP2 in vivo. 
To address the effects of nuclear SHP2 in vivo, we injected SUM1315 cells expressing 
dox-inducible SHP2 miR2 and dox-inducible HA-tagged SHP2 NLS wt, mut or del in the 
mammary fat pad of immunodeficient mice (Figure 36A). Inducing the knockdown of 
endogenous SHP2 and the expression of the different rescue constructs by dox food, we 
found that SUM1315 cells with only cytoplasmic SHP2 expressing the pLKO-TREX-
SHP2-HA NLS mutated construct formed significantly bigger tumors than cells expressing 
SHP2 NLS wt (located in cytoplasm and nucleus). No significant increase of tumor 
volume was found for NLS deleted xenografts (Figure 36B). The increased tumor volume 
for mice with NLS mutated xenografts was not caused by a higher overall expression of 
the rescue construct as checked by immunoblotting for the HA-tag (Figure 36C). 
 
 
Figure 36. Effects of depletion of nuclear SHP2 in vivo 
(A) Schematic overview of the in vivo experiment. 3 x 106 SUM1315 cells were injected in 
gland 2/3 of female NOD-SCID mice. Upon tumor onset, mice were fed with dox food to 
induce knockdown of endogenous SHP2 and expression of the different HA-tagged rescue 
constructs. 16 weeks after injection, the mice were sacrificed and tumors were dissected. 
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(B) Bar graph showing the tumor volumes. After dissection, the tumors were measured and 
the tumor volumes were calculated by the formula V = (a*b2)/2 where a is the length and b 
is the width of the tumor. Means ± SEM are shown (n=6 per group). *P < 0.05 by 
Student`s t test. n.s. = significant.  
(C) Representative immunoblot showing the expression level of the different rescue 
constructs in lysates from tumors. Equal expression of the HA-tagged rescue constructs 
among the different cohorts of mice was checked by immunoblotting of tumor lysates with 
anti-HA antibodies. ERK2 was used as a loading control. 
 
 
 
Microarray analysis. 
We then addressed the consequences of preventing nuclear import of SHP2 on gene 
expression by microarray analysis on these tumors. Gene expression in tumors from three 
animals per group was analyzed. The animals were selected on the basis of having the 
same level of rescue construct expression as checked by blotting against the HA-tag 
(Figure 36C). We found 15 genes that were commonly upregulated between tumors 
lacking nuclear SHP2 (NLS deleted and NLS mutated) when compared to tumors with 
nuclear and cytoplasmic SHP2 (NLS wt), while 44 genes were commonly downregulated 
between NLS mutated and NLS deleted when compared to NLS wt tumors (Figure 37A 
and B). Further in depth analysis will be required to understand the molecular effects of 
preventing nuclear import of SHP2. 
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Figure 37. Microarray analysis of tumors from NLS wt, mut, and del animals 
Gene expression of three SUM1315 xenografts per group (NLS wt mouse # 1, 2, and 4, 
NLS del mouse # 6, 7, and 8 and NLS mut mouse # 9, 10, and 11) was analyzed by 
microarray.  
(A) Venn diagrams showing the number of genes that were differentially expressed 
between the different experimental groups. 15 genes were found to be commonly 
upregulated in tumors lacking nuclear SHP2 (NLS del and NLS mut) when compared to 
the control NLS wt (left) and 44 genes were found to be downregulated (right). 
(B) List of the 20 most up- or downregulated genes between the NLS del and NLS mut 
tumors when compared to NLS wt tumors. The top 10 upregulated genes and their fold 
changes (FCs) are shown on the left and the top 10 downregulated genes their FCs are 
shown on the right. 
 
 
 
Investigation of nuclear substrates of SHP2 by SILAC proteomics. 
The physiological substrates of PTPs in the nucleus remain poorly defined, but they are 
important to understand the molecular mechanism of action of PTPs. Valuable tools to 
identify these substrates are substrate trapping mutants (Flint, Tiganis et al. 1997). These 
PTP mutants do not possess any catalytic activity and therefore bind tightly to their 
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tyrosine phosphorylated substrates. Hence, they can be used as tools to pull down their 
respective substrates from heterogeneous extracts. We used quantitative Stable Isotope 
Labeling by Amino acids in Cell culture (SILAC) proteomics in combination with 
substrate trapping mutants as an unbiased way to identify physiological substrates. 
We used a dox inducible system to knockdown endogenous SHP2. At the same 
time, we stably expressed dox-inducible HA-tagged SHP2 rescue constructs, either 
expressing the wild-type SHP2 sequence (wt) or a SHP2 double trapping mutant (trap) 
(Figure 38A-C). The double trapping mutant we used was previously described by Agazie 
and colleagues (Agazie and Hayman 2003) and contains two mutations compared to the wt 
SHP2 sequence. The Aspartic acid at position 425 was changed to Alanine and the 
Cysteine 459 at the catalytic site was changed to Serine rendering the phosphatase 
catalytically dead.  
 
 
 
 
Figure 38. Cell lines used for SILAC experiments 
(A) Schematic drawing of the constructs used. A small hairpin RNA SHP2 miR2 was used 
to knockdown endogenous SHP2 upon addition of dox. Dox also led to the expression of 
HA-tagged SHP2 with either the wild-type sequence (wt) or a double trapping mutant 
(trap) SHP2 with Asp425Ala+Cys459Ser mutations. 
(B) Representative immunoblot of SUM159 cells expressing dox inducible CTRL miR or 
miR2 targeting SHP2. Addition of dox led to the knockdown of endogenous SHP2 as 
shown in the blue box. ERK2 was used as a loading control. 
(C) Representative immunoblot of SUM159 cells expressing dox-inducible miR2 targeting 
endogenous SHP2 and dox-inducible HA-tagged SHP2 wt sequence or trapping mutant 
(trap). Expression of the rescue constructs is visualized by blotting with anti-HA 
antibodies and ERK2 was used as a loading control. 
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After ensuring the correct expression of all constructs, the cells were subjected to 
metabolic labeling by SILAC. A schematic overview of the quantitative SILAC MS 
procedure applied to detect differences in protein abundance between the SHP2 wt and 
SHP2 trapping mutant is given in Figure 39A.  
SUM159 or MCF10A HER2/3 SHP2 knockdown cells expressing the HA-tagged 
wt SHP2 were cultured in normal (light) medium, whereas cells expressing the HA-tagged 
SHP2 trapping mutant construct were cultured in heavy SILAC medium (containing 
13C615N4-Arginine and 13C6-Lysine). Sufficient incorporation above 95% of the heavy 
amino acids was reached after 5-6 cell doublings as checked by mass spectrometry (data 
not shown). Upon successful labeling, the cells were either lysed as whole cell lysates 
(WCL) or separated into nuclear and cytosolic fractions, processed and the peptides were 
subjected to mass spectrometry analysis.  
Validation of the IP efficiency in the cytosolic fraction, nuclear fraction and WCL 
showed good efficiency under the used conditions (Figure 39B). When separating the IP 
samples on 1D SDS gels, we detected many bands in each condition, each of them being 
one or more potential SHP2 substrates (Figure 39C). To verify the presence of SHP2 in 
each fraction, the bands around the molecular weight of SHP2 were excised and checked 
with mass spectrometry. This analysis confirmed the presence of SHP2 in the cytosolic 
and nuclear fraction of wt and trapping mutant cells (Figure 39D). 
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Figure 39. SILAC experiment with SUM159 cells 
(A) Schematic overview of the SILAC workflow. Cells were grown for 12 days in heavy 
(H) 13C615N4-Arginine and 13C6-Lysine containing or light normal medium (L) before 
being harvested as WCL or being fractionated into cytosolic and nuclear lysates. Equal 
amounts of protein of heavy and light fraction were mixed, immunoprecipitated with anti-
SHP2 antibodies and loaded onto a 1D SDS PAGE gel followed by O/N in gel tryptic 
digest. Purified peptides were analyzed by mass spectrometry, and the log2 ratios between 
the abundance in the heavy labeled condition over the not labeled condition grown in light 
medium was calculated for each protein identified (log2 ratios H/L). 
(B) Picture of a control immunoblot of the SUM159 samples before the anti-SHP2 IP 
(input) and after the IP (supernatants, SN). Shown are the cytosolic fraction, the nuclear 
fraction and the whole cell lysates (WCL) for wt SHP2 cells (wt) and cells expressing the 
trapping mutant (trap). While SHP2 is detected in all input fractions, no SHP2 signal is 
detected in the combined supernatant fractions (SN) showing a good efficiency of the IP. 
PARP is used as a nuclear marker and tubulin  is used as a cytoplasmic marker. 
(C) Picture of a Coomassie blue stained 1D SDS PAGE gel showing the IP samples of 
cytoplasmic and nuclear fraction and WCL before trypsin digest. Each band denotes one or 
more potential SHP2 substrates. 
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(D) Identification of SHP2 by mass spectrometry in all fractions. Visualization of SHP2 
peptides identified by Scaffold software analysis of the mass spectrometry data. Cytosolic 
and nuclear fractions of cells expressing wt SHP2 (C-WT and N-WT respectively) or 
trapping mutant SHP2 (C-Trap and N-Trap respectively) were analyzed. SHP2 was 
identified in all fractions and the number of peptides corresponding to SHP2 identified in 
each fraction is shown in green, indicating that the probability of correct identification is 
above 95%. 
 
 
The quantitative mass spectrometry experiment led to the identification of several 
known (such as GAB1, EGFR, and HER2 in MCF10A HER2/3 cells, STAT1 in SUM159 
cells and PZR and MVP in both cell lines) as well as several novel putative SHP2 
substrates.  
One interesting putative substrate that we found in the nuclear and WCL fraction is 
nucleolin. This multifunctional RNA-binding protein is mainly located in the nucleolus but 
also found in other nuclear regions as well as in the cytoplasm and at the plasma 
membrane (Borer, Lehner et al. 1989, Tuteja and Tuteja 1998, Ginisty, Sicard et al. 1999). 
Mammalian nucleolin has a predicted molecular mass of 77 kDa, however, because of 
highly phosphorylated residues in the N-terminal domain, the apparent mass is 100-110 
kDa (Bicknell, Brooks et al. 2005). With several predicted phospho tyrosine sites, 
nucleolin could therefore well be a SHP2 substrate (www.phosphosite.org, Figure 40A). 
We validated the interaction between SHP2 and nucleolin by co-immunoprecipitation 
experiments. Using SUM159 cells expressing the SHP2 trapping mutant, we could show 
the interaction between SHP2 and nucleolin by co-IP with anti-nucleolin antibodies 
followed by immunoblotting for SHP2, as well as by co-IP with anti-SHP2 antibodies 
followed by immunoblotting for nucleolin (Figure 40B). 
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Figure 40. Nucleolin is a putative substrate of SHP2 
(A) Schematic drawing of nucleolin sequence showing several tyrosine residues 
(www.phosphosite.org). 
(B) Picture of co-immunoprecipitations between SHP2 and nucleolin. Co-IPs were carried 
out using lysates from SUM159 cells expressing the D425A+C459S SHP2 trapping 
mutant. Lysates were immunoprecipitated using polyclonal anti-SHP2 antibodies and then 
immunoblotted using anti-nucleolin antibodies (left) or vice versa using anti-nucleolin 
antibodies for IP followed by immunoblotting with anti-SHP2 antibodies (right). In 
addition to the IP fraction, input (before IP) and supernatant (SN, after IP) were loaded as 
controls. The SHP2 IP was reprobed with anti-SHP2 antibodies and the nucleolin IP was 
reprobed with anti-nucleolin antibodies to check the IP efficiencies.  
 
 
 
Other putative substrates found in both cell lines included the Heat shock protein 
HSP90-beta encoded by the HSP90AB1 gene and the alpha2 subunit of the Guanine 
nucleotide-binding protein G(i) (Gi2) encoded by the GNAI2 gene. We could, however, 
not confirm the interaction between SHP2 and HSP90 using co-immunoprecipitation. The 
IPs and antibodies worked, but SHP2 was not co-immunoprecipitated in the anti-HSP90 IP 
and vice versa  HSP90 was not co-immunoprecipitated in the anti-SHP2 IP under the 
conditions used. Gi2 belongs to the Gi family of subunits that consists of the three 
members Gi1-3 (Wiege, Ali et al. 2013). Despite several attempts trying different 
commercially available antibodies and IP conditions, we could not find an antibody 
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detecting a specific band for Gi2. Therefore, we could not validate the interaction due to 
technical difficulties.  
 
Chromatin immunoprecipitation. 
We identified the silencing of several members of the HOX gene family in the absence of 
SHPβ as part of the “SHPβ signature” found by microarray analysis (Aceto, Sausgruber et 
al. 2012), suggesting a potential nuclear role of SHP2 in epigenetic regulation.  
In eukaryotic cells, chromosomal DNA is wrapped into nucleosomes around 
histone octamers, containing two copies each of histone H2A, H2B, H3, and H4 (Kornberg 
1977). Nucleosomes are then folded into chromatin fibers. Transcriptional regulation in 
eukaryotes is very complex and depends on RNA polymerases, transcription factors and 
co-regulators controlling their activity. Among these regulators, many proteins and 
enzymes modulating the chromatin by epigenetic mechanisms such as histone 
modifications or DNA methylation are found (Conaway 2012). 
To explore a possible function of SHP2 in these regulatory processes, we used 
chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq). 
Chromatin immunoprecipitation (ChIP) is a method used to study the interaction between 
a protein of interest and a specific region of genomic DNA (Carey, Peterson et al. 2009). 
ChIP-seq profiling was chosen because of its high signal-to-noise ratio, genome coverage 
and good spatial accuracy (Park 2009). To process the ChIP-seq data, the reads are aligned 
to the genome, followed by an evaluation of the read density pattern, which can be done by 
computational methods. Regions with statistically significant enrichment of reads aligned 
to the genome, indicate the binding of the protein of interest to this regions (Day, Luquette 
et al. 2010). 
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First, we tested whether SHP2 is found in the chromatin enriched fraction. During 
subcellular fractionations, the cells are divided into a cytoplasmic (C) and nuclear (N) 
fractions. The nuclear fraction can further be subdivided into a soluble part (N1) and a 
pellet, which is the chromatin enriched fraction N2 (Shiio, Eisenman et al. 2003, Liu and 
Fagotto 2011). We fractioned SUM159 and SUM1315 into cytoplasmic, nuclear and 
chromatin-enriched fractions and found SHP2 not only in the nuclear fraction N1, but also 
in the chromatin enriched fraction N2. SHP2 was further found in the chromatin-enriched 
fraction of MCF10A HER2/3, BT474 and MDA-MB-231 cells (Figure 41A). The histone 
mark H3K4me2 was used as a marker for the chromatin-enriched fraction. 
 
 
 
Figure 41. SHP2 is found in the chromatin enriched fraction N2 
Immunoblots of lysates from subcellular fractionations of SUM1315, SUM159, 
MCF10A HER2/3, BT474, and MDA-MB-231 cells into cytoplasmic (C), nuclear (N1) 
and chromatin enriched fractions (N2). Tubulin  was used as a marker for the 
cytoplasmic fraction, PARP for the N1 fraction, and the chromatin mark H3K4me2 was 
used as a marker for the chromatin enriched fraction.  
 
 
 
 For the ChIP-seq experiment, the genomic DNA and interacting proteins were 
crosslinked. Afterwards, the DNA strands were fragmented by sonication followed by an 
IP of the target protein SHP2. Following the IP pulling down all DNA fragments linked to 
SHP2, the DNA was de-cross linked, purified, and sequenced by deep-sequencing and the 
reads were mapped against the genome (Figure 42A). 
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Due to a lack of a commercially available ChIP grade anti-SHP2 antibody, we first 
validated the specificity of the SHP2 antibody for ChIP application. We detected a specific 
band for SHP2 that markedly decreased in SHP2 knockdown cells (Figure 42B and C). 
 
 
 
Figure 42. ChIP with anti-SHP2 antibodies 
(A) Schematic overview of the ChIP-seq experiment. 1) After crosslinking DNA and 
proteins in the nucleus, the DNA was fragmented into 300 bp pieces by sonication. 2) 
Next, DNA fragments bound to the protein of interest (SHP2) were isolated by co-
immunoprecipitation with SHP2. 3) De-crosslinking to remove the proteins from the DNA 
and DNA purification, 4) Sequencing of the isolated DNA fragments were sequenced and 
mapping of the reads to the genome. 
(B) Immunoblot of lysates from a ChIP experiment of SUM159 cell lysate showing a 
specific band for SHP2 in the SHP2 ChIP that is absent in the IgG control. Whole cell 
lysate was used as a positive control (input).  
(C) Immunoblot of lysates from a anti-SHP2 ChIP of SUM159 cells expressing the dox-
inducible miR2 targeting SHP2 in absence (-) or presence (+) of dox. The decrease of the 
SHP2 band in the SHP2 knockdown cells (+ dox) confirmed the specificity of the SHP2 
antibody under the experimental conditions used. 
 
 
After establishing the ChIP conditions for cells grown in 2D, we performed a ChIP 
experiment in SUM159 and SUM1315 cells followed by deep sequencing. Preparation of 
the DNA libraries was successful, as indicated by single peaks at the expected size (Figure 
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43A), and the samples were sequenced. The high-throughput sequencing was also 
successful, however, a poor signal-to-noise ratio made computational analysis of the data 
impossible. Nevertheless, manual analysis revealed several promising peaks which could 
not be explained by abundant repetitive elements (Figure 43B).  
 
 
 
Figure 43. ChIP-seq analysis of DNA regions purified by SHP2 immunoprecipitation 
(A) ChIP-seq library preparation. Snapshots of Agilent bioanalyzer quality control files are 
shown. After repairing the ends of the ChIP fragments, adding an A to the 3`ends and 
ligating the adapters, DNA fragments were selected for a size of 300 bp.  
(B) Examples of University of California Santa Cruz (UCSC) genome browser snapshots 
with an example of a peak identified on chromosome 5 found in SUM159 (top) and 
SUM1315 cells (bottom) by anti-SHP2 IP mapped to the genome. The y-axis depicts the 
peak amplitude and the x-axis shows the position of each peak on the genome. The 
RepeatMasker function identifies repetitive DNA elements such as short interspersed 
nuclear elements (SINEs) and long interspersed nuclear elements (LINEs), which can 
cause accumulations of reads. The red box indicates a manually identified peak on 
chromosome 5 that was found in both cells lines at a position devoid of repetitive 
elements.  
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Therefore, the next step was to design real-time PCR primers to amplify the region under 
the manually identified peaks and also for areas with no peaks as negative controls. 
Quantitative real-time PCR using these primers on input chromatin and ChIP fraction 
would allow calculating the fold-enrichment after ChIP giving means to improve the IP 
conditions. However, the signal for the designed real-time PCR primers was below 
threshold level for input and ChIP samples.  
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6.3 DISCUSSION 
 
Nuclear localization and nuclear import of SHP2. 
An increasing number of non-cytoplasmic functions for the phosphatase SHP2 were 
reported over the recent years in several cell lines, but only in one HER2-positive breast 
cancer cell line (Chughtai, Schimchowitsch et al. 2002). For the first time, we could 
demonstrate the presence of nuclear SHP2 in a panel of breast cancer cell lines including 
other subtypes such as triple-negative breast cancer. We examined the nuclear localization 
with different methods. First, we used subcellular fractionations followed by 
immunoblotting, second we used immunofluorescence techniques, and third we detected 
SHP2 in the nuclear fraction by mass spectrometry. In summary, we showed that SHP2 is 
found in the nucleus in several breast cancer cell lines. The amount of nuclear SHP2 in 
breast cancer cell lines was similar to what was previously reported for fibroblasts (Yuan, 
Yu et al. 2003). 
We further described a novel mechanism of nuclear import for SHP2 by a pat4 
nuclear localization sequence (NLS). Most of the reports describing nuclear functions of 
SHP2, did not comment on the mechanism of nuclear import. One study identified a half-
bipartite nuclear localization sequence within the carboxyl-terminal distal region of SHP1, 
but could not identify a NLS in the SHP2 sequence (Craggs and Kellie 2001). Chughtai 
and colleagues suggested STAT5a to act as a carrier to translocate SHP2 into the nucleus 
upon prolactin stimulation (Chughtai, Schimchowitsch et al. 2002). Other reports showing 
nuclear localization of the phosphatase did not comment on how SHP2 passes the nuclear 
pore complex to enter the nucleus (Jakob, Schroeder et al. 2008, Takahashi, Tsutsumi et al. 
2011).  
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What is the function of nuclear SHP2 in breast cancer? 
Using several in vitro assays, we tested the effects of cytoplasmic and nuclear versus only 
cytoplasmic SHP2. We did not find effects on the number of viable cells, but found 
increased colony formation capacity in absence of nuclear SHP2. We further found that 
nuclear SHP2 was dispensable for invasion in vitro. Testing the effects of depleting 
nuclear SHP2 in vivo, we found an increased tumor volume for xenografts of cells 
expressing the NLS mutated construct, but only a not significant trend for the NLS deleted 
construct. To assure that the bigger tumors in the NLS mutated and NLS deleted 
conditions were not the result of a higher overall SHP2 expression, we compared the 
expression levels in the tumors by anti-HA immunoblotting. This analysis revealed an 
even expression of SHP2 in all groups. Therefore, one could argue that the increased 
tumor growth is in fact the result of expression of only cytoplasmic SHP2. This would 
suggest, that a higher amount of SHP2 in the cytoplasm leads to more oncogenic signaling 
and hence more tumor growth. Following this line of thoughts, one can speculate that 
SHP2 translocation to the nucleus might have less of a functional role, but rather could be 
considered as a regulatory mechanism to stop from SHP2 signaling in the cytoplasm. 
However, to test this hypothesis and confirm these results, we will repeat the in 
vivo experiment. It would also be advisable to test the effect of depletion of nuclear SHP2 
in a second model to make sure the effects observed are not cell line specific. Repeating 
this experiment will also help to elucidate, if there are differences between deleting and 
mutating the NLS.  
 As three-dimensional modeling of the SHP2 protein showed the importance of the 
fourth Lysine residue of the NLS for the tertiary folding structure of the protein, we did not 
change this residue when mutating or deleting the NLS. However, it could still be possible 
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that the mutation or deletion caused structural changes that might explain the different 
results with the two constructs.  
 We also analyzed the gene expression profiles of tumors from each experimental 
group by microarray and found genes commonly up- or downregulated in absence of 
nuclear SHP2 when compared to NLS wt tumors. Understanding these changes upon 
depletion of nuclear SHP2 will require further in depth analysis of the microarray data. 
Repeating the in vivo experiment and microarray analysis in a second model would further 
be helpful, to unravel more general and not cell line specific changes.  
 
What are nuclear substrates of SHP2? 
We used an unbiased approach combining metabolic labeling proteomics and a 
phosphatase substrate trapping mutant to discover novel nuclear substrates of SHP2. Using 
quantitative SILAC proteomics, we identified several known and also novel putative 
substrates including nucleolin.  
 Nucleolin levels have been shown to be significantly elevated in many cancer cells 
(Tominaga, Srikantan et al. 2011) and more recently, cell-surface expressed nucleolin has 
been linked to tumor cell growth and angiogenesis (Destouches, El Khoury et al. 2008, Di 
Segni, Farin et al. 2008, Reyes-Reyes and Akiyama 2008). We confirmed the interaction 
between nucleolin and SHP2 by co-IP experiments. The next steps to validate nucleolin as 
a true SHP2 substrate will be: 1) To show increased phosphorylation of nucleolin in SHP2 
depleted cells, 2) to identify the tyrosine sites dephosphorylated by SHP2, and 3) to show 
that a tyrosine to phenylalanine mutant of the substrate (that cannot be phosphorylated by a 
PTK) can mimic the effects of SHP2. This mutant should rescue the downstream functions 
of SHP2 in SHP2-deficient cells.  
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Other putative SHP2 substrates we attempted to validate were HSP90-beta and Gi2. 
Although both were detected to be bound by the SHP2 trapping mutant by mass 
spectrometry, we did not succeed to validate the interaction by co-IP. This could be 
attributed to limitations of the antibodies used, or the co-IP conditions might need further 
optimization such as cross-linking to detect low affinity or transient interactions. 
Alternatively, one could try a pull-down assay in which, in contrast to the co-IP, not the 
antibody but a bait protein of the interacting pair is immobilized. Another advantage of the 
pull-down assay is that the amount of bait protein can be increased above native level.  
 However, both putative substrates are very interesting and worth future 
investigation. The chaperon protein HSP90 is often overexpressed in human tumors and 
mediates the folding and stabilization of many proteins playing important roles in a variety 
of signal transduction pathways including oncogenic proteins such as HER2, AKT and 
c-Raf (Pratt 1998, Maloney and Workman 2002). Further, there are some interesting 
parallels between Gi2 and SHP2 functions. Enhanced signaling through Gi2 produced a 
Noonan Syndrome (NS) like phenotype (Huang, Fu et al. 2009) and 50% of NS cases are 
caused by germline missense gain-of-function mutations of the PTPN11 gene encoding 
SHP2 (Tartaglia, Mehler et al. 2001). Another parallel placing SHP2 and Gi2 in the same 
pathway, was the finding of a tumor suppressive function of Gi2 in hepatocellular 
carcinoma (Yao, Liang et al. 2010), the one single cancer type in which SHP2 was found 
to be a tumor suppressor (Bard-Chapeau, Li et al. 2011) while acting as an proto-oncogene 
in many other cancers studied to date (Chan, Kalaitzidis et al. 2008). 
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Is SHP2 involved in epigenetic regulation? 
We also explored a possible involvement of SHP2 in epigenetic regulation. This 
hypothesis was based on our finding that several HOX family members were silenced in 
absence of SHP2 (Aceto, Sausgruber et al. 2012). We therefore attempted to address a 
potential direct or indirect role for SHP2 in chromatin remodeling. 
 Indeed, we could show that SHP2 is found in the chromatin enriched fraction of 
several breast cancer cell lines. We validated our SHP2 antibody as being suitable for 
ChIP, but were unable to test the fold enrichment of the IP fraction over the input fraction 
(lysates before IP), as there are no known targets of SHP2 to test for. Therefore, after 
establishing the conditions, we performed a "blind" ChIP experiment not knowing the fold 
enrichment, followed by high-throughput sequencing. The fold enrichment was not 
sufficient and resulted in to a poor signal-to-noise ratio that made computational analysis 
of the data impossible. Therefore, we manually screened the genome browser tracks for 
peaks apparent in both cell lines and which could not be explained by known repetitive 
structures in the genome. Sequencing the input of both cell lines would help to exclude 
noise and repeats specific to the cell lines used. Based on the manual analysis, we 
identified several promising peaks and designed real-time PCR primers to amplify these 
regions; however the primers designed did not give any detectable product in either input 
or ChIP fraction making it impossible to calculate the fold enrichment. Being able to 
calculate the fold enrichment would enable us to directly observe consequences of altering 
the experimental conditions such as cross-linking, salt concentrations or the antibody used. 
This would allow optimization before repeating the ChIP under the newly found 
conditions followed by deep sequencing. Other options worth exploring could be to test 
other antibodies or to perform ChIP against a tagged protein. 
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7 OUTLOOK 
 
 
We found that SHP2 knockdown eradicated tumor initiating cells (TICs), blocked primary 
tumor growth and reduced migration, invasion, and metastasis. These observations suggest 
SHP2 as a potential drug target in breast cancer, particularly in HER2-positive and triple-
negative breast cancer, the two preclinical models that we studied.  
 Our findings suggest that inhibition of SHP2 blocks tumor growth and metastatic 
spread. The effect of SHP2 on the primary tumor growth can be explained by the effects of 
SHP2 on TICs, which are thought to drive and sustain the tumor and have been implicated 
in the relapse of disease after successful initial treatment (Clevers 2011). The effect of 
SHP2 on metastasis can be explained as a consequence of depleting TICs, which have 
been also implicated in metastatic spread (Li, Tiede et al. 2007). Alternatively, this effect 
could be explained by blocking the migration and invasion of all tumor cells. 
 Our studies focused only on the effects of SHP2 depletion on the primary tumor 
and early stages of metastasis. It remains to be determined whether inhibition of SHP2 in 
already established metastases will be effective.  
 Further, it remains unknown whether SHP2 inhibition would be effective as 
monotherapy or if combination therapies would be needed. Because TIC fate represents a 
dynamic equilibrium, inhibition of TICs alone might not be successful, as non-stem cancer 
cells can transform into TICs (Iliopoulos, Hirsch et al. 2011). Therefore, the combination 
between SHP2 inhibition and agents targeting the bulk of the (non-stem) tumor cells might 
increase and sustain efficacy. 
Resistance to targeted therapies often occurs within a few months, especially when 
used as a single therapy (Sellers 2011). Studies addressing the effects of prolonged SHP2 
inhibition will be needed to investigate the potential resistance mechanisms that might 
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arise. It is conceivable that upon inhibition of SHP2, tumor cells might mutate the target 
and/or activate SHP2 downstream or bypass pathways. Functional genetic screens are 
warranted to address this question. These studies should allow the design of rational 
combination therapies. 
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8 MATERIALS and METHODS 
8.1 Materials 
8.1.1 General laboratory reagents 
General laboratory chemicals such as ethanol, methanol, isopropanol, glycerol, HCl, 
sodium hydroxide, Tris-HCl and Triton X-100 were obtained from Merck and Sigma. 
Bovine serum albumin (BSA) was purchased from Sigma. Purified water, phosphate 
buffered saline (PBS), 1 x LB-media and 1 x 2YT were prepared by the FMI media 
preparation facility according to standard protocols. 
8.1.2 DNA manipulation reagents 
DNA restriction enzymes, DNA markers and DNA modifying enzymes such as T4 ligase 
and CIP were obtained from New England Biolabs. DNA purification Miniprep and 
Midiprep system were obtained from GENOMED and PCR purification kits were from 
QIAGEN. Taq Polymerase and dNTPs were from ROCHE. Agarose and SYBR Safe DNA 
stain as well as 100 bp and 1 kb ladders were obtained from Invitrogen.  
8.1.3 Tissue culture reagents 
Dulbecco’s Modified Eagle Medium (DMEM), Roswell Park Memorial Institute (RPMI) 
1640 medium and anti-antibiotic cocktail (100 IU/ml of penicillin and 100 µg/ml of 
streptomycin) were obtained from the FMI media preparation facility. DMEM/F12 
medium (Cat#31330-038), 0.05% Trypsin-EDTA (Cat#25300-054), and Horse serum 
(Cat#16050-122) were from Invitrogen. HAM’s F1β medium (Cat#N6658), Fetal Bovine 
Serum (FBS; Cat#F7524), Hydrocortisone (Cat#H0888), Cholera Toxin (Cat#C8052), 
Doxycyclin (Cat#D9891) and human Insulin (Cat#I5500) were obtained from SIGMA. 
Human EGF (Cat#100-15) was from Peprotech. PD184352 (Cat#CI-1040) was purchased 
from Biovision. 
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8.1.4 Antibodies 
Table 1 Primary and secondary antibodies 
Antigen species Cat # company dilution 
Akt rabbit 9272 Cell Signaling WB 1:1000 
ERK2 (C-14) rabbit sc-154 Santa Cruz WB 1:1000 
ERK2 (D-2) mouse sc-1647 Santa Cruz WB 1:1000 
H3K4me2 rabbit 9725 Cell Signaling WB 1:1000 
HA mouse MMS-101P Covance WB 1:500 
HER2 mouse OP15 Calbiochem WB 1:1000 
HER3 rabbit sc-285 Santa Cruz WB 1:100 
N-Cadherin mouse 610920 BD Biosciences WB 1:5000 
p42/44 Erk rabbit 9102 Cell Signaling WB 1:1000 
pAkt S473 rabbit 9271 Cell Signaling WB 1:1000 
PARP  rabbit 9542 Cell Signaling WB 1:1000 
pFAK Y577  rabbit 3281 Cell Signaling WB 1:1000 
pPaxillin Y118 rabbit 2541 Cell Signaling IF 1:50 
pSrc Y416 rabbit 2101 Cell Signaling WB 1:1000 
pSrc Y530 rabbit 2105 Cell Signaling WB 1:1000, IF 1:50 
pTyr 4G10 mouse 05-321 Millipore WB 1:1000 
SHP2 (B-1) mouse sc-7384 Santa Cruz WB 1:1000, IF 1:500 
SHP2 (C-18) rabbit sc-280 Santa Cruz WB 1:1000, IP 1 µg / 1000 µg 
Src rabbit 2109 Cell Signaling WB 1:1000 
Src mouse 05-184 Millipore IP 4 g /1000 g protein 
Tubulin  mouse MS-581-P1 Neomarker WB 1:10000 
Secondary antibodies 
Alexa Fluor 488 mouse A11029 Invitrogen IF 1:200 
Alexa Fluor 488 rabbit A11034 Invitrogen IF 1:200 
Alexa Fluor 568 mouse A21202 Invitrogen IF 1:200 
Alexa Fluor 568 rabbit A10042 Invitrogen IF 1:200 
Alexa Fluor 633 mouse A21136 Invitrogen IF 1:200 
Alexa Fluor 633 rabbit A21071 Invitrogen IF 1:200 
Alexa Fluor 647 mouse A31571 Invitrogen IF 1:200 
Alexa Fluor 647 rabbit A21245 Invitrogen IF 1:200 
Alexa Fluor 680 mouse A21058 Invitrogen WB 1:10000, IF 1:200 
Alexa Fluor 680 rabbit A21076 Invitrogen WB 1:10000 
IRDye800 mouse 610-632-002 Rockland WB 1:10000 
IF: Immunofluorescence; IP: immunoprecipitation; WB: Immunoblot 
 
8.1.5 Vector information 
For the inducible shRNA studies, 97-mer shRNAmiR (miR) were obtained from Sigma, 
PCR-amplified, sequence-confirmed and cloned into the dox inducible lentiviral vector 
pINDUCER (Meerbrey, Hu et al. 2011). We used β miRs targeting SHPβ, SHPβ miR1 (5’-
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TGCTGTTGACAGTGAGCGCGGGCACGAATATACAAATATTTAGTGAAGCCACA
GATGTAAATATTTGTATATTCGTGCCCTTGCCTACTGCCTCGGA-γ’) and SHPβ 
miRβ (5’-TGCTGTTGACAGTGAGCGACCACGTATATTATGTAGTCTATAGTGAA 
GCCACAGATGTATAGACTACATAATATACGTGGGTGCCTACTGCCTCGGA-γ’) 
and miR targeting ZEB1 (5’-TGCTGTTGACAGTGAGCGAGCGCAATAACGTTAC 
AAATTATAGTGAAGCCACAGATGTATAATTTGTAACGTTATTGCGCCTGCCTA
CTGCCTCGGA-γ’). As a control, we used a miR targeting firefly luciferase (CTRL miR). 
Constitutive ERK5 shRNAs were obtained from Sigma. Rescue experiments were 
performed with retroviral vector pMSCV-neo-SHP2-WT, the retroviral vector pBabe-
puro-LIN28B (Addgene), lentiviral vector pSD-94-c-Myc (Duss, Andre et al. 2007) and 
the dox inducible lentiviral vector pLKO-TREX-HA (Wee, Wiederschain et al. 2008) 
expressing SHP2 WT or the catalytically inactive SHP2 C/S or SHP2 D/A+C/S mutant or 
SHP2 NLS deleted or mutated mutants. All SHP2 mutants were generated by site-directed 
mutagenesis of SHP2 WT. For in vivo monitoring by fluorescence or bioluminescence, the 
cells were infected with the lentiviral pFU-Luc2-eGFP vector expressing GFP-Luciferase 
(Liu, Patel et al. 2010). For lentiviral production the following helper plasmids were used: 
HDM-tat16, HDM-HgPM2, pRC-CMV-RaII and HDM-VSV-G. For retroviral production 
retroviral constructs were co-transfected with VSV and gag-pol into the packaging cell line 
293 EBNA. 
 
 
8.2 Cell Culture & cell based functional assays 
All cells were grown at 37°C in a humidified atmosphere with 5% CO2 in presence of 
100 IU/ml of penicillin and 100 µg/ml of streptomycin in their respective growth media. 
Regular Mycoplasma tests were performed by PCR. All cells were frozen in their 
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respective growth medium with 10% DMSO except MCF10A cell lines, which were 
frozen in their growth medium with 20% horse serum and 8% DMSO. 
 
Table 2 Culture condition of various cell lines 
Cell line medium additives 
BT474, HEK293T, MDA-MB-231 DMEM 10% FBS 
SUM159 Ham`s/F12 5% FBS, 10 µg/ml Insulin, 500 ng/ml 
Hydrocortisone 
SUM1315 Ham`s/F12 5% FBS, 10 µg/ml Insulin, 20 ng/ml EGF 
SKBR3 RPMI 1640 10% FBS 
MCF10A HER2/3 DMEM/F12 5% HS, 10 µg/ml Insulin, 20 ng/ml EGF,  
100 ng/ml Cholera toxin,  
500 ng/ml Hydrocortisone 
 
8.2.1 Mammosphere assays 
Single cells were seeded on Ultra Low Attachment Plates (ULA, Corning, Cat#734-1582) 
at a concentration of 100,000 cells/ml. For experiments with inducible miRs, dox was 
added at the beginning of the tumorsphere assay and refreshed every 2-3 days. 
Tumorspheres larger than 50 µm diameter were counted 7 days after seeding 
(1° tumorspheres). All the primary spheres were isolated from the rest of the cells, 
dissociated with HyQTase (Thermo Scientific) and filtered through a 40 µm cell strainer to 
obtain a single cell suspension. Equal numbers of single cells (20,000 cells/ml) were then 
seeded on new ULA plates in the presence of dox. The number of tumorspheres was 
counted after 7 days (2° tumorspheres). 
8.2.2 Transwell migration assays 
Migration assays were performed using transwell chambers (8 μm pore size, BD 
Biosciences, Cat#354778) according to the manufacturer's protocol. SUM159 or MDA-
MB-231 cells expressing either the CTRL miR or SHP2 targeting miR1 or miR2 were 
starved for 16 h prior to seeding into the top well of the transwell insert. 15,000 cells were 
seeded in 500 l medium containing 0.25% FBS (SUM159) or 0.5% FBS (MDA-MB-231) 
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and 750 l of full growth medium including 5% FBS (SUM159) or 10% FBS (MDA-MB-
231) was added to the lower well as the chemoattractant. Cells were allowed to migrate 
towards the FBS gradient for 24 h before the inserts were washed with PBS and non-
migrated cells remaining on the upper surface of the membrane were removed using cotton 
swabs. The cells that had migrated through the membrane were fixed with 4% PFA and 
stained with 0.2% Crystal violet. The whole membranes were then imaged using a Leica 
MacroFluo widefield microscope with a 2 x objective and 0.9 x motor zoom. Migrated 
cells were counted on the whole membrane in 3 independent experiments. The number 
counted for cells expressing CTRL miR was set to 100%.  
8.2.3 Invasion assay in vitro 
In vitro invasion experiments were performed using BD BioCoat™ Matrigel invasion 
chambers (BD Bioscience, Cat#354480). 15,000 serum starved SUM159 or MDA-MB-
231 cells were seeded into the upper well of the cell culture inserts containing an 8 μm 
pore size PET membrane with a thin layer of matrigel in 500 l medium containing 0.25% 
or 0.5% FBS respectively. 750 l full growth medium containing 5% FBS (SUM159) or 
10% FBS (MDA-MB-231) was added to the lower well as a chemoattractant. The cells 
were allowed to migrate for 40 h at 37°C, after which the filter was washed 1 x with PBS. 
Then, the non-invading cells were removed from the upper surface of the membrane using 
a cotton swab. After this, the invading cells attached to the bottom of the membrane were 
fixed and stained with 0.2% Crystal violet 4% PFA in PBS solution for 30 min at RT. 
After 3 washes with PBS, the membranes were allowed to dry, then imaged with a 
MacroFluo widefield microscope using a 2 x objective and a 0.9 x zoom factor. Invasive 
cells were counted in 3 independent experiments. The average number of invasive cells 
counted for cells expressing the control construct was set to 100%.  
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8.2.4 3D cell culture assay 
Growth factor reduced matrigel (BD Biosciences, Cat#354230) was thawed on ice O/N 
and 40 μl were spread evenly in each well of an 8-well glass chamber slide (BD Falcon, 
Cat#354108). The slide was put in the incubator (37°C) for 30 min to allow the matrigel to 
solidify. Then, MCF10A HER2/3 cells (4,500 cells per well) were seeded on the matrigel 
in a total volume of 400 μl in assay medium (DMEM/F12 medium supplemented with 2% 
matrigel, 2% HS, 5 ng/ml EGF, 0.5 µg/ml of hydrocortisone, 100 ng/ml of cholera toxin, 
10 µg/ml of insulin, 100 IU/ml of penicillin and 100 µg/ml of streptomycin). The next day, 
γ00 μl of assay medium containing 2% matrigel were added to the cells. On day 5, the 
medium was replaced with 400 μl fresh assay medium containing 2% matrigel. From this 
day on, the medium was replaced with 400 μl of assay medium every 4 days until the end 
of the experiment (14 days total). The same protocol was followed for the 3D culture of 
SUM159 and SUM1315 cells, only that these cells were cultured in their normal growth 
medium with reduced serum (2% FBS). After 2 weeks, the percentage of invasive 
structures was counted. 
8.2.5 WST-1 proliferation assay 
To compare the cell number of different cell lines, cell proliferation WST-1 reagent from 
ROCHE was used (Cat#05015944001). 2,000 SUM1315 cells in 200 μl were plated in 
triplicates in 96-well plates and incubated for 5 days. Then 10 μl WST-1 reagent was 
added to each well, incubated for 4 h at 37°C and read at 550 nm. The assay is based on 
the cleavage of the stable tetrazolium salt WST-1 into the dye formazan by metabolically 
active cells. The formazan dye formed is quantitated and the measured absorbance directly 
correlates to the number of viable cells. 
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8.2.6 Colony formation assay 
2,000 SUM1315 cells were seeded per well in 6-well plates in 2 ml culture medium for 2 
weeks. Then, the colonies were washed with PBS, fixed with 4% PFA and visualized by 
staining with 0.2% Crystal violet. The plates were scanned using an Epson Twain scanner 
and the area covered by colonies was analyzed and quantitated using ImageJ/Fiji software. 
Therefore, the images were converted to 8 bit format, followed by segmentation by 
adjusting the threshold, conversion to binary images and the number of colonies/area 
covered was obtained by using the analyze particles command. 
 
 
8.3 Microscopy 
8.3.1 Immunofluorescence  
8-well glass chamber slides (BD Falcon, Cat#354108) were coated with 200 µl of 
0.1 mg/ml Poly-L-Lysine (SIGMA, Cat#P6282) for 2 h at RT or 10 μg/ml Fibronectin 
(SIGMA, Cat#1141) for 1 h at 37°C. After the incubation, the slides were washed 2 x with 
dH2O. Then, 5,000 cells were seeded per well in normal growth medium. The next day, the 
cells were washed 2 x with PBS and fixed with 4% PFA shaking at RT for 10 min. Before 
the staining, cells were permeabilized with 0.1% Triton-X in PBS for 10 min at RT. 
Afterwards the cells were washed 3 x 5 min with PBS and blocked with 2.5% normal goat 
serum (NGS) in PBS for 1 h at RT. Then, the samples were incubated with the primary 
antibody in 2.5% NGS in PBS O/N at 4°C in a humidified chamber. As a negative control, 
1 well was left without primary antibody. The next day, the cells were washed 3 x 5 min 
shaking at RT with PBS+1% BSA, then incubated with the secondary antibody in 2.5% 
NGS in PBS for 1 h at RT in the dark. After 2 x 5 min washing with PBS, the nuclei were 
stained with DAPI (2 mg/ml; Invitrogen, Cat#1306) diluted 1:10,000 in PBS for 10 min at 
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RT. After 2 more washes for 5 min with PBS, the slides were dried and mounted with 1 
drop Prolong Gold antifade mounting medium (Invitrogen, Cat# P36934). 24 h later, the 
slides were analyzed or stored at 4°C. 
8.3.2 FRET acceptor photobleaching  
Fluorescence resonance energy transfer (FRET) is based on the non-radioactive transfer of 
energy from one fluorescent protein (donor) to another fluorescent protein (acceptor), that 
needs to reside in close proximity (Snapp and Hegde 2006). Upon excitation, the donor 
transfers energy to the acceptor which then emits energy, although it was not excited. 
There are several different FRET methods and instrumental setups (Jares-Erijman and 
Jovin 2003). FRET acceptor photobleaching most widely used, as it is relatively simple to 
set up and interpret (Snapp and Hegde 2006).  
 FRET samples were always prepared fresh the day before conducting the 
experiment. Cells were grown in 8-well chambers coated with 10 µg/ml Fibronectin 
(Sigma, Cat#1141). SHP2 and total Src or pSrc Tyr530 were labeled with specific primary 
antibodies and with a donor (Alexa 568) or acceptor (Alexa 633) fluorophore-conjugated 
secondary antibody. As endogenous proteins (used in this setup) are rarely expressed at the 
same level, the decision which protein to use as donor or acceptor is crucial. Generally, the 
protein with lower abundance is used as the donor, as an excess of unpaired acceptor 
molecules does not interfere with the results, while an excess of unpaired donor molecules 
dilutes the detected FRET signal (Snapp and Hegde 2006). In this setup, SHP2 was 
visualized using secondary anti-mouse Alexa 633-conjugated antibody (acceptor). Src and 
pSrc Tyr530 were visualized using secondary anti-rabbit Alexa 568-conjugated antibody 
(donor). As a positive control for FRET, SHP2 (mouse primary antibody) was labeled with 
anti-mouse Alexa 568 and anti-mouse Alexa 633, ensuring that donor and acceptor are in 
close proximity. As a negative control, Src (rabbit primary antibody) was labeled with 
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anti-rabbit Alexa 568 and anti-mouse Alexa 633, resulting in no FRET signal. Slides were 
mounted in a mix of 90% glycerol and 10% Tris-HCl pH 8.5 without anti-fading additives. 
Acceptor photobleaching was used to assess FRET efficiency on a Zeiss LSM700 confocal 
microscope equipped with a 40 x/1.3 oil immersion objective. Alexa 568 was excited with 
a 555 nm laser line and the emission was measured with a LP560 filter. Alexa 633 was 
excited with a 640 nm laser line and the emission was measured with a LP640 filter. 
Several regions of interest (ROIs) were designated. ROI 1 was the region bleached, ROI 2 
a region close by to control for unwanted bleaching and ROI 3 a region outside the cell to 
measure background fluorescence and serial images of the donor and acceptor intensities 
were taken before and after photobleaching. FRET efficiency (%E) was calculated by 
comparing the donor (D) intensities in the bleached ROI 1, before (Dpre) and after (Dpost) 
photobleaching. Donor intensities were corrected for background fluorescence (subtraction 
of ROI 3) before E was calculated as %E = (Dpost-Dpre)/Dpost. This formula calculates the 
fluorescence that has been quenched from the donor in presence of the acceptor (Snapp 
and Hegde 2006). For each condition, 4 to 10 cells from 2-3 experiments were assessed. 
8.3.3 Time-lapse microscopy 
For live imaging studies, randomly growing SUM159 or MDA-MB-231 cells expressing 
dox-inducible CTRL miR or one of 2 miRs targeting SHP2 (miR1 or miR2) cultured in 
presence of 1 g/l dox were seeded on 6-well polystyrene dishes (Corning) and imaged 
the following day. For time-lapse analysis, cells were incubated on a heated stage at 37°C 
in a 5% CO2 chamber. The imaging was carried out with a Zeiss Widefield Axiovert 200M 
enclosed in an incubator box with a CCD camera and 3-4 positions per well were imaged. 
Images were taken over a period of 12 h at 10 min intervals in the DIC channel using 
MetaMorph software. The acquired data was compiled to stacks, saved as movies and 
analyzed using ImageJ/Fiji software. Cell movement of 20 cells per movie was analyzed 
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using the ImageJ/Fiji plugin MTrackJ (Meijering, Dzyubachyk et al. 2012). Briefly, cells 
to be analyzed cells were randomly picked on the first frame of the movie. The position of 
one cell at a time was monitored manually by clicking on the nucleus of the cell in every 
second frame (20 min intervals) until the end of the movie, resulting in trajectories for 
each cell monitored. In the case of dividing cells, one of the daughter cells was randomly 
chosen and followed. Cells disappearing from the field of view were excluded from the 
analysis. 
 
8.3.4 Multiphoton intravital microscopy 
8.3.4.1 Microscope description 
For intravital imaging experiments, we used our previously described custom built 
microscope. Signals from the microscope are acquired and converted to real-time images 
by a custom-made algorithm based on Matlab (MathWorks, Natick, Mass. USA), before 
being analyzed offline (Bonapace, Wyckoff et al. 2012). 
8.3.4.2 Anesthesia and surgery of tumor-bearing animals 
1 x 106 SUM159 cells or 5 x 105 MDA-MB-231 GFP-Luciferase positive breast cancer 
cells were injected into gland 4 of six week old female NOD-SCID immunodeficient mice. 
After two weeks, the injections were checked by Luciferase expression. The tumors of 
both groups were allowed to reach 6-8 mm diameter (6 weeks after injection for SUM159, 
3 weeks for MDA-MB-231), before the knockdown of SHP2 was induced by feeding the 
mice with dox food. 10 days later, single cell movement in tumors was imaged by 
intravital microscopy using a custom built two-photon microscope (Bonapace, Wyckoff et 
al. 2012).  
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For the imaging, the mice were placed under anesthesia with 5% isoflurane and maintained 
for the course of the imaging session at 2.5% to 0.5% isoflurane to control constant 
breathing. Minimal surgery was performed to expose the tumor by removing a small skin 
flap. Then the mouse was put on the inverted microscope and imaged at 880 nm for GFP 
fluorescence. For visualizing the of the blood vessels and macrophages, β00 μl of β0 
mg/ml 70,000 kDa Texas red-dextran (Molecular Probes, Cat#D1894) in PBS were 
injected into the tail vein of the mice before surgery.  
8.3.4.3 Measurement of cell behavior 
Cell motility, matrix density, macrophage density and vessel leakiness were visualized by 
time-lapse multiphoton microscopy by taking 100 μm Z-stacks collected at 2 min intervals 
for at least 30 min. Image analysis was carried out using Fiji/ImageJ software. Raw data 
was arranged into 4D hyperstacks for analysis. Velocity, directionality and path length 
were analyzed using the plugin ROI tracker (Entenberg, Wyckoff et al. 2011).  
 
 
8.4 Molecular methods  
8.4.1 Transformation 
8.4.1.1 Preparation of chemically competent DH5 
A single colony of untransformed chemically competent DH5 cells was inoculated in 
2 ml LB-only media and incubated O/N at 37°C shaking. The next morning, 1 ml of the 
culture was added to 150 ml LB media and incubated at 37°C shaking until an OD600 of 
0.6 was reached (2.5-3 h). Then, the bacteria were pelleted by spinning for 15 min at 4,000 
rpm at 4°C. The pellet was resuspended in 1/10 of the initial volume (i.e. 15 ml for 150 ml 
initial culture volume) TSB media (1 x LB medium, 5% DMSO, 10 mM MgCl2, 10 mM 
Materials and Methods 
 
 
 129 
MgSO4, 10% PEG4000; filter sterilize (0.2 m) prior to use and store at 4°C) and kept on 
ice for 1 h. After the incubation, 1.5 ml Eppendorf tubes were placed on dry ice and the 
bacterial suspension was aliquoted into these tubes at 100 l per tube and the aliquots were 
stored at -80°C. 
8.4.1.2 Preparation of electrocompetent bacteria Stbl3 
Electrocompetent Stbl3 from a previous batch were streaked out on a LB plate without 
antibiotics and incubated at 37°C O/N. The next evening, a 50 ml culture of one colony 
was started in 2YT medium (16 g/l Bactotryptone, 10 g/l yeast extract, 5 g/l NaCl) and 
incubated at 37°C O/N shaking. After 2 h incubation, β5 μg/ml Streptomycin was added in 
order to keep the bacteria stable. The next morning, 5 ml from this culture were diluted in 
500 ml βYT with 50 μg/ml Streptomycin and grown to an OD600 of 0.6 to 0.8 (3-4 h) at 
37°C shaking. Upon reaching the desired optical density, the bacterial suspension was 
chilled on ice for 15 min, then centrifuged for 20 min with 4,000 rpm at 4°C and the pellet 
was resuspended in 500 ml sterile dH2O to remove the salt. After another 20 min of 
centrifugation with 4,000 rpm at 4°C, the pellet was resuspended in 40 ml sterile 10% 
glycerol. The bacteria were pelleted again by spinning them 10 min with 4,000 rpm at 4°C, 
before the pellet volume was estimated (about 500 μl from a 500 ml culture) and twice the 
volume of sterile 10% glycerol was added. Then, the cells were aliquoted on dry ice and 
stored at -80°C. 
8.4.1.3 Chemical transformation of E. coli DH5  
100 µl of competent DH5 cells were thawed on ice. 20 µl of 5 x KCM buffer (500 mM 
KCL, 150 mM CaCl2 and 250 mM MgCl2) and 100 pg-10 ng circular plasmid or the entire 
volume of the ligation mix were mixed on ice, topped up to 100 µl with dH2O and added to 
the cells. After addition of the DNA to the cells, the mixture was incubated on ice for 15 
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min before incubating the mix 5 min at 37°C and briefly placing it on ice afterwards. Then, 
1 ml LB media was added, and the mixture was incubated at 37°C for at least 30 min 
shaking. After the recovery period, the bacteria were plated onto LB-agar plates containing 
the appropriate selection marker. For high-efficiency plasmids 10-100 µl were plated, 
whereas for low-efficiency plasmids and ligations, the cell suspension was centrifuged and 
the supernatant was discarded. The bacterial pellet was then resuspended in the remaining 
media, and plated onto pre-warmed agar plates containing the appropriate antibiotic. Then 
the plates were incubated (agar-side up) at 37°C O/N. 
8.4.1.4 Electroporation of electrocompetent Stbl3 
The Gene Pulser electroporation system and cuvette holder (Bio-Rad) was used and the 
conditions for transformation were set according to the bacterial strain used. For Stbl3 
cells, the following settings were used: 25 FD capacitance, 200 Ohms resistance and 
1.8 kV. The time constant (tau value) should be 4.5-4.8 msec. Glass cuvettes and 2YT 
media without antibiotics were chilled on ice. Then, 1 l of DNA was added to a 1.5 ml 
Eppendorf tube and mixed with electrocompetent bacteria before adding the mix to a 
cooled cuvette. Any moisture was dried off the outside of the cuvette before placing it in 
the holder of the power source. Then, the holder was brought into position and the cells 
were shocked. After hearing a constant tone, 1 ml of 2YT medium was added to the cells 
and the cells were transferred into a fresh 1.5 ml Eppendorf tube and kept on ice until all 
samples were done. The bacteria were allowed to recover for at least 30 min at 37°C 
shaking. After the recovery period, the bacteria suspension was added to 100 ml 2YT 
medium containing 33 g/ml Streptomycin and 33 g/ml of the resistance marker on the 
plasmid DNA transfected into the bacteria and incubated shaking at 37°C O/N. 
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8.4.2 Plasmid DNA preparation 
8.4.2.1 Plasmid Miniprep  
For the isolation of the plasmid DNA from the O/N cultures, the JETQUICK Plasmid Spin 
Miniprep Kit (GENOMED) was used and the isolation carried out as described by the 
manufacturer (i.e. volumes of buffers as stated by the manufacturer, speed of 
centrifugation adjusted). For each transformation, single colonies of transformed E. coli 
containing the required plasmid DNA were picked using a sterile pipette tip and 
transferred into bacterial tubes containing 2 ml LB medium and the appropriate antibiotic. 
The cultures were incubated at 37°C shaking for 16 h. The next morning, the cultures were 
transferred into a 2 ml Eppendorf tubes and centrifuged at 12,000 rpm for 1 min to pellet 
the bacteria. Then, each pellet was resuspended in β50 μl cell resuspension buffer G1 and 
mixed by vortexing. Then, β50 μl lysis buffer G2 was added and mixed by inverting the 
tube 4-6 times. γ50 μl of neutralization buffer G3 were added to the clear lysate and mixed 
until a flocculent white precipitate formed and then centrifuged at 12,000 rpm for 10 min. 
To load and bind the plasmid DNA, the clear supernatant was transferred to a spin column 
in a 2 ml collection tube. The column was centrifuged for 1 min at 12,000 rpm at RT. The 
flow-through liquid was discarded, while the collection tube was kept for further steps. For 
the first washing step, the column was placed back in the collection tube and 500 μl GX 
buffer were added. For the second washing step 700 μl of wash buffer G4 were added to 
the column. Next, the column was centrifuged empty for 1 min to dry and remove all 
EtOH residues. To elute the bound plasmid DNA from the column, γ0 μl dH2O were 
pipetted directly onto the membrane and left on for 1 min before the column was placed 
into a fresh 1.5 ml microcentrifuge tube and centrifuged for 1 min. For a higher yield, the 
eluted DNA was pipetted again onto the membrane and centrifuged again.  
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8.4.2.2 Plasmid Midiprep 
DNA constructs required for transfection were prepared using a JETQUICK Midi Kit 
(GENOMED) following the instructions by the manufacturer. Briefly, 100 ml LB medium 
cultures containing the appropriate selective marker and were grown at 37°C O/N shaking. 
Cells were harvested by centrifugation at 4,000 rpm for 20 min at 4°C in an Eppendorf 
5810R centrifuge in 50 ml Falcon tubes. After removal of the supernatant, the bacterial 
pellet was resuspended in 4 ml buffer E1 by vortexing. The cell suspension was lysed with 
4 ml of lysis buffer E2 and mixed thoroughly by inverting the tube 5 times. For the 
precipitation of genomic DNA, 4 ml of chilled buffer E3 were added and mixed 
immediately by gentle inversion followed by 15 min incubation on ice. The supernatant 
was separated from the precipitate by centrifugation in polypropylene tubes at 4,000 rpm 
for 30 min at 4°C. Meanwhile, a Lysate Filter Unit (LFU) was equilibrated by applying 
10 ml buffer E4. After the centrifugation, the supernatant containing the plasmid DNA was 
filtered through medical gauze onto the LFU column and allowed to enter the resin by 
gravity flow. The LFU column was washed twice with 10 ml buffer E5. Afterwards, the 
DNA was eluted into a new centrifuge tube containing 3.5 ml isopropanol using 5 ml 
elution buffer E6 to precipitate the DNA. The solution was mixed and centrifuged at 
4,000 rpm for 30 min at 4ºC. The supernatant was decanted carefully and the DNA pellet 
was washed with 2 ml of RT 70% EtOH and centrifuged at 4,000 rpm for 10 min at 4°C. 
The supernatant was discarded and the pellet was air-dried for 10 min. Then the pellet was 
dissolved in 200-300 µl dH2O and transferred to a fresh 1.5 ml Eppendorf tube. 
8.4.2.3 Quantification of DNA Concentrations 
All DNA concentrations were directly measured with a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies). To do so, the spectrophotometer was first 
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calibrated, then 1.5 µl undiluted sample was pipetted onto the spectrophotometer and the 
sample concentration in ng/µl as well as the purity ratio was read of. 
8.4.2.4 Gel electrophoresis of DNA 
Linearized DNA was separated on agarose gels of the appropriate percentage. For example 
1% agarose gels were cast by dissolving 1 g agarose in 100 ml of 1 x TAE (40 mM Tris 
pH 7.6, 20 mM acetic acid, 1 mM EDTA) buffer in a microwave. SYBR Safe DNA stain 
(Invitrogen, Cat#S33102) was added to the transparent agar solution, before the gel was 
poured into a gel tray and a Teflon comb was inserted to form the wells. Then, the gel was 
left to solidify at RT for 30-45 min before the gel was placed into an electrophoresis tank 
containing enough electrophoresis buffer (1 x TAE) to cover the surface of the gel. DNA 
samples were mixed with 1/5 volume of 6 x loading buffer (10 mM Tris-HCl pH 8, 60 mM 
EDTA, 60% glycerol, 0.1% orange G) and loaded into the wells. Either a 100 bp or 1 kb 
DNA marker (Invitrogen) was loaded in a separate well to determine the fragment sizes of 
the DNA sample. Agarose gels were run at 100 V for 45 min or until the dye front had run 
approximately 80% through the gel. 
8.4.2.5 Visualization of DNA with SYBR Safe DNA stain 
DNA fragments were visualized by placing the gel on a transilluminator and captured on 
Polaroid film. 
8.4.2.6 Isolation of DNA fragments from agarose gels 
DNA fragments required for cloning were purified in the appropriate percentage agarose 
gel, before the desired bands were visualized under UV light and quickly cut out with a 
clean scalpel. The exposure to the DNA damaging UV light was kept was short as 
possible. The gel pieces were then placed in individual 1.5 ml Eppendorf tubes and the 
weight of each piece was determined.  
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8.4.2.7 Gel Extraction clean up 
The QIAquick Gel Extraction Kit (QIAGEN) was used to isolate of DNA fragments from 
gel pieces. All pieces had a weight of about 0.1 g and therefore an approximate volume of 
0.1 ml. 300 µl solubilization buffer QG (i.e. 3 x the gel volume) was added per tube and 
the mixture was incubated at 50°C for 10 min and mixed by vortexing every 2-3 min until 
the gel pieces had melted. Then, 1 gel volume of isopropanol (100 µl) was added to each 
sample and mixed. Fresh QIAquick spin columns were placed in 2 ml collection tubes and 
a maximum of 800 µl of the DNA/agarose solution was added at a time. The assembly was 
centrifuged at 12,000 rpm for 1 min and the flow through was discarded. To remove all 
traces of agarose, 500 µl of buffer QG were added to each column and centrifuged at 
12,000 rpm for 1 min. For a washing step, 750 µl PE DNA wash buffer was added to each 
column and centrifuged at 12,000 rpm for 1 min. To dry the column matrix, the 
column/tube assembly was centrifuged at 12,000 rpm for 1 min and after transferring the 
columns into fresh 1.5 ml Eppendorf tubes, the plasmid DNA was eluted with 30 µl dH2O 
by centrifugation at 12,000 rpm for 1 min. After the agarose gel extraction, the 
concentration of the plasmid DNA was determined using the NanoDrop 
spectrophotometer. 
 
8.4.3 Enzymatic modification of DNA 
8.4.3.1  Digestion of DNA with restriction enzymes 
Plasmids, vectors and fragments were digested with various endonucleases using the 
buffers provided with the enzymes. Preparative restriction digests were conducted during 
cloning in order to isolate the desired insert and to open the target vector. Analytical 
restriction digests on the other hand, were done to identify positive clones after 
transformation of bacterial cells and isolation of the plasmids from these cells by 
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Miniprep. Digests were carried out in 20 µl volumes. When preparing inserts or vectors, a 
double digests with 2 appropriate enzymes was carried out at 37°C for 2 h. The double 
digests were performed using the buffer with the lower salt concentration if a compatible 
buffer was not available. Restriction enzymes units were used according to the amount of 
DNA present in sample, ensuring that the enzyme concentration was not in excess to 
prevent star activity. In order to verify the correct insertion of the protein sequences into 
the target vector, analytical restriction digests were carried out using the respective 
restriction enzymes.  
20 µl reactions were set up using 1 µg DNA, 0.5 µl per enzyme, 1 x of the suitable 
buffer (final concentration), 1 x BSA (final concentration) and water. The restriction 
digests were incubated at 37°C and the products visualized by gel electrophoresis using a 
1% agarose gel containing SYBR Safe DNA stain. 
8.4.3.2 Inactivation of enzymes 
Before cleaning the opened target vector, it was treated with 1 µl calf intestine alkaline 
phosphatase (CIP) (NEB) and incubated for 1 h at 37°C to remove 5' phosphates to prevent 
self-ligation of the target vector. 
8.4.3.3 Ligation 
T4 DNA ligase (NEB) catalyses the formation of phosphodiester bonds between adjacent 
5’ phosphate and the γ’ hydroxyl residues of adjacent nucleotides in either cohesive-ended 
or blunt-ended fragments. For all ligations an approximate molar insert:vector ratio of 3:1 
was used. About 30-100 ng of the linearized target vector were used per ligation. The 
needed amount of insert to yield a molar insert:vector ratio of 3:1 was calculated using the 
following formula: 
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Insertng
Vector
Insert
ratioMolar
Insertsizekb
InsertsizekbVectorng   
 
20 µl reactions were set up using the calculated amount of vector and insert, 1 µl T4 DNA 
ligase, 1 x T4 DNA ligase buffer (50 mM Tris-HCl, 10 mM MgCl2, 10 mM DTT, 1 mM 
ATP; pH 7.5) and dH2O. The ligation reaction was incubated at 4°C O/N. The following 
day, 10-20 µl of ligation mix were used to transform 100 µl of E. coli DH5 competent 
bacteria. 
 
8.4.4 Site specific mutagenesis 
Primers were designed according to the QuikChange Manual (Stratagene) and ordered 
HPLC-purified from microsynth (Balgach, Switzerland). The QuikChange site directed 
mutagenesis protocol can be applied in any plasmid vector for deletion, insertion of single 
or multiple amino acids. The QuikChange site-directed mutagenesis method is performed 
using high fidelity PfuTurbo DNA polymerase which replicates both plasmid strands.  
Mutation was performed in 50 μl PCR reaction mix containing 5 μl 10 x PfuTurbo 
buffer, 40 ng template DNA in 5 μl, 1 μl forward primer 10 mM and 1 μl reverse primer 10 
mM, 1 μl dNTP mix, γ6 μl dH2O and 1 μl PfuTurbo DNA polymerase. The PCR reaction 
was performed as follows: 95°C initial denaturation for 30 sec, 95°C denaturation for 30 
sec, 55°C annealing for 1 min and 72°C extension for 7 min until 16 cycles. Then, 5 μl 
Dpn I buffer and 1 μl of Dpn I was added to the PCR mixture and incubated at 37°C for 
2 h. The control reaction was prepared in the same way, but without PfuTurbo DNA 
polymerase. 10 μl of the PCR product were transformed into E. coli. Mutated sequences 
were verified by direct DNA sequencing.  
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Table 3 Primers used for site directed mutagenesis 
name sequence 
SHP2 D425A fwd 5’-TTCGGACCTGGCCGGCCCACGGCGTGCCCAGCGACCCTGGGGGCG-3’ 
SHP2 D425A rev 5’-TGGGCACGCCGTGGGCCGGCCAGGTCCGAAAGTGGTATTGCCAGA-3’ 
SHP2 C459S fwd 5’-TTGCCACACAAGGCTCCCTGCAAAACACGGTGAATGACTTTTGGC-3’ 
SHP2 C459S rev 5’-CCGTGTTTTGCAGGGAGCCTTGTGTGGCAATGTAACTCTTTTTGG-3’ 
NLS mut fwd 5’-CCAAGTGCAACAATTCAAGTCCCAGTAAGAGTTACATTGCCACAC-3’ 
NLS mut rev 5’-GTGTGGCAATGTAACTCTTACTGGGACTTGAATTGTTGCACTTGG-3’ 
NLS del fwd 5’-TCATGCCTGAATTTGAAACCAAGAGTTACATTGCCACACAAGGCTGC-3’ 
NLS del rev 5’-TGTGGCAATGTAACTCTTGGTTTCAAATTCAGGCATGATGATATTTG-3’ 
 
8.4.5 Direct DNA sequencing 
Sequencing was outsourced to the Novartis sequencing facility. Therefore, the DNA 
template (250-500 ng for PCR products or 0.5-1 µg for plasmids) dissolved in dH2O was 
mixed with 1 µl of 10 mM sequencing primer and given to the Novartis facility for the 
readout.  
8.4.6 Lentiviral production 
Linear polyethylenimine (PEI; Polysciences Inc., Cat#23966-2) was used as a transfection 
reagent and a 1 μg/μl solution was made in dH2O, neutralized with HCl to pH 7.2 and 
sterilized using a 0.2 μm filter (VWR international, Cat#28145-481). Aliquots were stored 
at -80°C or kept at 4°C for up to 4 months. 8 h before transfection, HEK293T cells were 
plated in T75 flasks at 80% confluency in normal growth medium. Before transfection, the 
medium was replaced with 7 ml of serum-free medium. In an Eppendorf tube, 10 µg DNA 
and helper plasmids (2 µg HDM-tat16, 2 µg HDM-HgPM2, 2 µg pRC-CMV-RaII, and 
4 µg HDM-VSV-G) were mixed in 1 ml of serum free medium. PEI was added in a 4:1 
PEI:DNA ratio (4 μg of PEI for every μg of DNA) to the diluted DNA, vortexed 
immediately and incubated for 15 min at RT. After the incubation, the mix was added to 
the cells in the T75 flask. 16 h after the transfection, the medium was changed to DMEM 
containing 10% FBS. 3 days later, the viral supernatant was harvested for the first time and 
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the cells were fed with 8 ml fresh DMEM 10% FBS medium. 2 days later, the second viral 
supernatant was harvested, filtered and combined with the first harvest (stored at 4°C in 
the meantime). The pooled virus supernatant was centrifuged at 1,000 rpm for 5 min and 
filtered through 0.45 µm filters (VWR international, Cat#28145-505) to remove cell 
debris. Then, the filtered virus was concentrated using Amicon Ultra-15 Centrifugal Filter 
Units with Ultracel-30 Membrane (Millipore, Cat#UFC903096), aliquoted and stored at 
-80°C. 
8.4.7 Lentiviral infection of target cells 
24 h before in infection, target cells were plated in 24-well plates (20,000 cells per well). 
Cells were infected at the desired Multiplicity of Infection (MOI) by incubation with the 
appropriate amount of virus supernatant in normal growth medium supplemented with 
8 μg/ml Polybrene (Sigma, Cat#H9β68) for 16 h at 37°C. The media was then changed and 
the cells were incubated another 24 h at 37°C before starting selection with the appropriate 
concentration of Puromycin (BD Bioscience, Cat#P7255), G418 (ROCHE, 
Cat# 04727878001) or Zeocin (Invitrogen, Cat# R25001). 
 
 
8.5 Biochemistry 
8.5.1 Protein extraction 
8.5.1.1 SDS hot lysis 
The cells were washed with PBS at RT and total proteins were extracted by lysis with 
SDS-Buffer (250 mM Tris HCl pH 7.4, 2.5% SDS) at 95°C. The lysates were sonicated for 
10 sec to disrupt the genomic DNA and centrifuged for 5 min at 12,000 rpm before protein 
quantification.  
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8.5.1.2 Lysis in RIPA buffer 
Cells were placed on ice and washed twice with cold PBS, before ice cold RIPA buffer (50 
mM Tris, pH 8.0, 150 mM sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, 
0.1% SDS, 10 mM NaF, 2 mM PMSF, 2 mM Na3VO4, 1 x EDTA-free protease inhibitor 
cocktail (ROCHE, Cat#11873580001)) was added. Then, cells were scraped into an 
Eppendorf tube and kept on ice. Cells were incubated for 10 min, followed by 
centrifugation at maximum speed for 15 min at 4°C. The supernatant containing total 
cellular proteins was collected and stored at -80°C. 
8.5.2 Immunoprecipitation 
Cells were placed on ice, washed with ice cold PBS and lysed in IP buffer (20 mM Tris 
HCl pH 7.5, 100 mM NaCl, 1% NP-40, 10% glycerol, 5 mM idodoacetic acid, 1 x EDTA-
free protease inhibitor cocktail (ROCHE, Cat#11873580001)). After protein measurement, 
lysates containing 0.5-1 mg of total protein were mixed with the recommended amount of 
antibody and incubated on a rotating wheel at 4°C O/N. The next morning, 50 μl of 50% 
Protein A or G coupled agarose bead slurry (Millipore) per samples were washed with IP 
buffer to remove all traces of EtOH and added to each IP sample. The samples were then 
incubated rotating at 4°C for 2 h. Following the incubation, the immuno-complexes were 
pelleted by centrifugation at 2,000 rpm at 4°C for 1 min and washed 5 x with ice-cold IP 
buffer. Each time, complexes were collected by centrifugation at 2,000 rpm at 4°C for 
1 min. After the last wash, 5 x Laemmli loading buffer was mixed 1:1 with IP buffer and 
60 μl were added to each IP sample and proteins were denatured by heating to 95°C for 5 
min. Protein A or G agarose was pelleted by centrifugation at 12,000 rpm at RT for 10 min 
and supernatants, containing immunoprecipitated proteins were analyzed by SDS-PAGE 
electrophoresis. 
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8.5.3 Subcellular fractionation 
Subcellular fraction is an enrichment method allowing the separation of cell organelles 
based on biological or physical properties. The fractionation is divided in two major steps: 
First, the cellular organization is disrupted by homogenization and then, the cell organelles 
are separated into fractions based on their physical and biological properties for example 
by centrifugation (Pasquali, Fialka et al. 1999). 
Cells were grown on 10 cm dishes and washed 3 x with cold PBS. Then, 400 µl of 
ice-cold hypotonic buffer A (10 mM HEPES-KOH pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 
0.2 mM PMSF, 1 mM DTT) was added directly onto the plates on ice for 10 min. Plates 
were swirled every 2 min to avoid drying of the cells. After the incubation time, cells were 
scraped off the plate using cell lifters (Corning, Cat#3008) and transferred to Eppendorf 
tubes. Each tube was then vortexed for 10 sec and centrifuged for 10 sec at full speed. The 
supernatant (cytoplasmic fraction) was transferred to a new tube without disturbing the 
pellet and kept on ice. The nuclear pellet was washed by resuspending it in 500 µl buffer 
A, pipetting gently up and down and vortexing for 10 sec followed by 10 sec 
centrifugation at full speed. The supernatant was discarded and the washing step was 
repeated 3 more times. Depending on the size, the nuclear pellet was then resuspended in 
20-100 µl of cold buffer B (20 mM HEPES-KOH pH 7.9, 25% glycerol, 420 mM NaCl, 
1.5 mM MgCl2, 0.2 mM EDTA pH 8, 0.2 mM PMSF, 1 mM DTT), pipetted 3 x up and 
down and incubated on ice for 20 min. After the incubation, the mixture was centrifuged 
for 2 min at full speed and the supernatant (nuclear fraction N1) was transferred to a new 
tube. To also isolate the crude membrane and DNA (N2, chromatin enriched fraction), the 
pellet was resuspended in RIPA buffer. For checking the purity of each fraction by 
immunoblotting, -tubulin was used as a marker for the cytoplasmic fraction and PARP 
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was used as a marker for the nuclear fraction. The histone mark H3K4me2 was used as a 
marker for the chromatin enriched fraction N2. 
 
8.5.4 Immunoblotting 
8.5.4.1 Quantification of protein concentration 
To determine protein concentrations, a DC protein assay (Bio-Rad, Cat#500-0116) was 
used according to the manufacturer’s instructions. Briefly, 5 µl of protein standards (10, 5, 
2.5, 1.25, 0.625, 0.313 µg/ml BSA) and samples were pipetted in duplicates into a 96-well 
plate. 20 µl of reagent S were added to 1 ml of reagent A and β5 µl of this mix A’ were 
added to each well. Then, 200 µl reagent B were added to each well and after mixing and 
incubating for 15 min at RT, the absorbance was measured at 750 nm using an ELISA 
plate reader. 
8.5.4.2 Sample preparation 
The desired amount of protein (10-50 µg) was mixed with 5 x loading buffer (62.5 mM 
Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 5% ȕ-mercaptoethanol, 0.01% bromophenol 
blue). Before loading, the samples were denatured by boiling them for 5 min at 95°C. 
Samples were loaded onto the prepared gel alongside with 8 µl of pre-stained protein 
marker Precision Plus Protein (Bio-Rad Laboratories). 
8.5.4.3 SDS-polyacrylamide gel electrophoresis (PAGE) 
For gel electrophoresis, a 8% resolving gel (8% acrylamide mix, 0.39 M Tris pH 8.8, 
0.1% SDS, 0.1% APS, 0.06% TEMED) was prepared and poured into a mini 
Polyacrylamide Electrophoresis system (BioRad Laboratories, Hercules, CA) immediately. 
After allowing the resolving gel to solidify, a 5% stacking gel (5% acrylamide mix, 0.13 M 
Tris pH 6.8, 0.1% SDS, 0.1% APS, 0.01% TEMED) was prepared and pipetted on top of 
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the resolving gel and a comb was inserted. The electrophoresis was performed at 80 V 
until the samples began separating and then at 100 V at RT using a MINI-PROTEAN® II 
Electrophoresis Cell tank (Bio-Rad Laboratories, Hercules, CA) in 1 x SDS running buffer 
(250 mM Tris (unbuffered), 250 mM glycine, 0.1% SDS). 
8.5.4.4 Semi-dry protein transfer 
Proteins were transferred by electrophoresis from the polyacrylamide gel to a PVDF 
Immobilon-FL membrane (Millipore, Cat#IPFL00010) using a Trans-Blot SD Semi-Dry 
Transfer Cell (Bio-Rad Laboratories). The membrane was soaked in MetOH for 1 min, 
then in water for 1 min and subsequently in Transfer Buffer (250 mM Tris (unbuffered), 
250 mM glycine, 0.1% SDS, 20% MetOH) for 10 min. In the meantime, the gels and 
Whatman papers were also soaked in Transfer Buffer. Then, the gel and the PVDF 
membrane were sandwiched between the Whatman papers and the transfer was performed 
at 15 V for 30 min for one gel in the chamber and at 20 V for 45 min for two gels. 
8.5.4.5 Antigen detection 
The nitrocellulose membrane was blocked in milk solution (5% skim milk powder in 
TBST (20 mM Tris HCl pH 7.5, 150 mM NaCl, 0.05% Tween20) for 1 h at RT. For 
immunodetection, blots were incubated with the primary antibodies in 10 ml blocking 
solution or TBST and 0.02% sodium azide O/N at 4°C shaking. The day after, blots were 
washed (3 x 15 min) in TBST and incubated with the fluorescent secondary antibodies in 
10 ml blocking solution for 1 h at RT in the dark. After the incubation, membranes were 
washed (3 x 15 min) with TBST and the fluorescence signal was detected using the 
ODYSSEY Classic Infrared Imaging System (LI-COR) and analyzed with the Odyssey 2.1 
software.  
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8.5.5 RNA extraction 
The cells were lysed with TRIzol Reagent (Invitrogen, Cat#15596-018), vortexed and left 
for 15 min at RT. Subsequently the samples were centrifuged at 12,000 rpm for 15 min at 
4°C and the highest phase, which contains the RNA, was transferred to a new 1.5 ml 
Eppendorf tube. The RNA was precipitated by adding 0.5 ml of isopropanol per 1 ml 
solution and centrifuging at 12,000 rpm for 10 min at 4°C. The RNA pellet was washed 
with 1 ml of 75% EtOH (diluted in DEPC-treated water) and the samples were centrifuged 
at 7,500 rpm for 5 min at 4°C. The RNA pellet was then air dried for 10-15 min and 
dissolved in 80 μl DEPC treated dH2O at 55°C for 10 min to allow RNA solubilization. 
The RNA samples were stored at -80°C. 
 
8.5.6 Quantitative real-time PCR 
8.5.6.1 Reverse transcription PCR 
The reverse transcription reaction was performed via the ThermoScript RT-PCR System 
(Invitrogen, Cat#11146-024) according to the manufacturer’s protocol. Biefly, the primers 
(Oligo (dT)20), RNA (1μg) and dNTPs were mixed and denatured by incubation at 65°C 
for 5 min. Subsequently the cDNA Synthesis Buffer, DTT, RNaseOUT and ThermoScript 
RT were added to the reaction and incubated at 50°C for 60 min. The retro-transcriptase 
reaction was terminated by incubating the samples at 85°C for 5 min. The residual RNA 
was then eliminated by incubating the samples with 1 μl of RNase H at γ7°C for β0 min. 
8.5.6.2 SYBR green quantitative real-time PCR 
SYBR based quantitative real-time PCR was performed for quantification of the transcript 
levels. 25 μl reactions were set up using 1β.5 μl Platinum SYBR Green qPCR SuperMix-
UDG with ROX (Invitrogen, Cat#11744), 5 μl cDNA (of a 1:5 dilution of the reaction mix 
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from the RT-PCR per well), 1 μl 10 mM forward primer, 1 μl 10 mM reverse primer and 
5.5 μl dH2O in a Fast 96-well Reaction Plate (Applied Biosystems, Cat#4346907). The 
plate was then covered with an optical adhesive cover (Applied Biosystems, Cat#4360954) 
and centrifuged briefly. The real-time PCR was performed using the StepOnePlus 
Real-Time PCR System (Applied Biosystems) with the following settings: step1: 95°C for 
15 min, step2: 95°C for 15 sec, 60°C for 30 sec, 72°C for 30 sec (40 cycles) and step3: 
95°C for 15 sec and 60°C for 1 min (melting curve). The data was either analyzed using 
the standard curve method (absolute quantification) or the comparative CT method for 
relative quantification. All the primers were designed to specifically amplify human 
transcripts. 
Table 4 SYBR green quantitative real-time PCR primers 
gene forward reverse 
HOXA5 5’-GCTGCAAAACGGGGGAAATAAAG-3’ 5’-TTTCCCTCGCAGTTCCATTAGGA-3’ 
HOXA9 5’-GAGGGGAGGGGACAGAGAGGTAG-3’ 5’-CTCCGCTGCTTTATGTTCCTGCT-3’ 
HOXA13 5’-GGCTCCAAGAAACACCCATTCTG-3’ 5’-GCAGTGGGGACAGGTCAGGTAAT-3’ 
HOXB5 5’-AAAGCCCAACCCCTGCTCTAAAA-3’ 5’-AGTCGCCGGGAGAGAAAGAAAC-3’ 
HOXB6 5’-CGACTGAGAAAAGGGTTGCTGGT-3’ 5’-CAATCGCTGGATTCAACCACTCA-3’ 
HOXB9 5’-ACGCTTTATCAGGCAGTCGGAAA-3’ 5’-CCTGCTCAACTTCTCAGCCAACA-3’ 
HOXD10 5’-TTCCAGTTTAGAGCCTGCCTTGC-3’ 5’-GATGATATATGGGCGGGCACAG-3’ 
HOXD11 5’-CGGGTGGAAGAGAAATCTGGAAC-3’ 5’-GTCTAAGGACAGTGGGGCAGTCG-3’ 
HOXD13 5’-TTTATAAACGTCCCGCGATGAGC-3’ 5’-TAGCCCTCTCTCCCTCTGTGAGC-3’ 
ZEB1 5’-GCACCTGAAGAGGACCAGAG-3’ 5’-TGCATCTGGTGTTCCATTTT-3’ 
Fibronectin1 5’-CAGTGGGAGACCTCGAGAAG-3’ 5’-TCCCTCGGAACATCAGAAAC-3’ 
Vimentin 5’-GAGAACTTTGCCGTTGAAGC-3’ 5’-GCTTCCTGTAGGTGGCAATC-3’ 
N-cadherin 5’-ACAGTGGCCACCTACAAAGG-3’ 5’-CCGAGATGGGGTTGATAATG-3’ 
LIN28B 5’-CTGTCAGAGCATCATGCACATG-3’ 5’-GGGTGGCTGTGCAACATTTT-3’ 
GAPDH 5’-ACCCAGAAGACTGTGGATGG-3’ 5’-TCTAGACGGCAGGTCAGGTC-3’ 
ACTIN 5’-TTGCCGACAGGATGCAGAA-3’ 5’-GCCGATCCACACGGAGTACT-3’ 
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8.5.7 Chromatin immunoprecipitation (ChIP) 
For the crosslinking, 11 x formaldehyde solution was prepared by mixing 7.1 ml Paro Fix 
(50 mM Hepes pH 8.0 (NaOH), 1 mM EDTA pH 8.0, 0.5 mM EGTA pH 8.0, 100 mM 
NaCl) with 2.9 ml Formaldehyde (stock 37%). Then 1/10 of the 11 x formaldehyde 
solution was added into the cell into medium, e.g. 800 µl for 8 ml medium and the medium 
was redistributed to the cells and incubated at RT for 10 min. The crosslinking was 
stopped by adding 0.125 M glycine and incubation on ice for 10 min. 
To prepare the chromatin, the cells were rinsed with 5 ml cold PBS, scraped off in 
1 ml PBS + 1 x Complete Protease Inhibitor EDTA-free (PI, ROCHE), collected in a 15 
ml Falcon tube and centrifuged for 5 min at 600 g at 4°C. Each pellet was then 
resuspended in 5 ml Paro Rinse 1 (10 mM Tris pH 8.0, 10 mM EDTA pH 8.0, 0.5 mM 
EGTA pH 8.0, 0.25% Triton X-100) + 1 x PI and incubated for 10 min on ice, followed by 
centrifugation for 5 min at 600 g at 4°C. Each pellet was then resuspended in 5 ml Paro 
Rinse 2 (10 mM Tris pH 8.0, 1 mM EDTA pH 8.0, 0.5 mM EGTA pH 8.0, 200 mM 
NaCl)+ 1 x PI and incubated for 15 min on ice, followed by centrifugation for 5 min at 600 
g 4°C. Then, the pellets were resuspended in 300 µl Lysis buffer (50 mM HEPES/KOH 
pH 7.5, 500 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% DOC (10 mM Tris pH 8, 
0.25 M LiCl, 0.5% NP-40, 0.5% DOC, 1 mM EDTA pH 8), 0.1% SDS) + 1 x PI and 
incubated on ice for at least 10 min up to O/N. Then, the chromatin concentration was 
measured with a Fluorometer and diluted to ~150 ng/µl with Lysis buffer + PI if necessary. 
300 µl aliquots of 150 ng/µl chromatin were sonicated with 30 sec of ON & 45 sec OFF 
cycles at HIGH & 1C settings using a Diagenode sonicator to obtain fragments in range of 
300 bp-1000 bp (11 cycles). Samples were spun for 10 min at 14,000 g at 4°C and the 
supernatant was taken. 20 µl were reverse crosslinked as indicated for the input and the 
sonication size was checked on a 1.2% agarose gel. 
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For the immunoprecipitation, the volume of all samples was adjusted to 600 l with Lysis 
buffer + PI. To pre-clear the chromatin, 40 l tRNA pre-blocked Protein G Agarose beads 
(Millipore, Cat#16-266) were added per sample with a cut tip and the samples were 
incubated on a rotating wheel for 1 h at 4°C. Then, the samples were centrifuged for 1 min 
at 4°C, kept on ice for 1 min and the supernatants were collected. 6 l chromatin (1%) for 
input fraction were saved and stored at -20°C. Then 5 l of SHP2 antibody (sc-280) was 
added and the samples were incubated O/N at 4°C rotating. The next morning, 40 l pre-
blocked Protein G Agarose beads were added and the samples were incubated for 3 h at 
4°C rotating. After the incubation, the samples were centrifuged for 1 min at 10,000 rpm at 
4°C and kept on ice for 2 min before the SN was discarded. Then the beads were 
resuspended in 1 ml lysis buffer + 20 l PI using a 1ml tip. After 5 min incubation RT 
rotating, the samples were spun for 1 min at 10,000 rpm at 4°C, kept on ice for 2 min and 
the SN was discarded. The wash was repeated one more time with lysis buffer and 1 x with 
DOC buffer (10 mM Tris pH 8, 0.25 M LiCl, 0.5% NP-40, 0.5% DOC, 1 mM EDTA pH 
8). Afterwards, the beads were transferred into a new Eppendorf tube in 1 ml TE pH 8.0 
and spun for 2 min at 10,000 rpm at 4°C, kept on ice for 2 min before all SN was removed. 
For elution, the beads were resuspended in 150 l elution buffer (0.1 M NaHCO3, 1% 
SDS) and incubated for 20 min at RT with overhead shaking. Then, the samples were 
centrifuged for 1 min at RT and the SN was saved. The elution was repeated with 150 l 
elution buffer and the elutes were pooled (300 l final volume). 
To reverse the crosslinking for the IP fraction, 0.2 mg/ml RNase A was added to 
the 300 l elute, vortexed, and incubated for 30 min at 37°C. Then, 10 mM EDTA, 40 mM 
Tris pH 6.5, 50 g/ml proteinase K were added and the mix was incubated at 55°C for 
2.5 h followed by O/N incubation at 65°C at 550 rpm shaking. 
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For Input fraction (6l) or to reverse crosslink to check sonication size, the volume of the 
samples was adjusted to 300 l with TE pH 8.0. Then, 0.2 mg/ml RNase A was added to 
the 300 l elute, vortexed and incubated for 30 min at 37°C. Afterwards 1% SDS, 100 mM 
NaCl, 200 g/ml Proteinase K were added and the mix was incubated at 55°C for 2.5 h 
and then O/N at 65°C shaking at 550 rpm. 
To extract the chromatin for Input and IP fraction, 350 l Buffered Phenol was 
added to each sample. Samples were vortexed, spun for 10 min at RT at max speed and the 
upper layer was transferred to a new tube. Next, 350 l chloroform/IAA were added, 
vortexed, spun for 10 min at RT at max speed and the upper layer was transferred to a new 
tube. To precipitate the chromatin, 700 l 100% EtOH (-20°C), 35 l 3M NaOAc pH 5.2 
and 1 l glycogen was added. The samples were centrifuged for 2 h at 4°C, before the SN 
was removed and a small white pellet was visible. The pellet was washed with 70% EtOH, 
vortexed and spun for 20 min at 4°C. The SN was removed and the pellet was air dried, 
before it was resuspended in 40 l TE and heated to 50°C for 5 min to completely 
dissolve. 0.5 l of IP or Input were used for real-time PCR. 
 
Table 5 ChIP validation primers 
name forward reverse 
ChIP_Chr1 5’-TGCGGTTTTGACCTGCGGGCCT-3’ 5’-ACGCAGGCGGGGGCTGTTCTT-3’ 
ChIP_Chr6 5’-ACGACCACTTACCGTCGCAGGCCA-3’ 5’-AGGGGCGCACGATGGTCCCG-3’ 
ChIP_Chr11 5’-GCAGCCAAAGTGCCATTAAAGC-3’ 5’-GAGGCGAATTGCGGAGTTCTTA-3’ 
ChIP_control 5’-GCACCAAAGTGCCATTAAAGC-3’ 5’-GAGGCGAATTGCGGAGTTCTTA-3’ 
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8.6 In vivo experiments 
8.6.1 Orthotopic xenografts 
Cells were injected orthotopically into female 6 weeks old non-obese diabetic severe 
combined immunodeficient (NOD-SCID) mice in mammary gland 2/3 (SUM1315 NLS 
experiment) or in gland 4 (intravital imaging and metastasis studies). For the injections 5 x 
105 MDA-MB-231 cells, 1 x 106 SUM159 or 3 x 106 SUM1315 cells were counted and 
resuspended in 100 μl of a 50% phenolred-free matrigel 50% PBS mixture. Unless 
otherwise indicated, the mice were treated with 200 mg/kg doxycycline (PROMIVI KIBA 
SA, Kaiseraugst, Switzerland) in the food as soon as the tumors became palpable (tumor 
diameter 2-3 mm). Tumor dimensions were measured twice weekly with a caliper in two 
directions, and the volume of xenografts was calculated by the formula V = (a*b2)/2 where 
a stands for the length and b the width of the tumor. At the end of the experiment, the mice 
were sacrificed, the tumor and the lungs were dissected and analyzed. 
8.6.2 Bioluminescence imaging in vivo 
Luciferase positive cell lines were used in order to monitor xenograft tumor growth and 
metastases formation in vivo. Therefore D-Luciferin (Biosynth, Cat#L-8220) solution was 
prepared at 15 mg/ml and sterilized through a 0.β μm filter. Luciferin was injected at 
10 μl/g bodyweight (e.g. β00 μl for a β0 g mouse) intra-peritoneally (i.p.) 10-15 min 
before imaging. The IVIS Lumina XL imaging system (Caliper LifeSciences) was used to 
detect the bioluminescent signal. 
8.6.3 Powderizing xenografts for immunoblotting 
Snap frozen tumor pieces stored at -80°C were cooled on dry ice and quickly dipped into 
liquid nitrogen, before the tissue was grinded using a liquid-nitrogen cooled mortar and a 
ceramic pestle (Scienceware). All equipment used was cooled on dry ice making sure that 
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the tumor pieces and powder stayed frozen during the entire procedure. The tumor powder 
was either directly lysed in RIPA buffer (50 mM Tris, pH 8.0, 150 mM sodium chloride, 
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 mM NaF, 2 mM PMSF, 2 mM 
Na3VO4, 1 x protease inhibitor cocktail (ROCHE)) or stored at -80°C. 
8.6.4 Fixation of tissue and embedding 
The dissected tumors and lungs were fixed in 3.7% PFA O/N at 4°C and kept on 70% 
EtOH at 4°C until they were embedded in paraffin and cut with the Microm HM 355 S 
(Thermo Scientific) in γ μm thick sections. The sections were dried for 24 h at 37°C and 
stained to analyze them. 
8.6.5 FACS analysis of circulating tumor cells 
50-100 µl blood was drawn from the jugular vein of anesthetized tumor bearing mice into 
EDTA coated tubes and placed on ice. Red blood cells were lysed using 4 ml of red blood 
cell lysis buffer (SIGMA, Cat#R7757) for 15 min, centrifuged and the pellet was 
resuspended in another 4 ml of red blood cell lysis buffer and incubated for 15 min. Then, 
the cells were washed in PBS and either stained for EpCAM (APC anti-human CD326, 
BioLegend, Cat#324207) and analyzed on the FACSCalibur based on GFP and EpCAM 
expression (MDA-MB-231 xenografts) or based RFP and GFP expression (SUM159 
xenografts). For both cell lines, GFP-positive CTRL miR expressing cells were cultured in 
the presence of dox to induce RFP expression and used as a positive controls (RFP and 
GFP positive) and blood from non-tumor bearing mice was used as negative controls. The 
gates were set according to these controls. 
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8.7 Immunohistochemistry 
8.7.1 Hematoxylin and Eosin (H&E) staining  
Paraffin sections were deparaffinated and dehydrated by incubating them for 45 min at 
60°C and placing them immediately after for 2 x 3 min into Ultraclear solution. Excess 
Ultraclear was removed before placing the slides 2 x 3 min in 100% EtOH, followed by 
3 min in 95% EtOH, 3 min in 70% EtOH and 5 min in dH2O. For the Hematoxylin 
staining, slides were placed 3 min into Hematoxylin, rinsed with dH2O and placed 5 min 
into tap water for bluing. Subsequently, the slides were dipped eight times into acid EtOH 
to destain and rinsed 2 x in tap water and then 2 min in dH2O. Excess water was removed 
before staining the slides for 30 sec in Eosin, followed by 2 x 2 sec in 95% EtOH and 2 x 
2 sec in 100% EtOH. After removing excess EtOH, the slides were placed 2 x 5 min in 
Neo-clear solution for clearing. After blotting off excess Neo-clear, the slides were 
mounted with drop of Neo-mount and dried at least 30 min at 37°C. Sections were imaged 
with a Nikon DX1200 camera attached to a Nikon Eclipse 600 widefield microscope using 
a 10 x objective. 
8.7.2 CD31 staining 
Staining of tumor tissues for mouse CD31 was performed automatically in a DiscoveryXT 
instrument (Roche Diagnostics, Mannheim). The procedure “Research IHC BlueMap XT” 
was used, with a mild CC1 pre-treatment, incubation with the anti-mouse CD31 
(PECAM-1) rat monoclonal antibody (Dianova, Cat#DIA310) at a dilution of 1:50 for 1 h 
at 37°C, followed by incubation for 32 min with the secondary biotinylated anti-rat 
secondary antibody (Jackson Lab, Cat#712-065-153) at a dilution of 1:100 and substrate 
incubation for 1 h. The counterstaining was done with Hematoxylin. Sections were imaged 
with a Nikon DX1200 camera attached to a Nikon Eclipse 600 widefield microscope using 
a 4 x objective. 
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8.8 Proteomics 
8.8.1 Purification of tyrosine phosphorylated peptides 
Cells were washed with cold PBS before 1 ml Lysis Buffer (8 M urea, 200 mM 
ammonium bicarbonate pH 7.5, 1 x PhosSTOP (Roche), 1 mM Na3VO4) was added per 
15 cm plate. Cells were scraped off and transferred to a 15 ml Falcon tube and incubated 
on ice for 10 min. Then, the cell lysates were sonicated 3 x 30 sec (placed on ice 1 min 
between bursts) and spun 10 min at 12,000 rpm at RT. The supernatant was transferred to 
a new tube.  
For in-solution reduction, 1/10 of the volume of the supernatant of reduction 
solution (110 mM DTT) was added to a final concentration of 10 mM and incubated 1 h at 
RT. Then 1/10 of the volume of alkylation solution (660 mM iodoacetamide) was added to 
a final concentration of 55 mM and incubated for 1 h at RT in the dark. Then, the urea 
concentration was diluted 4 x with 50 mM ammonium bicarbonate (e.g. 15 ml were added 
to 5 ml of lysate). An aliquot was taken to be checked by immunoblotting later on. Then 
20 μg sequencing grade trypsin (Promega, Cat#V5111) were added per tube and incubated 
O/N at 37°C. The next morning, the samples from before and after digest were loaded on a 
SDS-PAGE gel to check the digestion. Then 1% Trifluoroacetic acid (TFA) was added and 
incubated 10 min at RT, before centrifugation at 4,500 rpm. The supernatant was kept.  
The desalting was done using Sep-Pak C18 cartridges (Waters, Cat#WAT020515). 
Therefore the cartridges were pre-wet with ACN 0.1% TFA and washed 2 x with 10 ml 
0.1% TFA. Then, the peptide mixture was loaded onto the cartridges and washed 2 x with 
10 ml 0.1% TFA. The peptides were eluted into a 15 ml Falcon tube using 5 ml 60% ACN 
0.1% TFA and 5 aliquots of 1 ml were prepared and cooled at -20°C for 30 min before 
O/N drying in the Speedvac.  
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For immunoprecipitation with anti-pTyr antibodies, 50 μl of anti-pTyr (Y99)-agarose 
(Santa Cruz, Cat#sc-7020AC) were pipetted into low-bind Eppendorf tubes (200 μl of 
slurry) and washed 4 x with IP buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% Octyl ȕ-D-
glucopyranoside, 1 mM PMSF, 1 x PhosSTOP) by centrifuging 1 min and discarding the 
supernatant. Then the dried peptides were dissolved in 1 ml IP buffer and incubated at RT 
for 5 min standing and 10 min shaking to dissolve the peptides. Then, the samples were 
centrifuge 5 min at 12,000 rpm to remove remaining insoluble material. Afterwards, the 
pH was checked and adjusted 7.4 if necessary using 1.5-β μl 1 M NaOH and 1 ml was 
transferred to the anti-pTyr agarose for IP and incubated O/N at 4°C rotating. The 
following day, the samples were centrifuged at 2,000 g for 1 min at 4°C and the 
supernatants were collected and stored at -20°C to monitor the pSer/pThr enrichment. The 
agarose beads were washed 3 x with 1 ml cold IP buffer (without PMSF) and centrifuged 
for 1 min at 2,000 g in between and the supernatants were discarded. The wash steps were 
repeated 3 x with 1 ml H2O. Then, 50 μl of 0.5% TFA was added to the beads and the 
tubes were tapped on the bench several times to disperse the agarose. After 10 min 
incubation at RT, the samples were centrifuged for 1 min at 2,000 g and the supernatants 
were transferred to fresh tubes before the step was repeated by adding another 50 μl of 
0.5% TFA to the beads, incubating and spinning. The supernatants were pooled and 
centrifuged again for 1 min at 2,000 g to remove any remaining particles and the 
supernatant was transferred to new tube.  
For further desalting, the peptides were filtered through POROS filled tips. To 
prepare the tips, a small piece of C-18 extraction disk was cut and inserted into a 20 µl gel 
loading tip. POROS oligo-R3 powder was mixed with ACN (5 mg in 200 µl) and 10 µl of 
the mix were added to the tip to fill the column with POROS powder. 1.5 ml Eppendorf 
tubes were closed and a hole, big enough to hold the tip columns, was poked into the lid. 
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These tubes were used as reservoirs for the columns during centrifugation steps. All 
centrifugation steps were done in mini centrifuges at 6,600 rpm until the all liquid passed 
through the columns. For humidification, the columns were washed with 40 µl ACN 0.1% 
TFA followed by 2 washes with 40 µl 0.1% TFA for equilibration. Then, the tubes 
containing the columns were replaced by fresh ones. Then 100 µl of the peptide mixture 
was loaded, the flow-through kept and reloaded. The 2nd flow-through was stored at -80°C. 
The columns were washed 2 x with 40 µl 0.1% TFA before the tubes containing the 
columns were exchanged for fresh ones. Then the peptides were eluted using 40 µL 80% 
ACN 0.1% TFA and 60 µl of 80% ACN 2.5% TFA and 1 M glycolic acid were added to 
the 40 µl elute to give a total volume of 100 µl. 
For further enrichment of phosphopeptides, Titanium dioxide (TiO2) columns were 
used. Therefore a small piece of C8 extraction disk was cut and inserted into a 20 µl gel 
loading tip. 2 µg TiO2 beads were mixed with ACN and the mix was added to the tip. Then 
the TiO2 beads were washed with 80 µl 80% ACN 2.5% TFA and centrifuged until 
everything went through the column. After this, the beads were washed with 80 µl 80% 
ACN 2.5% TFA 1 M glycolic acid and the reservoir tubes were changed afterwards. Then 
100 µl of the peptide mixture was loaded, the flow-through kept and reloaded. The 2nd 
flow-through was stored at -80°C. The columns were washed with 80 µl 80% ACN 2.5% 
TFA 1 M glycolic acid followed by a wash with 100 µl 80% ACN 2.5% TFA. The tubes 
containing the columns were exchanged before eluting the peptides with 2 x 60 µl of 
ammonium hydroxide solution (20 µl NH4OH, 300 µl ACN, 680 µl H2O). 12 µl of 100% 
formic acid were added before the eluted peptides were placed at -80°C for 15 min 
followed by 15 min lyophilization.  
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8.8.2 Analysis of phosphoproteomics MS data 
For LC-MS/MS, the purified phosphopeptides were resuspended in 10% formic acid and 
injected onto a 15 cm x 75 µm ProteoPep 2 PicoFrit column (New Objectives), connected 
to an LTQ-OrbiTrap Elite mass spectrometer (Thermo). Buffer A consisted of dH2O with 
0.1% FA and Buffer B of 100% ACN with 0.1% FA. Peptides were separated using a 
120 min gradient from 2% B to 40% B. Data acquisition was done using a ‘Top 15 
method’, where every full MS scan was followed by 15 data-dependent scans on the 15 
most intense ions from the parent scan. Full scans were performed in the Orbitrap at 
120,000 resolution with target values of 106 ions and 200 msec injection time, while 
MSMS scans were done in the ion trap with 104 ions and 200 msec. Database searches 
were performed with Mascot Server using the human IPI database (version 3.87). Mass 
tolerances were set at 10 ppm for the full MS scans and at 0.8 Da for MSMS. Search 
results were validated using Scaffold (Proteome Software) and peptide identifications 
accepted which exceeded the 95% confidence level. In case of ambiguous assignments, 
spectra were manually interpreted for confirmation of identity and localization of the 
phosphorylation site. Label free quantification was performed on duplicate LC-MS runs 
for each sample using Progenesis LC-MS (Nonlinear Dynamics Software). 
 
8.8.3 SILAC proteomics 
Cells were cultured in SILAC Advanced DMEM/F12-Flex medium (Invitrogen, Cat#06-
0032DK) without arginine (Arg) and lysine (Lys), which was supplemented with 12C6 
(Arg) and 12C614N2 (Lys) for the light normal growth medium and with SILAC [U-13C6]-L-
Lysine (Lys*) and SILAC [U-13C615N4]-L-Arginine (Arg*) (Invitrogen) for the heavy 
growth medium. The medium was further supplemented with SILAC Glucose (Invitrogen, 
Cat#06-033SA), L-glutamine (Invitrogen, Cat#25030-149) and dialyzed FBS (Invitrogen, 
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Cat#26400) and cell line specific additives. Cells were cultured for at least 5 passages in 
SILAC medium and the level of incorporation was measured by mass spectrometry to be 
> 95%.  
Cells were either harvested as whole cell lysates (WCL) or separated into nuclear 
and cytosolic fraction and immunoprecipitated using anti-SHP2 antibodies. 20 µl buffer 
with reducing agent was added to each sample and the beads were boiled for 10 min at 
70°C. Then, the samples were mixed with loading dye and run on a 4-12% pre-cast 
gradient gel in MOPS SDS running buffer (50 mM MOPS, 50 mM Tris Base, 0.1% SDS, 1 
mM EDTA, pH 7.7) for 10 min at 30 mA then 1 h at 60 mA. Afterwards, the gel was 
stained with Coomassie blue (0.1% Coomassie Brilliant Blue R-250, 50% MetOH and 
10% glacial acetic acid) for 1 h at RT and destained (10% MetOH and 10% glacial acetic 
acid) O/N at 4°C. 
The next day, the bands were cut in small pieces and each gel piece was placed in a 
separate well of a 96-well plate. To prepare the samples for MS analysis, the gel pieces 
were washed 3 x with 150 µl 50% ACN + 50% 50 mM NH4CO3, followed by 10 min 
incubation with 150 µl 100% ACN for dehydration. For reduction, 50 µl 10 mM DTT 
were added and the mix was incubated at 65°C for 45 min. Afterwards, 50 µl 55 mM 
iodoacetamide solution was added and the mix was incubated at RT in the dark for 30 min 
for alkylation. Then, the gel pieces were washed with 150 µl 50 mM NH4CO3 for 10 min 
at RT shaking followed by a dehydration step with 150 µl 100% ACN for 10 min at RT. 
Finally 20 µl Trypsin (Promega, Cat#V5280) was added to each well, followed by 50 µl 
NH4CO3 and the gel pieces were incubated at 37°C O/N. 
 The next morning, 5 µl of 50% formic acid was added to each well to stop the 
tryptic reaction and the first peptides were collected in the collection plate by 
centrifugation for 2 min at 1,500 rpm. 50 µl collection buffer (50% ACN, 1% formic acid) 
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was added to each well and incubated for 20 min at RT, before the plate was centrifuged 
for the 2nd collection of peptides. Then, the plate was put into the speedvac for 2-3 h to dry 
the mixed peptide collection. Samples were analyzed on the MS XL Orbitrap. 
 
 
8.9 Computational analysis  
8.9.1 Motif activity response analysis 
We used motif activity response analysis (MARA) (Suzuki, Forrest et al. 2009) to model 
genome-wide gene expression patterns in terms of computationally predicted transcription 
factor binding sites. We calculated the means and standard errors of the activities of over 
200 human regulatory motifs in the CTRL, SHP2 miR1 and SHP2 miR2 samples, 
identifying those motifs that were consistently downregulated in both SHP2 miR1 and 
SHP2 miR2 samples. 
 
8.9.2 Analysis of let-7 target genes from microarray data 
Contrasts between SHP2 miRs samples – CTRL miR were calculated for both MCF10A-
HER2/3 cells grown in 3D cultures and BT474 tumors in the presence or absence of SHP2. 
Using the TargetScan 5.1 resource (www.targetscan.org), we defined three groups of 
expressed genes (average log2 expression level greater than 4.0): genes that are not 
targeted by let-7, genes that are predicted let-7 targets and genes that are the 100 most 
likely let-7 targets sorted by TargetScan scores. For each group of genes, we plotted the 
relative frequency (density) of log2-fold changes induced by SHP2 knockdown. 
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8.9.3 Microarray analysis 
Total RNA was extracted with TRIzol reagent from BT474 tumors. RNA was processed, 
hybridized to GeneChip Human Gene 1.0 ST arrays (Affymetrix, Santa Clara, CA) and 
scanned according to the manufacturer’s instructions. All gene arrays were processed in R 
(www.r-project.org) using bioconductor and the package oligo. Robust multi-array average 
(RMA) was performed using the following command: expr <- rma(read.celfiles 
(filenames, pkgname=”pd.hugene.1.0.st.v1”), target=”probeset”). Expressions for 
transcript clusters were calculated by averaging corresponding probeset values (using array 
annotation from Affymetrix). We plotted the contrast between SHP2 miR1–CTRL miR 
and SHP2 miR2–CTRL expressing tumors and found that 210 Affymetrix IDs were either 
upregulated or downregulated in both SHP2 miRs expressing tumors. Out of these 210 
IDs, 182 had a human gene annotation. 180 genes were downregulated whereas only 2 
were upregulated in SHP2 miR1/2 tumors. These 180 downregulated genes were 
considered as the “SHPβ signature”. 
For the transcriptome analysis of the SUM1315 xenografts expressing SHP2 NLS 
wt, SHP2 NLS deleted or NLS mutated constructs, RNA was extracted from three 
biological replicates per condition using TRIzol reagent and further purified using the 
RNeasy Plus Mini Kit (QIAGEN) according to the manufacturer’s instructions. RNA 
concentration was measured using a NanoDrop ND-1000 and the quality of the RNA 
assessed using the Agilent 2100 bioanalyzer and RNA Nano Chip. Aliquots (100 ng) of 
extracted total RNA were amplified using the Ambion WT Expression Kit and the 
resulting sense-strand cDNA was fragmented and labeled using the Affymetrix GeneChip 
WT Terminal Labeling Kit. Affymetrix GeneChip Human Gene 1.0 ST arrays were 
hybridized following the GeneChip Whole Transcript (WT) Sense Target Labeling Assay 
Manual (Affymetrix) with a hybridization time of 16 h. The Affymetrix Fluidics protocol 
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FS450_0007 was used for washing. Scanning was performed with Affymetrix GCC Scan 
Control version 3.0.0.1214 on a GeneChip Scanner 3000 with autoloader. Probe sets were 
summarized and probeset level values normalized with the justRMA() function from the R 
(version 2.12.0)/Bioconductor (version 2.6) package affy using annotation as provided by 
Bioconductor. Differentially expressed genes were identified using the R package limma 
(Gentleman, Carey et al. 2004) and by selecting genes with a minimum absolute log2 fold 
change of at least 1.5 and a P-value of <= 0.05 and an average expression of at least 4. 
Venn diagrams were drawn using the overLapper() and vennPlot() functions of the limma 
package. Top 10 up- or downregulated gene lists were created sorted by logFC. 
 
8.9.4 Analysis of public microarray data 
CEL files were downloaded (http://www.ncbi.nlm.nih.gov/geo , accessions: GSE12276 for 
the Bos dataset, GSE2034 for the Wang dataset, GSE1456 for the Stockholm dataset and 
GSE2109 for the Bittner dataset) and normalized using gcrma from R/bioconductor. 
Probesets were linked to genes using Affymetrix annotation, and for genes represented by 
multiple probesets, the one with maximal variance across samples was selected. Genes not 
clearly detected (average log2 level below 4.0) were removed. For clustering and 
visualization, Z-scores were calculated from expression levels of each gene by subtracting 
the mean and dividing by the standard deviation. Patients were split into two groups by k-
means clustering, and expression polarization was defined as the absolute difference 
between the mean expression levels over genes and patients in each group. 
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8.10 Statistical Analysis 
All values represent mean ± SEM of at least 3 independent experiments unless otherwise 
indicated. Normally distributed data was analyzed by the Student’s t-test or Fisher`s exact 
test, otherwise a Mann-Whitney test was used. P-values of < 0.05 were considered a 
statistically significant difference. 
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9 APPENDICES 
 
9.1 Abbreviations 
2D  Two-dimensional 
3D  Three-dimensional 
4D  Four-dimensional 
ACN  Acetonitrile 
AD  Anno Domini 
ADH  Atypical ductal hyperplasia 
Ala  Alanine (A) 
AML  Acute myelogenous leukemia 
APS  Ammonium persulfate 
Arg  Arginine (R) 
Asp  Aspartic acid (D) 
BC  Before Christ 
BCR  Breakpoint cluster region 
protein 
BCR-ABL  ABL kinase-BCR protein fusion 
bona fide Latin: in good faith 
bp  Base pair 
BSA  Bovine serum albumin 
CagA  Cytotoxin-associated gene A 
CAS  Crk-associated substrate 
Cat#  Catalogue number 
CD  Cluster of differentiation  
ChIP  Chromatin immunoprecipitation 
CIP   Calf-intestinal alkaline 
phosphatase 
CSC  Cancer stem cell 
Csk   c-Src kinase 
c-Src  Cellular Src 
CTC  Circulating tumor cell 
CTRL  Control 
Cys  Cysteine (C) 
D2S  Distance to start 
DAPI  4′,6-diamidino-2-phenylindole 
DCIS  Ductal Carcinoma in situ 
de novo  Latin: from the beginning 
del  NLS deleted 
DEPC  Diethylpyrocarbonate 
DMEM  Dulbecco’s modified eagle’s 
  medium 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
dNTPs  Deoxyribonucleotides 
Dox  Doxycyline 
DTT  Dithiothreitol 
E. coli  Escherichia coli 
ECM  Extracellular matrix 
EGF(R)  Epidermal growth factor 
(receptor) 
EMT  Epithelial-Mesenchymal  
  Transition 
EpCAM  Epithelial cell adhesion  
  molecule 
ER  Estrogen receptor 
ERBB2  Epidermal growth factor  
  receptor 2 (HER2) 
ERK  Extracellular signal-regulated 
  kinase 
EtOH  Ethanol 
FA  Formic acid 
FACS   Fluorescence-activated cell 
  sorting 
FAK  Focal adhesion kinase 
FBS  Fetal bovine serum 
FEA  Flat epithelial atypia 
FGF(R)  Fibroblast growth factor  
  (receptor) 
FRET  Fluorescence resonance  
  energy transfer 
GAB2  GRB2-associated binding 
protein 2 
GAP  GTPase-activating proteins 
GAPDH  Glyceraldehyde-3-phosphate 
dehydrogenase 
GEF   Guanine-nucleotide exchange 
  factors 
GFP  Green fluorescent protein 
GOF  Gain-of-function 
GRB2  Growth factor receptor-bound 
  protein 2  
Gi2  Guanine nucleotide-binding 
protein Gi, alpha 2 subunit 
h  hour/s 
H&E  Hematoxilin & Eosin 
H. pylori Helicobacter pylori 
HCC  Hepatocellular carcinoma 
HEK 293 Human embryonic kidney cells 
HER2  Epidermal growth factor  
  receptor 2 
HGF  Hepatocyte growth factor 
HR   Hormone receptor 
HS  Horse serum 
HSP90  Heat shock protein 90 
i.p.  Intra-peritoneal  
IDC  Infiltrating ductal carcinoma 
IF  Immunofluorescence 
IGF-I  Insulin-like growth factor I 
IgG  Immunoglobulin G 
IHC  Immunohistochemistry 
IL6  Interleukin 6  
in vitro  Latin: in glass 
in vivo  Latin: in the living 
IP  Immunoprecipitation 
IVM   Intravital multiphoton 
Jak   Janus kinase 
JMML  Juvenile myelomonocytic  
  leukemia 
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KCL  Potassium chloride 
kDa  kilo Dalton 
LB medium Luria-Bertani 
LC-MS/MS Liquid chromatography-mass 
  spectrometry 
LINE  Long interspersed nuclear 
  elements 
LOF  Loss-of-function 
LS  LEOPARD syndrome 
Lys  Lysine (K) 
mA  Milliampere 
MAPK  Mitogen-activated protein 
  kinase  
MET  Mesenchymal-Epithelial  
  Transition 
MetOH  Methanol 
min  Minute/s 
ml  Milliliter/s 
MOI  Multiplicity of infection 
MOPS  3-(N-orpholino) propane 
sulfonic acid 
MPM  Multiphoton microscope 
MS  Mass spectrometry 
msec  Millisecond/s 
mTOR  Mammalian target of rapamycin 
mut  NLS mutated  
NaCl  Sodium chloride 
NGS  Normal goat serum 
NLS  Nuclear localization signal 
nm  Nanometer/s 
NOD  Non-obese diabetic 
NPC  Nuclear pore complexe 
NRG  Neuregulin 
NS  Noonan syndrome 
NSCC  Non-stem cancer cell 
O/N  Overnight 
OD600  Optical density at 600 nm 
PAGE  Polyacrylamide gel  
  electrophoresis 
PARP   Poly (ADP-ribose) polymerase  
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PDGF(R) Platelet-derived growth factor 
  (receptor) 
PEI  Polyethylenimine 
PFA  Paraformaldehyde 
PI3K  Phosphatidylinositol 3-kinase 
PMSF  Phenylmethylsulfonyl fluoride 
PR  Progesterone receptor 
Pro  Proline (P) 
PTK  Protein tyrosine kinase 
PTP  Protein tyrosine phosphatase 
PTPN11  Gene encoding SHP2 
PTPN6  Gene encoding SHP1 
PuroR  Puromycin resistance cassette 
PZR  Protein zero-related 
qPCR  Quantitative real-time PCR 
Rac  Ras-related C3 botulinum toxin 
  substrate 
RET  Rearranged during 
transformation kinase 
RhoA  Ras homolog gene family  
  member A 
RISC  RNA-induced silencing  
  complex 
ROI  Region of interest 
rpm  Rounds per minute 
RPMI   Roswell Park Memorial  
  Institute  
RT  Room temperature 
RTK  Receptor tyrosine kinases 
SCID  Severe combined  
  immunodeficient 
SDS  Sodium dodecyl sulfate 
sec  Second/s 
SEM  Standard error of the mean 
Ser  Serine (S) 
SFK  Src family kinase 
SH2  Src homology 2 
SHP1  Src-homology phosphotyrosyl 
  phosphatase-1 
SHP2  Src-homology phosphotyrosyl 
  phosphatase-2 
SILAC  Stable isotope labeling by  
  amino acids in cell culture 
SINE  Short interspersed nuclear 
  elements 
SN   Supernatant 
SRC  Gene encoding c-Src 
STAT  Signal transducer and activator 
  of transcription 
TBNC   Triple-negative breast cancers 
TBS  Tris buffered saline 
TEMED  Tetramethylethylenediamine 
TERT  Telomerase reverse  
  transcriptase 
TFA  Trifluoroacetic acid 
TGFα  Transforming growth factor 
  alpha 
Thr   Threonine (T) 
TIC  tumor initiating cell 
TiO2  Titanium dioxide 
TKI   Tyrosine kinase inhibitor 
tRFP  Turbo red fluorescent protein 
Tyr  Tyrosine (Y) 
ULA   Ultra low attachment 
VEGF(R)  Vascular endothelial growth 
  factor (receptor) 
v-Src  Viral SRC 
WCL  Whole cell lysates 
WHO  World Health Organization 
wt  Wild-type g  Microgram/s l  Microliter/s m  Micrometer/s 
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9.2 SHP2 phosphoproteomics list 
 
 
Description Peptide sequence Log2 ratios KD/wt 
SRC EERPTFEYLQAFLEDYFTSTEPQYQPGENL 3.61 
YES1 DERPTFEYIQSFLEDYFTATEPQYQPGENL 3.48 
FYN ERPTFEYLQSFLEDYFTATEPQYQPGENL 3.27 
PIK3R1 SREYDRLYEEYTR 3.05 
CRIM1 QNHLQADNFYQTV 2.74 
LYN AEERPTFDYLQSVLDDFYTATEGQYQQQP 1.97 
MAPK8 TAGTSFMMTPYVVTR 1.89 
GAB1 HVSISYDIPPTPGNTYQIPR 1.73 
PARVB QLEEDLYDGQVLQK 1.70 
PIK3R2 EYDQLYEEYTR 1.67 
PKM2 EAEAAIYHLQLFEELRR 1.64 
LIMD1 VFCEEDFLYSGFQQSADR 1.50 
LCK SVLEDFFTATEGQYQPQP 1.50 
PRKCD RSDSASSEPVGIYQGFEK 1.46 
TMEM192 AKPEPDILEEEKIYAYPSNITSETGFR 1.44 
GAB1 APSASVDSSLYNLPR 1.43 
PTPRE VVQDFIDIFSDYANFK 1.39 
BCR GHGQPGADAEKPFYVNVEFHHER 1.35 
CTNND1 SYEDMIGEEVPSDQYYWAPLAQHER 1.30 
DCBLD1 AHTFSAQSGYRVPGPQPGHK 1.28 
FLNB AIVHDNKDGTYAVTYIPDK 1.27 
PIK3R1 EYDRLYEEYTR 1.25 
DLG3 RDNEVDGQDYHFVVSR 1.23 
TNS3 QQQMVVAHQYSFAPDGEAR 1.17 
MYH9 ALELDSNLYR 1.17 
EFNB1 VSGDYGHPVYIVQEMPPQSPANIYYKV 1.16 
PIK3CB ERVPFILTYDFIHVIQQGK 1.13 
ACP1 QLIIEDPYYGNDSDFETVYQQCVR 1.05 
CAV1 YVDSEGHLYTVPIR 0.98 
TLN2 AVGSSMAQLLTCAAQGNEHYTGVAAR 0.97 
DAB2IP QLLAPLSFQNPVYQMAAGLPLSPR 0.96 
PTPRA VVQEYIDAFSDYANFK 0.96 
TLN1 TMQFEPSTMVYDACR 0.92 
CAV1 YVDSEGHLYTVPIR 0.92 
CTNND1 HYEDGYPGGSDNYGSLSR 0.87 
GDI2 TDDYLDQPCYETINR 0.86 
SGK223 LNLSHSETNVHDESHFSYSLSPGNR 0.86 
CLTC ALEHFTDLYDIKR 0.83 
PTK2 AAAYLDPNLNHTPNSSTK 0.82 
TLN1 EAAAQAAYLVGVSDPNSQAGQQGLVEPT 0.81 
PEAK1 NAIKVPIVINPNAYDNLAIYK 0.79 
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TENC1 GPLDGSPYAQVQRPPR 0.78 
PKM2 TATESFASDPILYRPVAVALDTK 0.77 
EEF1A2 STTTGHLIYK 0.76 
NCK1 PDSASPADDSFVDPGERLYDLNMPAYVK 0.75 
TLN1 TLAESALQLLYTAK 0.72 
LPXN STLQDSDEYSNPAPLPLDQHSR 0.72 
PEAK1 NAIKVPIVINPNAYDNLAIYK 0.71 
TKT NMAEQIIQEIYSQIQSK 0.71 
KIRREL AIYSSFKDDVDLK 0.70 
MAGI1 IEDPVYGIYYVDHINR 0.68 
EEF1A1 EHALLAYTLGVK 0.67 
CCDC50 PARPPPPIMTDGEDADYTHFTNQQSSTR 0.64 
TXNRD1 KVVYENAYGQFIGPHR 0.63 
EPHB4 FLEENSSDPTYTSSLGGK 0.61 
CTNNA1 ATASDDASQHQGGGGGELAYALNNFDK 0.59 
DCBLD1 TFRPMDTDAEEAGVSTDAGGHYDCPQR 0.57 
PIK3R1 DQYLMWLTQK 0.56 
FLNA KTHIQDNHDGTYTVAYVPDVTGR 0.54 
AFAP1L2 VAQQPLSLVGCEVVPDPSPDHLYSFR 0.53 
DYRK1A KVYNDGYDDDNYDYIVK 0.51 
GIT1 LQPFHSTELEDDAIYSVHVPAGLYR 0.45 
TLN1 AVSSAIAQLLGEVAQGNENYAGIAAR 0.45 
STAT3 YCRPESQEHPEADPGAAPYLK 0.44 
SET IDFYFDENPYFENK 0.43 
MSN APDFVFYAPR 0.43 
INPPL1 NSFNNPAYYVLEGVPHQLLPPEPPSPAR 0.42 
CDCP1 GPAVGIYNGNINTEMPR 0.41 
PXN ECFTPFVNGSFFEHDGQPYCEVHYHER 0.41 
KIRREL EEYEMKDPTNGYYNVR 0.40 
TJP1 RYEPIQATPPPPPLPSQYAQPSQPVTSASL 0.40 
USP6NL ASPAAEDASPSGYPYSGPPPPAYHYR 0.38 
CTTN LPSSPVYEDAASFK 0.38 
PEAK1 ACSVEELYAIPPDADVAK 0.37 
MYH9 YLYVDKNFINNPLAQADWAAK 0.34 
PTK2 CIGEGQFGDVHQGIYMSPENPALAVAIK 0.32 
PTK2 KPPRPGAPGHLGSLASLSSPADSYNEGVK 0.30 
TYK2 LLAQAEGEPCYIR 0.28 
KIAA1217 NEGFYADPYLYHEGR 0.26 
INPPL1 NSFNNPAYYVLEGVPHQLLPPEPPSPAR 0.26 
SEPT2 QQPTQFINPETPGYVGFANLPNQVHR 0.26 
TWF1 KIEIDNGDELTADFLYEEVHPK 0.25 
MAPK7 GLCTSPAEHQYFMTEYVATR 0.25 
BCAR1 GLPPSNHHAVYDVPPSVSK 0.24 
BCAR1 HLLAPGPQDIYDVPPVR 0.24 
CARKD IGVVGGCQEYTGAPYFAAISALK 0.23 
RPLP0 IIQLLDDYPK 0.23 
CDCP1 SPPESESEPYTFSHPNNGDVSSK 0.23 
SHC1 ELFDDPSYVNVQNLDK 0.22 
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EPHA2 TYVDPHTYEDPNQAVLK 0.21 
ACTN1 AIMTYVSSFYHAFSGAQK 0.19 
STAT3 YCRPESQEHPEADPGSAAPYLK 0.19 
FLNB ESPLQFYVNYPNSGSVSAYGPGLVYGVA 0.19 
SEPT9 APVDFGYVGIDSILEQMR 0.19 
PEAK1 VPIVINPNAYDNLAIYK 0.17 
YES1 LIEDNEYTAR 0.16 
WDR1 AHDGGIYAISWSPDSTHLLSASGDK 0.16 
ROS1 QVAYCPSGKPEGLNYACLTHSGYGDGSD 0.15 
STARD13 VDDLYTLLPR 0.15 
ANXA2P2 SLYYYIQQDTK 0.15 
GIT1 LQPFHSTELEDDAIYSVHVPAGLYR 0.14 
GAB1 HGMNGFFQQQMIYDSPPSR 0.14 
PDLIM1 VITNQYNNPAGLYSSENISNFNNALESK 0.14 
CTNND1 HQDHSHLLYSTIPR 0.13 
TLN1 VSQMAQYFEPLTLAAVGAASK 0.13 
LPP GQIYGSGPQGYNTQPVPVSGQCPPPSTR 0.11 
PKP4 SAVSPDLHITPIYEGR 0.09 
MAPK1 VADPDHDHTGFLTEYVATR 0.07 
ZDHHC5 LVPTGPTHREPSPVRYDNLSR 0.01 
PRPF4B LCDFGSASHVADNDITPYLVSR 0.00 
LIMD1 SAFHQPGPCEDPSCLTHGDYYDNLSLA 0.00 
TNS3 WDSYENLSADGEVLHTQGPVDGSLYAK -0.01 
HARS LIYDLKDQGGELLSLR -0.03 
EGFR GSHQISLDNPDYQQDFFPK -0.03 
MAPK3 IADPEHDHTGFLTEYVATR -0.03 
BCAR1 GPNGRDPLLEVYDVPPSVEK -0.04 
PTK2 THAVSVSETDDYAEIIDEEDTYTMPSTR -0.05 
ANKS1A EEDEHPYELLLTAETK -0.06 
FCHSD2 SPKPHASLPPLPLYDQPPSSPYPSPDKR -0.06 
PKP4 TVHDMEQFGQQQYDIYER -0.07 
FERMT2 QSEDEALELEGPLITPGSGSIYSSPGLYSK -0.08 
FLNA LQVEPAVDTSGVQCYGPGIEGQGVFR -0.08 
FXR1 VLKDPDSNPYSLLDNTESDQTADTDASE -0.09 
NEDD9 GPVFSVPVGEIKPQGVYDIPPTK -0.09 
NEDD9 DGVYDVPLHNPPDAK -0.10 
PKM2 EAEAAIYHLQLFEELR -0.12 
CTNND1 LNGPQDHSHLLYSTIPR -0.14 
ARHGAP35 SSPWLPQDGFDPSDYAEPMDAVVKPR -0.15 
RAB9A EFIYYADVKEPESFPFVILGNK -0.16 
PFKP NESCSENYTTDFIYQLYSEEGK -0.16 
LIMS1 VYKEFCDFYAK -0.17 
PHPT1 IHVYGYSMAYGPAQHAISTEK -0.18 
BCAR1 VLPPEVADGGVVDSGVYAVPPPAER -0.19 
TRIP6 VNFCPLPSEQCYQAPGGPEDR -0.20 
PIK3R2 NETEDQYALMEDEDDLPHHEER -0.21 
TNK2 KPTYDPVSEDQDPLSSDFKR -0.22 
ARHGAP12 ATTPPNQGRPDSPVYANLQELK -0.22 
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ARRB2 DFVDHLDKVDPVDGVVLVDPDYLKDR -0.22 
SPTAN1 QVEELYHSLLELGEK -0.22 
TWF2 KIEIGDGAELTAEFLYDEVHPK -0.23 
CTTN GPVSGTEPEPVYSMEAADYR -0.23 
EPHA2 SEQLKPLKTYVDPHTYEDPNQAVLK -0.25 
PEAK1 VPIVINPNAYDNLAIYK -0.26 
PLEKHN1 DPGYDHLWDETLSSSHQK -0.27 
SNORA6 ADHQPLTEASYVNLPTIALCNTDSPLR -0.27 
ENO2 AAVPSGASTGIYEALELR -0.29 
DDX3X KGADSLEDFLYHEGYACTSIHGDR -0.30 
ACTB TTGIVMDSGDGVTHTVPIYEGYALPHAILR -0.32 
EPHA2 SEQLKPLKTYVDPHTYEDPNQAVLK -0.32 
SLC38A2 FSISPDEDSSSYSSNSDFNYSYPTK -0.33 
PHLDB2 DLPHSVIDNDNYLNFSSLSSGALPYK -0.33 
NEDD9 DVYDIPPSHTTQGVYDIPPSSAK -0.33 
PTK2 EDGSLQGPIGNQHIYQPVGKPDPAAPPK -0.35 
CRKL TLYDFPGNDAEDLPFK -0.36 
RASAL2 ALNQPGGLQPLSFQNPVYHLNNPIPAMPK -0.36 
LDHA ATLKDQLIYNLLK -0.37 
ZDHHC8 DSLFGDSGVYDAPSSYSLQQASVLSEGPR -0.39 
LDHA DQLIYNLLK -0.39 
BCAR1 GLLPSQYGQEVYDTPPMAVK -0.39 
NEDD9 QAGRPDLRPEGVYDIPPTCTKPAGK -0.39 
PIK3R1 EWLGNENTEDQYSLVEDDEDLPHHDEK -0.40 
SLC38A2 SHYADVDPENQNFLLESNLGK -0.41 
EPHA2 TYVDPHTYEDPNQAVLK -0.41 
ACLY TTDGVYEGVAIGGDR -0.42 
LDLR TTEDEVHICHNQDGYSYPSR -0.42 
EPHB4 VYIDPFTYEDPNEAVR -0.43 
PSMA2 LAQQYYLVYQEPIPTAQLVQR -0.44 
TNS3 LSLGQYDNDAGGQLPFSK -0.45 
BCAR1 AQQGLYQVPGPSPQFQSPPAK -0.47 
NAT10 EELEALFLPYDLKR -0.48 
NEDD9 HQSLSPNHPPPQLGQSVGSQNDAYDVPR -0.49 
DCBLD1 HEYALPLAPPEPEYATPIVER -0.50 
FER GAQLHQNQYYDITLPLLLDSLQK -0.51 
PARD3 ISHSLYSGIEGLDESPSR -0.53 
NEDD9 YQKDVYDIPPSHTTQGVYDIPPSSAK -0.53 
CRK GGPEPGPYAQPSVNTPLPNLQNGPIYAR -0.54 
VIM SLYASSPGGVYATR -0.55 
CTTN LPSSPVYEDAASFK -0.56 
PTK2 THAVSVSETDDYAEIIDEEDTYTMPSTR -0.57 
TUBB2C NSSYFVEWIPNNVK -0.58 
BCAR1 DPLLEVYDVPPSVEK -0.59 
NEDD9 SLSPNHPPPQLGQSVGSQNDAYDVPR -0.59 
RIN1 EKPAQDPLYDVPNASGGQAGGPQRPGR -0.59 
BCAR1 VGQGYVYEAAQPEQDEYDIPR -0.60 
NEDD9 DVYDIPPSHTTQGVYDIPPSSAK -0.61 
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SIRPA EYASIQTSPQPASEDTLTYADLDMVHLNR -0.61 
ERBB2IP SATLLYDQPLQVFTGSSSSSDLISGTK -0.61 
ANKS1A IIASLADRPYEEPPQKPPR -0.62 
PCBP2 IPYRPKPSSSPVIFAGGQAYTIQGQYAIPQP -0.63 
OSMR PGPCICFENLTYNQAASDSGSCGHVPVSP -0.63 
ELMO2 EPSSYDFVYHYG -0.63 
PTK2 LSRGSIDREDGSLQGPIGNQHIYQPVGKPDPAAPPK -0.63 
TNK2 VSSTHYYLLPERPSYLER -0.65 
ARHGEF7 SLVDTVYALKDEVQELR -0.69 
GDI2 NPYYGGESASITPLEDLYK -0.73 
MPZL1 SLPSGSHQGPVIYAQLDHSGGHHSDK -0.74 
NCK1 LYDLNMPAYVK -0.74 
BCAR1 EETYDVPPAFAK -0.76 
IRS2 APYTCGGDSDQYVLMSSPVGR -0.82 
SDCBP QTAFSANPANPAILSEASAPIPHDGNLYPR -0.82 
EPHA3 TYVDPHTYEDPTQAVHEFAK -0.88 
RFFL MQAYSNPGYSSFPSPTGLEPSCK -0.89 
ARPC3 DTDIVDEAIYYFK -0.92 
DCBLD2 AGKPGLPAPDELVYQVPQSTQEVSGAGR -0.95 
CASP8 GIIYGTDGQEAPIYELTSQFTGLK -0.95 
NUDT3 VLQYHKPVQASYFETLR -0.95 
DCBLD1 AGRHEYALPLAPPEPEYATPIVER -0.96 
DCBLD1 GGFSPVAGVGAQDGDYQRPHSAQPADR -1.02 
TFRC SAFSNLFGGEPLSYTR -1.04 
HSPA8 GPAVGIDLGTTYSCVGVFQHGK -1.05 
CRKL YGIPEPAHAYAQPQTTTPLPAVSGSPGAAI -1.06 
FRK HGHYFVALFDYQAR -1.06 
PXN FIHQQPQSSSPVYGSSAK -1.11 
DCBLD1 HEYALPLAPPEPEYATPIVER -1.11 
ARHGAP12 ATTPPNQGRPDSPVYANLQELK -1.13 
PTPN11 IQNTGDYYDLYGGEK -1.15 
PKP4 NNYALNTTATYAEPYRPIQYR -1.16 
HMGB1 RPPSAFFLFCSEYRPK -1.20 
LASP1 PHHIPTSAPVYQQPQQQPVAQSYGGYK -1.23 
DCBLD1 AGVGAQDGDYQRPHSAQPADRGYDRPK -1.35 
TJP2 HPDIYAVPIK -1.36 
DNAJA1 NVVHQLSVTLEDLYNGATR -1.42 
PDLIM5 YTEFYHVPTHSDASK -1.50 
SIRPA NNHTEYASIQTSPQPASEDTLTYADLDMVH -1.54 
SGK223 EATQPEPIYAESTKR -1.71 
HNRNPA2B1 GDGYNGYGGGPGGGNFGGSPGYGGGR -1.74 
BCAR3 VPSSPSAWLNSEANYCELNPAFATGCGR -1.76 
EPHA3 TYVDPHTYEDPTQAVHEFAK -1.78 
ITSN2 EEPEALYAAVNK -1.83 
ANXA2P2 LSLEGDHSTPPSAYGSVK -1.87 
CDK3 IGEGTYGVVYK -2.06 
EPHA2 VLEDDPEATYTTSGGK -2.12 
PKP4 NNYALNTTATYAEPYRPIQYR -2.40 
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ARHGAP35 NEEENIYSVPHDSTQGK -2.80 
MPZL1 SESVVYADIR -2.94 
CDK3 IGEGTYGVVYK -2.95 
LPP NDSDPTYGQQGHPNTWK -3.01 
PXN VGEEEHVYSFPNK -3.23 
GSK3A GEPNVSYICSR -3.46 
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